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Maintenance of adequate physical activity (PA) is a key recommendation for 
people with and without chronic disease, with well-established health benefits. 
However, there is uncertainty in the level of objectively assessed PA in people 
with heart failure (HF) and how exercise-based cardiac rehabilitation (CR) 
interventions can impact upon PA levels (chapter 1). 
Methods 
Four linked research studies were undertaken. A systematic review and meta-
analysis to determine whether participation in exercise-based CR increases PA 
levels of patients with coronary heart disease and HF (chapter 2). A laboratory-
based calibration study to estimate HF specific accelerometer intensity 
thresholds for moderate-to-vigorous PA (MVPA) and inactivity (chapter 3). A 
cross-sectional study to quantify the PA levels of 247 HF patients participating 
in a randomised controlled trial of a home-based CR intervention (REACH-HF) 
in HF patients (chapter 4). A pooled analysis study to assess the effects on PA 
of the REACH-HF intervention in HF patients and explore the patient 
characteristics associated with a change in PA level (chapter 5).  
Results 
The systematic review and meta-analysis identified 40 randomised controlled 
trials (6480 patients). Moderate evidence was found to support that CR 
positively impacts PA levels of patients with coronary heart disease and HF 
compared to control. The calibration study determined HF specific 
accelerometer values relating to inactivity (right wrist: 18.6mg (95% CI 8.8 to 
28.4mg), left wrist: 16.7mg (95% CI 7.8 to 25.6mg), waist: 7.6mg (95% CI -3.1 
to 18.4mg)) and moderate intensity PA (right wrist: 45.5mg (95% CI 31.9 to 
59.1mg), left wrist: 43.6 (95% CI 38.5 to 56.3mg), waist: 40.6mg (95% CI 24.3 
to 57.0)), lower than the non-specific thresholds used in most HF patient studies 
based on healthy adults. PA levels of 247 HF patients were examined and 45% 
were found to meet current PA recommendations of 150 minutes per week of 
MVPA. However, MVPA ranged widely from 0 to 375.2 minutes per week. HF 
patient age, body composition, employment status, New York Heart Association 
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class, smoking status, NT-proBNP level, and exercise tolerance were 
associated (P<0.05) with baseline MVPA levels. At final follow-up, there was 
evidence of an increase in light PA (26.9 mins/day, 95% CI: -0.05 to 53.8, 
p=0.05) and a decrease in inactivity (-38.31 mins/day, 95% CI: -72.1 to -4.5, 
p=0.03) during weekdays in HF patients undertaking home-based CR 
compared to control. Exercise tolerance, HADS anxiety score, presence of 
diabetes, and living with a parent or child >18 years were associated with a 
change in PA. 
Conclusions 
Objective measurement of PA in HF remains under researched. This thesis 
discusses methodological, and clinical implications for the future measurement 
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Chapter 1: Introduction  
This chapter provides an overview of the concept of physical activity (PA) 
(section 1.1), summarises the relevant evidence for its key benefits to health 
(section 1.2), and discusses the current challenges in its assessment (section 
1.3), particularly with accelerometry (section 1.4). This is then followed by a 
description of heart failure (HF) (section 1.5.1), PA levels of HF patients (section 
1.5.2), evidence for PA benefits (section 1.5.3), and the impact of exercise 
based cardiac rehabilitation (CR) (section 1.5.4). The overarching aim of this 
thesis, and specific aims of each of the empirical studies is also described 
(section 1.7).   
 
1.1 Physical activity – definitions and guidelines 
PA is defined as any bodily movement produced by skeletal muscles resulting 
in energy expenditure beyond resting expenditure. [1] PA includes, in addition to 
sports and structured exercise, occupational, household, personal care, leisure 
time and transportation activity. [1] PA is a different concept to physical fitness, 
although the two are often related. [2] Physical fitness comprises multiple 
components (i.e. health-related and skill-related) that enable an individual to 
perform PA without undue fatigue. [1] 
PA patterns are often quantified according to the following four dimensions: 
• Frequency: how often the PA occurs, e.g. three times per week, 
• Duration: the length of time one bout of PA is sustained for, 
• Type: the mode of PA performed, i.e. walking, swimming, etc, 
• Intensity: the effort required to undertake PA. 
The majority of PA guidelines and recommendations are based on systematic 
reviews and consensus statements of studies using subjective measures of PA 
and have consistently identified 150 minutes per week of moderate-to-vigorous 
intensity PA (MVPA) as providing considerable health benefits. [3-5] 
Internationally, the current PA recommendation for the health of adults and 
older adults is at least 150 minutes of MVPA per week, or 30 minutes MVPA on 
at least 5 days per week. In addition, individuals should undertake activities 
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aimed at improving or maintaining muscular strength, balance and flexibility on 
at least two days per week. [6-9] This is also the standard PA recommendation 
for cardiac patients by the British Association for Cardiovascular Prevention and 
Rehabilitation (BACPR) and the Scottish Intercollegiate Guidelines Network 
(SIGN). [10-12] World Health Organisation (WHO) guidelines indicate that 
MVPA minutes should be obtained in bouts of at least 10 minutes for potential 
health benefits. [7] A bout refers to the duration a session of PA is sustained for. 
Emerging research is suggesting that PA undertaken in bouts of <10 minutes 
may also have positive health benefits. [13-15] This has led to updated United 
Kingdom and United States guidelines, where MVPA can be accumulated in 
bouts of any length. [6, 8] 
When examining the total profile of human behaviour in terms of movement or 
energy expenditure, sedentary behaviour should also be considered. Sedentary 
behaviour refers to a combination of sitting or reclining and low energy 
expenditure (<1.5 METS) during waking hours. [16]. A large body of research 
has recognised the detrimental effects to health of prolonged sedentary time, 
and report that sedentary time is a risk factor for poor health outcomes, 
independent of MVPA levels. [17-19] However, some epidemiological studies 
have demonstrated that associations between sitting time and all-cause 
mortality and cardiovascular disease are dependent on MVPA (Figure 1.1). [20-
22] Furthermore, the evidence base for sedentary behaviour is not as strong as 
for PA, with unclear biological mechanisms and reliance on surrogate 
outcomes, such as time spent watching television, and so specific quantitative 
guidelines for sedentary time have not been established yet. Therefore in a 
recent review, authors recommend clinicians prioritise a message focussed on 
increasing PA at any intensity, until the evidence base for sitting or sedentary 




Figure 1.1: Conceptualisation of the associations between health outcomes and 
sitting, with physical activity as an effect modifier (adapted from Stamatakis et 
al. [20]). 
 
1.2 Evidence for PA and health benefits 
In the 1950s the first epidemiological studies suggesting a link between PA at 
work being beneficial to health began to emerge, when Morris et al. found that 
London bus drivers developed a higher rate of coronary heart disease (CHD) 
than the bus conductors, and likewise in postal clerks compared to postmen. 
[23] Similarly, Paffenberger et al. showed those with more sedentary jobs 
compared to physically active on the San Francisco docks had higher rates of 
CHD, [24] and the Harvard alumni study showed that men who expended more 
energy per week in sports, walking and stair climbing had a lower risk of 
developing CHD than less physically active classmates. [25] 
Since then, it has been estimated that physical inactivity is responsible for 6-
10% of the major non-communicable diseases worldwide, making it comparable 
to smoking and obesity as a risk factor for disease. [26] It is widely accepted 
that engagement in MVPA is an important primary prevention strategy to 
promote health, and secondary prevention strategy to manage and minimise the 
severity of disease. [27] Many studies have shown the long-term health benefits 
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of self-reported PA in the general population, across the life course, with risk 
reductions for all-cause mortality, and reduced rates of non-communicable 
diseases such as CHD, obesity, type 2 diabetes mellitus, and dementia. [28-30] 
Other benefits include reduced risk factors for chronic diseases; reduction in 
inflammatory biomarkers, systolic and diastolic blood pressure, reduced 
cholesterol levels, and improved cardiovascular fitness. [31-33] PA is also 
associated with reduced risk of functional limitations and disability in older age, 
and improved health related quality of life (HRQoL). [3, 34] 
In more recent studies, relationships between health outcomes and objectively 
measured PA levels have been assessed. Ekelund et al. performed a 
harmonised meta-analysis of 8 studies, involving 36,383 adults (mean age 62.6 
years; 72.8% women) and showed a non-linear dose-response relationship 
between accelerometer measured PA and improvement in all-cause mortality in 
adults. [35] Saint-Maurice et al. showed risk reductions for all-cause mortality 
with increased amounts of accumulated sporadic or bouted MVPA range from 
60-80%. [15] Loprinzi showed that a 60 minute increase in light PA 
(independent of MVPA) resulted in a 16% reduction in hazard of all-cause 
mortality. [36] Rees-Punia et al. performed a statistical computation, and 
showed a hypothetical replacement of 30 minutes/day sitting time with light 
intensity PA was associated with a 14% mortality risk reduction, and 
replacement with MVPA was associated with 45% mortality risk reduction. [37] 
Associations between accelerometer measured PA and cardiovascular disease 
risk factors, physical function, and frailty in older populations have also been 
reported. [38, 39] 
 
1.3 PA measurement methods 
There are a wide range of tools available to researchers to measure PA that 
vary in feasibility and accuracy. Ideally, PA assessment methods should 
measure all four of the dimensions of PA. Some methods are more appropriate 
for measuring PA in terms of energy expenditure, for example doubly labelled 
water or indirect calorimetry, however these methods are expensive, and aren’t 
feasible for use in larger scale studies. [40] Tools that are appropriate for 
measuring PA in terms of behaviour include direct observation, activity diaries, 
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questionnaires, accelerometers, pedometers, and even commercial devices 
such as Fitbits and smartphones, for example. These methods can be further 
categorised as subjective or objective approaches.  
Subjective methods of assessing PA include questionnaires (self- or interview 
administered), and PA diaries or logs (i.e. records kept over a specific 
timeframe), which vary in length, depth of information captured and recall 
periods. [40] These methods rely on self-report, and are often cost-effective and 
convenient ways to collect PA data from large samples in a relatively short 
period of time.  
Objective methods of assessing PA levels often continuously measure energy 
expenditure or bodily movement and are generally considered more accurate as 
they are not subject to response and recall bias as with subjective methods. 
Advances in technology has meant body-worn devices (such as acceleromters, 
pedometers or Fitbits) have become smaller, and data capacity and battery 
power have increased alongside capability to measure multiple integrated 
responses to PA, therefore these devices are increasing in popularity. [41] Over 
recent years, accelerometers have become the most popular PA monitors for 
research purposes and have been used successfully in many large-scale, 
population studies, with proven acceptability to participants. [36, 42, 43] 
Both approaches have their relative advantages and disadvantages and vary in 
their ability to assess the multiple dimensions of PA, i.e. frequency, duration, 
type and intensity, which are summarised below. 
1.3.1 Frequency 
Subjective PA measures in the form of questionnaires or diaries are able to 
capture PA frequency, often by asking individuals to recall the frequency of 
performing activities from a given list, or using rating scales (e.g. never, 
sometimes, mostly, always). Recall durations range from a day to up to a year, 
and many require individuals to determine the frequency of PA over a ‘usual’ or 
‘typical’ period of time. Since frequency of many activities fluctuates over weeks 
or monthly periods, sometimes due to seasonal changes, individuals are likely 
to report their highest recent or desired frequency of participation. [44] Reliance 
on individuals accurately recalling PA over long time frames or a ‘typical’ period 
23 
 
may lead to recall and response bias, and have been found to be unreliable 
methods of measuring PA in older adults and cardiac patients. [45, 46] For 
example, cardiac patients answering the Health Survey for England PA 
interview often overestimated the number of days they were active compared to 
accelerometer measured PA, resulting in the survey misclassifying 63% of 
participants. [47]   
Objective assessment methods will provide varying degrees of information 
about PA frequency. Pedometers and doubly labelled water are unable to 
determine PA frequency. But, accelerometers, heart rate monitors and direct 
observation methods are able to provide much more detailed records of daily 
and weekly PA. [46] Accelerometers continuously record acceleration, and are 
able to collect data on the number of bouts of continuous or intermittent activity 
for up to 60 days. [48] Many accelerometers are now waterproof, and have 
enough battery power to last for measurement periods of at least a week, 
placing minimal burden on the participant to remember to remove the device to 
bathe or charge the device. These methods are also advantageous as they do 
not rely on self-report, so recall and response biases are diminished. [46, 49] 
1.3.2 Duration  
Similar to PA frequency, subjectively assessed PA duration data are often 
collected from questions regarding the length of time spent in hours or minutes 
performing specific PAs over the different recall periods, or on each PA 
occasion. As well as being limited by the above-mentioned misreporting and 
recall biases, intermittent, sporadic or unstructured PAs are difficult to measure 
and recall using subjective assessment methods. Some questionnaires do not 
take into account PAs that have a duration of less than 10 or even 30 minutes. 
[44, 47] This may be particularly important information to gather in older 
individuals or those with chronic diseases, as the majority of their PA will be 
made up of short bouts of activity that occur as part of routine daily activity. [50] 
Indirect calorimetry and heart rate monitors are able to capture PA duration by 
assessing the time spent in activities which gives outputs over predetermined 
intensity thresholds such as heart rate zones or metabolic equivalents (METS) 
values. [46] Accelerometers collect data continuously over pre-defined time 
periods (epochs) ranging from 1-60 seconds. [51] Selection of smaller epochs 
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will capture greater levels of variation in PA patterns, and will enable 
researchers to pick up continuous, intermittent and sporadic activities. [52] 
Accelerometers also record PA with a time stamp, which allows for examination 
of both duration and timing of PA, which may be valuable information for 
interventions targeting sedentary periods throughout the day. [53]  
1.3.3 Type 
Whilst the absolute values for frequency and duration may be subject to 
inaccuracies and bias with recall, they can provide useful insight into the context 
of PA behaviour, with information about the type of activities performed. By 
understanding not only the volume of activity undertaken, but the type of 
activities or sedentary behaviours undertaken, researchers may be able to 
provide more personalised or targeted interventions. However, some self-report 
methods can influence the number and type of activities reported by individuals 
through the use of leading questions or providing a set list of PAs, which may 
not cover activities older adults or those with chronic diseases would typically 
undertake such as household chores and walking. [44] 
Although objective PA assessment methods are generally considered to be 
superior to subjective methods, methods such as accelerometry and pedometry 
are limited in their ability to capture certain PA types such as swimming, cycling 
and walking on an incline or stairs. [2, 46, 54] Current advancements in 
accelerometer measured PA are attempting to use machine learning methods 
to identify patterns in the raw data which represent specific types of PA, 
however these methods remain in early stages of development. [55] In contrast, 
such activity monitors are generally believed to provide better assessments of 
ambulatory activities such as walking that have proved difficult to capture via 
self-report, and make up the majority of adult, and particularly older adults PA. 
[2, 56, 57] 
1.3.4 Intensity 
Subjective PA assessment methods often express PA intensity in one of two 
ways. Firstly, to ask the individual to rate the activity themselves using 
descriptive cues (e.g. moderate, hard, very hard, or breathing normally, slightly 
out of breath, too out of breath to carry on a conversation). [46] Perceptions and 
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reporting of PA intensity can be influenced by a number of factors including the 
perceived desirability of a given response and often result in individuals 
misclassifying PAs, with a tendency to overestimate time spent in MVPA. [40, 
44, 51, 58] 
The second method is to assign a MET value, a measure of energy 
expenditure, to the PA. METS are defined as the ratio of the working metabolic 
rate to the resting metabolic rate. The standard definition of one MET, which 
represents the energy used whilst at rest, is equal to 3.5 ml/kg/min or 1.0 
kcal/kg/hour in adults. METS are used to categorise PA into intensity levels, 
namely: sedentary/inactivity (<1.5 METS), light PA (1.5-2.9 METS), moderate 
PA (3.0-5.9 METS), vigorous PA (>6.0 METS). METS can be expressed in 
absolute terms, i.e. as an absolute value relative to body mass or resting 
metabolism (assuming everyone expends energy in the same way), or in 
relative terms, i.e. relative to peak exercise capacity.  
Often, MET values are obtained via standard tables such as the Compendium 
of Physical Activities which consists of a wide-ranging list of PAs that have been 
categorised, coded and given a corresponding MET value. [59] However, 
employing this method focuses on the absolute rather than the relative intensity 
of PAs, not taking into account large inter- and intraindividual variations in 
energy expenditure depending on age, sex and body mass. [47] For example, 
asking individuals to specify the speed at which they walk, and using that to 
assign a MET value. Researchers have demonstrated weak relative agreement 
between accelerometer and self-reported (International Physical Activity 
Questionnaire – Long Form) estimations of PA intensity, with participants self-
reporting higher MVPA levels (r=0.12, 95% CI 0.08 to 0.14). [60] In addition, 
MET values in these tables are based on data from young healthy adults. Both 
exercise capacity and resting metabolism decline with age, resulting in higher 
metabolic costs of PAs, so whilst these estimates may be suitable for the 
general adult population, they may not be appropriate for the unfit, elderly or 
those with capacity limiting chronic diseases. [44, 50, 58, 61-64] 
A further issue with subjective PA assessment methods is the fact that many do 
not capture data for low intensity PAs, with some not counting PAs with 
intensities lower than brisk walking. [44, 46, 50] Studies have shown that lower 
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intensity PAs are more difficult to recall accurately. [65] However capturing this 
information in older adults and those with chronic disease is important as this is 
the type of PA these populations tend to participate in most frequently. [50] 
Objective PA assessment approaches are able to determine PA intensity via 
various methods. Most pedometers are able to accurately record accumulated 
steps during walking, but are less useful for measuring PA intensity. [2] Indirect 
calorimetry uses average oxygen consumption to gauge PA intensity, however 
the need for bulky equipment to measure this severely limits its use beyond 
laboratory experiments into free-living environments. Accelerometers will 
estimate PA intensity through identifying periods or bouts activity where 
accelerometer signals lie above predetermined thresholds or cut-points for the 
various intensity categories (i.e. sedentary, light, moderate and vigorous). [46] 
However, these methods are also subject to similar limitations as subjective PA 
assessments in the use of absolute cut-points to categorise PA intensity, based 
on studies of young healthy adults. Further discussion around the complexity of 
measuring PA intensity via accelerometer will be presented in the following 
section (section 1.4.2).  
1.3.5 Comment on consensus 
In general, objective PA assessment methods demonstrate less variability in 
validity and reliability compared to self-report measures in a variety of 
populations including older adults and CR participants. [40, 45, 46, 49] 
However, there exists extreme variability in the methodological quality of 
studies, as well as choice of criterion or comparison measure, and reported 
outcome metrics. [45, 46] This has meant that data synthesis is challenging, 
and many reviews are only able to report comparisons between total energy 
expenditure or PA rather than examining the four dimensions of PA in detail. 
Furthermore, many of the studies that compared self-report to objective 
measures of PA examined the relationship using correlations and did not report 
the level of agreement between methods. This means only the strength of the 
relationship between the two methods is known, and does not rule out that 




Given the complexity of PA, its dimensions and measurement there remains a 
lack of consensus on a gold standard assessment method. Researchers must 
weigh up the various pros and cons of the different tools available to measure 
PA levels, considering the population under investigation, and the outcome 
measures of interest. [66] Accelerometers are able to provide detailed 
information on the frequency, duration and intensity of PA, and wrist-worn 
accelerometers have been used successfully in multiple large-scale population 
studies such as NHANES, UK Biobank, and Whitehall II studies, with high 
adherence rates. [42, 43, 51] PA measured via accelerometer has also been 
reported to have stronger associations with cardiometabolic biomarkers 
compared to self-report measured PA. [67] Developments in raw-accelerometry, 
and transparent data processing methods means that comparisons and 
harmonisation between studies are now much more achievable, which enables 
better understanding of the relationship between PA and health. [35] Chapters 
2-5 of this thesis use wrist-worn accelerometer measured PA data, therefore 
further information about accelerometers is provided in the following section.  
 
1.4 Accelerometry 
Accelerometers are small electronic devices, usually worn at the waist or on the 
wrist but can also be worn on the upper arm, thigh or ankle. They measure the 
direction and magnitude of acceleration associated with bodily movement, in 1-
3 axes (mediolateral (x), vertical (y), and anteroposterior (z); figure 1.2) [48, 
69].The signal is then summarised over a user-defined time period or epoch, 




Figure 1.2: The directions of the mediolateral (x), vertical (y) and anteroposterior 
(z) axes. [68] 
 
Early accelerometers such as the Actigraph GT1M (Pensacola, FL) produced 
proprietary outcome metrics, ‘activity counts’ which are collected over pre-
defined time periods (epochs), ranging from 1-60 seconds. [51] The key 
limitation with such accelerometers is that the proprietary algorithm used to 
derive the brand-specific activity counts is kept confidential, making 
comparison, interpretation or harmonisation of data across accelerometer 
brands and studies challenging. Comparatively, accelerometers that undertake 
no onboard processing and provide the raw acceleration in gravitational units (g 
or mg), are now more available as small, low-cost devices enabling researchers 
to collect raw accelerometer data continuously for extended periods.  
Chapters 3-5 of this thesis will focus on accelerometer measured PA in HF 
patients using the GENEActiv accelerometer (Activinsights Ltd, 
Cambridgeshire, UK) which provides high resolution accelerometer data in its 
raw format (figure 1.3). The GENEActiv accelerometer has been validated for 
both wrist and hip worn use in adults for measurement of PA and sedentary 
time. [69-71] It has strong relations with habitual PA patterns measured by the 
Actigraph GT3X+, another popular tri-axial raw accelerometer, and are 




Figure 1.3: GENEActiv accelerometer 
 
It is also worthwhile to note that with the vast technological developments over 
recent years, there is now a wealth of commercially available fitness trackers 
and smart watches, often equipped with multiple sensors including 
accelerometers, which provide health and PA information to consumers via 
mobile apps and proprietary algorithms. However, the rate at which companies 
release new devices means that few well-established brands and models are 
thoroughly validated for use in research. [73] 
1.4.1 Data processing of raw acceleration 
Data collected from accelerometers is only a proxy for PA and therefore needs 
to be translated into meaningful behavioural units. An advantage of using raw 
accelerometer data in health research is that new data processing techniques 
can be applied to previously collected PA data sets, providing opportunities for 
data harmonization and comparisons and therefore better understanding of PA 
levels on a public health level, or population specific. 
Methods for data reduction and analysis of raw accelerometer data are well-
defined, openly available and reproducible. In this thesis three data reduction 
techniques are explored and are described below. Each are designed to 
quantify the magnitude of acceleration during a given epoch, combining the 
signals from the three axes to a single vector magnitude expressed in 
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milligravity units, where higher values correspond to higher intensity of PA. [69, 
74, 75] 
Firstly, Euclidean Norm Minus One (ENMO), developed by van Hees et al. 
where the vector magnitude is calculated in each epoch, and 1000mg (one 
earth gravitational unit) is removed, negative ENMO values are rounded to 0.  
The argument for this process is that negative values are potentially a result of 
calibration error rather than bodily movement. [74] 
𝐸𝑁𝑀𝑂 = √𝑥2 + 𝑦2 + 𝑧2 − 1𝑔 
Mean amplitude deviation (MAD), developed by Vaha-Ypya et al in 2015, 
describes the mean distance of data points about the mean, and gives output in 
mg. This method was shown to successfully classify different PAs based on the 
intensity, regardless of accelerometer brand. [75]   
𝑀𝐴𝐷 =  
1
𝑛
 ×  ∑ |𝑟𝑖 − 𝑟|̅        
Where;  
𝑟𝑖 =  √𝑥𝑖
2 + 𝑦𝑖
2 + 𝑧𝑖
2      
?̅? = 𝑚𝑒𝑎𝑛 𝑣𝑒𝑐𝑡𝑜𝑟 𝑚𝑎𝑔𝑛𝑖𝑡𝑢𝑑𝑒 𝑤𝑖𝑡ℎ𝑖𝑛 𝑡ℎ𝑒 𝑡𝑖𝑚𝑒 𝑝𝑒𝑟𝑖𝑜𝑑 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 
Finally, gravity-subtracted sum of vector magnitudes (SVM), where the vector 
magnitude is calculated in each epoch and 1g is subtracted, when the 
accelerometer is static and the earth’s gravitation pull is the only acceleration, 
the result is 0. [69] 
𝑆𝑉𝑀 =  ∑ |√𝑥2 + 𝑦2 + 𝑧2 − 1𝑔 | 
1.4.2 PA analysis with accelerometers 
Figure 1.4 (adapted from Bai et al. [76]) depicts the data reduction methods and 
pathways that can be used to analyse raw accelerometer data to answer 




Figure 1.4 Analysis pathways in accelerometer measured PA research. 
Adapted from Bai et al. [76].  
 
Given that international PA recommendations are intensity specific, it is 
important to be able to differentiate between PA intensities. A key feature of 
accelerometers is the ability to determine the intensity of PA by using the 
acceleration data captured per unit of wear time through the application of 
intensity thresholds or cut-points (calibration equations and cut-point methods 
pathways (figure 1.4).  
The accelerometer thresholds or cut-points for PA intensities are derived from 
calibration studies where accelerometer values that relate to the intensity of 
interest (i.e. sedentary (<1.5 METS), light (1.5-2.9 METS), moderate (3.0 – 5.9 
METS) or vigorous (>6.0 METS)) are calibrated against an objective gold 
standard measure of energy expenditure such as indirect calorimetry. These 
are usually derived from regression equations or receiver operator characteristic 
(ROC) curves. [52]  
The majority of early calibration studies were performed with uniaxial ActiGraph 
accelerometers, and cut-points denoted in proprietary counts per minute (CPM) 
ranging from 1810-2743 CPM for the lower bound of moderate intensity PA. 
Common to all these early calibration studies was the use of young and healthy 
individuals (mean age range 22-30 years) performing treadmill based running or 
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walking activity. [51, 77-80] Accelerometer thresholds based on treadmill or 
indoor track running and walking have been shown to be less accurate in 
assessing free-living PA than when based on larger numbers of more typical 
lifestyle activities. [81] 
Over more recent years, with the emergence of tri-axial and raw 
accelerometers, and new methods to process raw data in ways that are more 
transparent and comparable, cut-points and intensity thresholds have been 
derived and reported in gravitational units (g or mg). There have also been 
improvements in the calibration protocols, including more ‘typical’ lifestyle 
activities such as household chores and sedentary activities, improving 
applicability to measuring both PA and sedentary behaviour in free living 
conditions. [69, 82, 83] However, much like early calibration studies the 
samples of participants were young, healthy adults (mean age range 34-49). 
Furthermore, many of these cut-points tend to be based on absolute MET 
values, using standard MET calculations (i.e. assuming a resting metabolic rate 
of 3.5 ml/kg/min), which as mentioned previously in section 1.3.4 does not take 
into account the inter- and intraindividual variability of energy expenditure. [47]  
Currently, there is no universally accepted and standardised approach for 
measuring PA using accelerometers in health research, particularly in special 
populations such as the elderly or those with chronic disease. Researchers 
have proposed guidelines and protocols for best practices in using 
accelerometers for PA measurement in health research, [56] which aids in 
making decisions about device placement and data collection, and how to 
report use in publications, yet there is still uncertainty around which published 
intensity thresholds to use. [84] When different thresholds for MVPA are used to 
predict PA levels and whether individuals are meeting PA guidelines it becomes 
difficult to compare results. [54] Furthermore, multiple studies in both adults and 
children have demonstrated that application of different intensity thresholds to 
the same data set can result in wide variations in MVPA minutes and different 
conclusions about PA levels, with cut-point choice having a larger influence on 
PA estimations than accelerometer wear site. [81, 85-87] In light of these 
challenges there has been a call for standardisation of PA monitor calibration, 
along with data collection, processing and analysis, preferably with the use of 
raw accelerometer data where possible. [88, 89] 
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1.4.3 Effects of age, exercise capacity and chronic disease on 
accelerometer output  
Multiple studies have applied the various cut-points identified above to samples 
of older adults and those with chronic disease including HF, without evidence 
that it is appropriate to do so. [43, 51, 90-92] A fundamental flaw of these 
methods is the application of a single threshold to all within a population. 
Increasing age is associated with decreases in both cardiorespiratory fitness or 
exercise capacity and resting metabolic rate, which results in higher metabolic 
costs of PAs including walking and daily lifestyle activities compared to younger 
adults. [62, 64] Knaggs et al. demonstrated that metabolic costs of activities are 
further increased with the presence of mobility issues. [63] Hall et al. also 
confirmed that those with chronic conditions demonstrated significantly greater 
work rates in terms of METS compared to healthy counterparts for a given task. 
[61] Consequently, estimating PA intensity based on accelerometer thresholds 
that were derived from studies of healthy adults would likely lead to 
misclassification of PA in certain populations, i.e. participants who are elderly or 
living with chronic disease may not be credited for engaging in MVPA if the 
accelerometer threshold used to determine MVPA is too high. Therefore there 
has been a call for researchers to perform calibration studies in other 
populations, including older adults, and those with chronic disease to establish 
appropriate thresholds that relate more closely to the metabolic cost of activities 
within the specific population. 
A number of calibration studies have been performed in older adults without 
exercise-limiting chronic disease. [64, 92-95] The majority of these studies used 
actigraph accelerometers and were lab-based with a mixture of daily lifestyle 
activities or treadmill walking. However, derived cut-points were expressed in 
single axis, proprietary counts per minute over different epochs, which means 
comparison is still limited. With the exception of the calibration of the Actical by 
Hooker et al., [64] all authors demonstrated that cut-points for MVPA in older 
adults (mean age range 52-75.5 years) were lower than those published based 
on younger adults. 
In addition to the effect of age, the effect of exercise capacity or fitness has also 
been investigated. In a study of 106 older adults (mean age 77.6 +/- 4.0 years) 
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Pruitt et al. calculated individual activity count thresholds for ‘meaningful’ PA 
collected during a 400m walk and found that individualised thresholds were 
more effective in differentiating PA levels of participants than accelerometry 
variables of overall activity (eg. activity counts per day). [96] The individual 
thresholds varied widely (between 149 to 3133 counts per minute), and authors 
applied previously published cut-points and demonstrated that this would likely 
have resulted in misinterpretation of PA levels in their sample of older adults.  
Similarly, Ozemek et al. demonstrated the extreme variability in individual 
accelerometer values when undertaking activities at moderate intensity relative 
to the individual (~2000-7500 cpm), with low and moderate fitness groups 
having significantly lower cut-points compared to the high fit group. [97] Rejeski 
et al. also observed large variability in activity counts achieved during 
supervised walking at a moderate intensity (rating of perceived exertion (RPE) 
13), emphasising that MVPA is a relative construct. These studies support the 
concept that exercise capacity influences energy expenditure during PA, and 
that application of standard accelerometer cut-points to individuals with low 
exercise capacity risks underestimating their PA level. [98] 
Although individualised cut-points may be preferable, this is often not feasible in 
public health or large-scale studies, nor for providing clinical advice or guidance 
to chronic disease patients in order to increase their PA levels. Furthermore, PA 
is often measured as a secondary outcome in clinical studies of chronic disease 
patients, which would make it difficult to dedicate valuable resources towards 
establishing individual thresholds for MVPA. Therefore, in order to better 
estimate the energy cost of activities from accelerometer data in adults with 
chronic disease, the best solution at present requires population specific 
thresholds of accelerometer data. 
There are a small number of studies that have performed accelerometer 
calibration or validation studies in chronic disease populations including 
Parkinson’s, [99] diabetes, [100] multiple sclerosis, [101] and chronic 
obstructive pulmonary disease (COPD). [102] Clearly there is a need for further 
research in this area, with focus on other exercise limiting chronic diseases. 
Appropriate, accurate, reliable and valid assessment of PA in the elderly and 
chronic disease populations is an important area of research. Improving the way 
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in which we measure PA in these populations will enable researchers to better 
understand relationships between PA levels and health outcomes. One 
important chronic disease population that requires further investigation is HF. 
 
1.5 Heart failure (HF) 
1.5.1 Definitions, treatment and incidence 
HF is a complex, long-term clinical syndrome defined as the reduced ability of 
the heart to pump and/or fill with blood, meaning there is inadequate cardiac 
output to meet the metabolic demands of the body. [103] In the UK, 
approximately 900,000 people are living with HF, it is responsible for 
approximately 5% of all emergency hospital admissions and costs the NHS 
around £1bn per year, up to 2% of all NHS expenditure. [104] It is an important 
public health issue, the burden of HF is increasing with rising prevalence due to 
population growth, an ageing population, and increasing prevalence of HF risk 
factors, especially diabetes, hypertension and obesity. [105, 106] Another 
postulation for these increases is that advances over recent years in 
cardiovascular surgery and medicine, have led to a decrease in the mortality 
rates of acute cardiac syndromes such as myocardial infarction, valvular and 
congenital heart diseases, hypertension and arrhythmias. However, in 
prolonging these patients’ lives, many are living with resultant myocardial 
damage and are at risk of developing HF. Incidence of HF is increasing in 
people aged over 85 years, a group of patients who are often excluded from 
randomised controlled trials (RCTs). Data are often extrapolated to these 
patients, so there remains uncertainty as to whether standard HF therapies are 
as safe and effective in the very elderly. [106] In addition, patient profiles appear 
to be changing, with HF patients increasingly surviving into older years and 
therefore living with greater numbers of associated comorbidities, such as 
hypertension, atrial fibrillation, osteoarthritis and COPD. As a result, HF 
management is becoming more complex. [105] 
The typical symptoms of HF include dyspnoea or shortness of breath, fatigue, 
weakness or tiredness, reduced exercise tolerance and increased time to 
recover after exercise, fluid retention presenting as peripheral and/or abdominal 
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oedema. Other symptoms may also include difficulty sleeping, wheezing, 
nocturnal cough, loss of appetite, feeling bloated, dizziness, and depression. 
[103] 
HF is categorised into three subtypes, namely HF with preserved ejection 
fraction (HFpEF), HF with reduced ejection fraction (HFrEF), and HF with mid-
range ejection fraction (HFmrEF) [103] Ejection fraction is usually >50% in 
patients with HFpEF, where the volume of the left ventricle is typically normal, 
but the left ventricular wall is thicker and more stiff with a high ratio of left 
ventricular mass/end-diastolic volume. HFpEF has historically been harder to 
diagnose due to its more complex and heterogeneous nature compared to 
HFrEF. [107] HFmrEF patients have an ejection fraction between 40-50%. 
Ejection fraction in HFrEF patients is <40%, with dilated left ventricles, and 
normal or reduced left ventricular mass/end-diastolic volume ratio.[108] 
Ischaemic heart disease and previous myocardial infarction are more common 
in HFrEF patients, whereas hypertension and valve disease are more common 
in HFpEF patients [104]. It is currently estimated that about half of HF patients 
have HFpEF, with the proportion of HFpEF patients increasing, and expected to 
rise to about 65% of hospitalised patients with HF by 2020. There is no data 
currently on the trends on the emerging HFmrEF category. [109] 
Clinically, HF is classified into four functional classes defined by the New York 
















I No limitations of physical activity. Ordinary physical activity 
does not cause undue fatigue, palpitations, or dyspnoea. 
II Slight limitation of physical activity. Comfortable at rest. 
Ordinary physical activity results in fatigue, palpitations, or 
dyspnoea. 
III Marked limitation of physical activity. Comfortable at rest. Less 
than ordinary activity causes fatigue, palpitations, or dyspnoea. 
IV Unable to carry on any physical activity without discomfort. 
Heart failure symptoms are present even at rest or with 
minimal exertion. 
 
The updated 2018 National Institute for Health and Care Excellence (NICE) 
guidelines in the UK recommend the following pharmacological treatment to 
alleviate symptoms and extend survival: diuretics, for the relief of congestive 
symptoms and fluid retention; then for HFpEF patients, medical management of 
comorbidities such as hypertension, atrial fibrillation, ischaemic heart disease 
and diabetes. For HFrEF patients, management of symptoms controlled with a 
combination of renin-angiotensin-aldosterone system blockers (ACE inhibitors, 
ARBs), β-adrenoreceptor blockers, mineralocorticoid receptor antagonists 
(MRA) and further or alternative medications if symptoms persist or patients 
experience intolerances to certain medications. Some patients are also offered 
surgical interventions, with placement of internal devices such as pacemakers 
and implanted cardioverter defibrillators, or cardiac resynchronisation therapy. 
In addition to the pharmacological treatments, NICE guidelines also recommend 
a number of non-pharmacological treatments for all HF patients including CR. 
Lifestyle advice should be offered, with information regarding salt and fluid 
restriction, smoking and alcohol consumption. [110] 
Prior to the 1990s, patients with HF were generally discouraged from 
exercising, and bedrest was recommended. [111] Since then, numerous studies 
have demonstrated the safety and efficacy of exercise programmes in patients 
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with HF, and as a result, national and international guidelines now recommend  
that stable HF patients participate in CR. [103, 110, subsection 1.9]  
Despite major advances in the treatment of HFrEF over recent years, there has 
been little progress made in therapy for HFpEF patients, who have not been 
shown to respond well to standard pharmacological treatments. [104, 108] The 
mechanisms causing this type of HF are not well understood, nor are the 
mechanisms underlying these patients exercise intolerance which is often the 
primary chronic symptom, resulting in poor health related quality of life 
(HRQoL). [112] However, recent research indicates that exercise and PA  
interventions are beneficial for patients with HFpEF, with improvements in both 
exercise capacity and HRQoL. [113] Further, patients have indicated a 
preference for HRQoL rather than length of life, so the focus of research is 
shifting in this direction. [114] Exercise capacity, PA, and HRQoL present 
important alternative clinical outcomes, and targets for interventions. 
1.5.2 PA levels of HF patients  
A small number of studies have assessed PA levels of patients with HF, 
however these studies are limited by PA measurement methods that may not 
be accurate or appropriate in this population.  
Studies using self-reported measures of PA have demonstrated that many 
patients are non-compliant with non-pharmacological recommendations, and 
indicated that many HF patients do not engage in any form of regular exercise. 
[115, 116] In the TOPCAT (Treatment of Preserved Cardiac Function Heart 
Failure With an Aldosterone Antagonist Trial) trial, [117] HFpEF patients PA 
levels were subjectively assessed, by asking participants “What has the 
subject’s usual pattern of exercise been during the past 2 weeks?”, and 
calculating the product of the number of minutes, and frequency of activities per 
week for three intensity categories of activity corresponding to MET estimations 
from the Compendium of physical activities. [59] It was found that only 11% of 
patients were meeting the national recommended guidelines for PA. Those with 
poor PA levels were more likely to be female and NYHA class III, and those that 
did meet PA guidelines were less likely to have a number of comorbidities or 
risk factors including high BMI, diabetes, chronic kidney disease, and less likely 
to have a history of prior HF hospitalisation. 
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Yates et al. [118] measured PA levels of 29 HFrEF patients both objectively via 
Actiheart accelerometer and subjectively via Modified 7-day PA Recall 
Questionnaire, which has been validated in older people with cardiac problems, 
but not specifically patients with HF. [119] Based on subjective data, only 38% 
of patients met PA guidelines of 150 minutes of MVPA, but based on 
accelerometer data no patients met PA guidelines, and engaged in <1 minute of 
MVPA per day. The authors applied absolute cut-points for categorising PA 
intensity from Freedson et al. [77], which were developed in a study of healthy 
adults, and have been shown to be unsuitable for application in populations with 
low exercise capacity. [97]  
Dontje et al. measured PA levels of 68 HF patients via accelerometry using the 
SenseWear® Pro3 Armband (BodyMedia, Inc., Pittsburgh, PA), a bi-axial 
accelerometer, which has not been specifically validated for HF patients, and 
PA intensity was categorised via proprietary algorithms to calculate energy 
expenditure in Kcal. Results showed that around half performed less than 30 
minutes of moderate intensity PA per day, alongside findings that those with 
higher NYHA classes and lower self-efficacy had reduced PA levels. [120] 
Yavari et al. also measured PA levels of HF patients using the SenseWear Mini 
Armband (BodyMedia, Inc., Pittsburgh, PA), a tri-axial accelerometer, which 
also has not been validated specifically in HF patients. Again, PA intensity was 
calculated using the energy expenditure output of the accelerometer. The 
authors found that HF patients had highly sedentary lifestyles (78-79% of 
waking time) and suggested that HFpEF patients achieved virtually no 
continuous MVPA. [121] 
Most recently, Barker et al. compared accelerometer measured PA levels of 
people with chronic disease to healthy individuals of the same age, and 
reported that patients with cardiovascular disease, and HF in particular have 
low levels of PA.  However, the authors applied the same cut-points for MVPA 
to all study participants, whether healthy or living with chronic disease, which 
assumes that a moderate intensity activity for a healthy adult has the same 
energy expenditure for a patient with HF of the same age. Given the limitations 
to exercise capacity with chronic disease, including HF, this method may not be 
appropriate. [90]  
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HF patients are often elderly and the most common symptom of HF is limited 
exercise tolerance, [105] both of which are factors that have been demonstrated 
to affect energy expenditure and result in lower accelerometer thresholds for 
MVPA. Studies have shown that for HF patients the energy requirements to 
perform simple daily lifestyle activities may require a much greater percentage 
of their peak aerobic capacity, potentially leading to early onset of fatigue, early 
termination of a given activity, and an overall reduction in the volume of daily 
activity. Furthermore, it has been shown that resting metabolic rate decreases 
in HF patients with increasing NYHA class. [121, 122] 
Although HF patients may perform less PA than healthy adults of a similar age, 
the magnitude of the difference, and reports that patients perform little to no 
daily MVPA may be exaggerated by use of inappropriate PA measurement 
methods. In a systematic review that aimed to assess whether activity monitors 
were appropriately validated for use in populations with chronic diseases, Van 
Remoortel et al. [123] found most validation studies were highly heterogeneous 
and had been performed in healthy adults, with only 12% validation studies 
performed in those with chronic diseases (1 in patients with HF).  Moreover, 
common limitations amongst the studies included in this systematic review 
include small sample sizes, and inclusion of younger patients which may not be 
representative of the wider HF population. In addition, use of proprietary 
accelerometers limits comparisons across studies and accelerometer brands. At 
present, there are no accelerometer calibration studies in HF patients. 
Therefore, further studies investigating PA levels of HF patients using raw 
accelerometry, and transparent data reduction and analysis techniques that 
allow better comparison to other studies and other populations are warranted to 
improve our understanding of PA in this population. 
1.5.3 Effect of PA on HF and associated mechanisms  
Several systematic reviews and meta-analyses have clearly demonstrated the 
importance of HF patients engaging in regular exercise for health benefits 
including improvements in exercise capacity, reduced all-cause and HF-specific 
hospital admissions, and health related quality of life. [124-127] The benefits of 
PA are less well researched. Exercise training or regular PA is recommended 
by national and international guidelines and supported by a class I 
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recommendation (i.e. evidence or general agreement that the treatment or 
procedure should be performed) for HF patients who are able to participate. 
[103, 110, 128] 
Higher PA levels have been shown to be important prognostic predictors in HF 
patients. Loprinzi measured free-living PA via accelerometry of 189 patients 
who identified as having congestive HF, and found that for every 60 minute 
increase in free-living PA (which included total engagement of PA per week, i.e. 
all non-sedentary movement), HF patients had a 35% reduced risk of all-cause 
mortality (figure 1.5).[129] This was double the reduction found in the coronary 
artery disease patients of the same study where a 60 minute increase in PA 
resulted in a 16% reduced risk of all-cause mortality. [130] 
 
Figure 1.5: Kaplan-Meier all-cause mortality survival curve across PA level 
above or below 250 min/week total PA (light-to-vigorous intensity). Reproduced 
from Loprinzi [129]. 
 
In the TOPCAT trial of HFpEF patients, PA levels lower than the national 
recommendations was associated with a greater risk of HF hospitalisation (HR, 
1.93; 95% CI, 1.16–3.22), cardiovascular mortality (HR, 4.36; 95% CI, 1.37–
13.83), and all-cause mortality (HR, 2.95; 95% CI, 1.44–6.02) after adjustment 
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for potential confounders. [117] Similarly, Cacciatore et al. showed that self-
reported PA levels of patients with advanced HF (NYHA IIIb) is a predictor of 
mortality, regardless of comorbidities, disability and physical function. [131] 
Daily PA levels have also been shown to have strong associations with exercise 
capacity, rehospitalisation, clinical prognosis, NYHA class, along with burden of 
comorbidities, health related quality of life, depression and sleep apnoea in HF 
patients. [132-136] Lee et al. [137] showed that maintaining PA is a key 
component alongside improving functional status and enhancing exercise self-
efficacy for maintaining and improving health related quality of life and 
independence in HF patients, which HF patients express preference for, over 
length of life. [116] 
There are a number of mechanisms by which PA can be beneficial to health in 
HF patients, including cardiac, cognitive, vascular and cardiovascular disease 
risk factors, summarised below in figure 1.6. [32, 138-140] The mechanisms for 
benefits of PA in patients with HFpEF are less well established. However, 
researchers have proposed the following potential explanations; reduced left 
ventricular filling pressures, less diastolic stiffness and favourable left ventricular 
structure and function. [141] 
 
Figure 1.6: Mechanisms for PA benefits to health in patients with HF. Adapted 




Current understanding about the relationship between PA and HF outcomes is 
mostly based on self-reported PA measures, or studies that have 
inappropriately applied accelerometer data analysis methods based on studies 
of healthy young adults, which could impact upon the strength of associations 
seen. For example, Loprinzi et al. demonstrated that application of different 
accelerometer cut-points for MVPA influenced estimates for associations 
between PA and health outcomes such as obesity, high C-reactive protein 
levels and low high-density lipoprotein levels. [142] More precise, population 
specific measurement of PA in HF patients should enable aetiological, 
epidemiological and observational studies to confirm, clarify and better 
understand the relationships between PA and health benefits in this challenging 
population. 
 
1.5.4 Impact of exercise-based CR in HF on PA 
CR is a complex intervention defined by the BACPR as “The coordinated sum 
of activities required to influence favourably the underlying cause of 
cardiovascular disease, as well as to provide the best possible physical, mental 
and social conditions, so that the patients may, by their own efforts, preserve or 
resume optimal functioning in their community and through improved health 
behaviour, slow or reverse progression of disease”. [10] It comprises 
components of health education with advice on cardiovascular risk reduction, 
psychosocial care and stress management alongside structured exercise. [10, 
143] 
Considerable evidence exists in support of CR for HF patients, and it is now 
recommended in international guidelines for HF management, with a class IIa 
recommendation (i.e. evidence or opinion that it is reasonable to perform the 
treatment or procedure).[103, 104, 128, 144, 145] Recent trial level and 
individual patient level meta-analyses have shown CR has significant benefits 
for HF patients. Pooled data from 44 randomised trials showed exercise-based 
CR reduces overall hospital admissions (relative risk RR 0.70, 95% CI 0.60 to 
0.83, p=0.0001), and HF-specific hospitalisation (RR 0.59, 95% CI 0.42 to 0.84, 
p=0.003). CR also showed potentially clinically important improvements in 
HRQoL up to 12 months follow-up (standardised mean difference -0.60, 95% CI 
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-0.82 to -0.39, p<0.0001). [124] In a recent individual patient data meta-
analysis, participation in CR resulted in improvements in exercise capacity, 
measured via 6-min walk test (mean 21.0m, 95% CI 1.57 to 40.4m, p=0.034) 
and Minnesota Living with HF score (mean improvement 5.9; 95% CI 1.0 to 
10.9, p=0.018). [127] 
Traditionally, CR programmes have prioritised increasing exercise capacity or 
fitness as a priority, rather than increasing overall PA levels. Whilst it is 
established that CR can improve exercise capacity with programmes as short 
as 4 weeks, an increase in PA requires a more profound change in behaviour of 
the patients as improvements in exercise capacity do not necessarily result in a 
more active lifestyle. [146] Patients report that adherence to exercise 
recommendations are more difficult than other behavioural changes required for 
HF including smoking and alcohol cessation, medication, and follow-up 
appointments. [147] Two systematic reviews investigating the effect of CR on 
PA in CHD patients have been previously conducted in 1998 and 2015 and both 
concluded that there was insufficient evidence of CR impacting PA levels of 
patients. [148, 149] Neither of these studies included HF patients, nor did they 
attempt meta-analysis. Therefore the impact of CR on PA of HF patients 
remains uncertain. 
Ideally, CR interventions should lead to long-term, maintained lifestyle change, 
with both improved exercise capacity and PA level, resulting in better HRQoL at 
a cost that represents good value for the NHS. [150] However, Ramadi et al. 
[151] found that although patients maintained exercise capacity improvements 6 
months post-CR, many patients failed to maintain PA levels post-CR, with 
MVPA and sedentary time comparable to pre-CR levels. Other studies have 
also indicated the need for CR interventions that successfully increase PA 
levels and reduce sedentary time, and maintain these healthy lifestyle changes 
in the long-term post-intervention. [152-153] The potential reasons for these 
findings have not been explored in the literature, therefore it is unclear whether 
it may be due to poor PA measurement methods in this population, or due to 
behavioural changes. With a lack of gold standard PA measurement, data 
processing, analysis and reporting methods, PA outcomes previously reported 
in CR trials are often confusing, not suitable for comparison and not necessarily 
measuring PA behaviour change. Many studies have relied on self-reported 
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measures of PA, and where accelerometers have been used researchers have 
applied inappropriate accelerometer cut-points, both of which risk misclassifying 
PA levels of HF patients, and makes it difficult to tease out small changes in PA 
levels. Furthermore, single, aggregated measures of PA such as weekly MVPA 
levels may mask important patterns of change in PA data. For example, an 
observational study in older adults showed that an aerobic exercise training 
program resulted in an increase in exercise capacity, but PA increases were 
offset by a compensatory decline in PA outside the training programme. [154] 
Therefore, improvements in PA measurement in HF patients, using population 
appropriate cut-points to determine PA intensity, and looking beyond a single 
measure of PA may help to provide better understanding of how CR 
interventions work.  
 
1.5.5 REACH-HF research programme 
Despite the strong evidence base for CR in HF, uptake remains poor, in the UK 
less than 20% of patients are offered CR post-discharge after HF diagnosis, 
and less than 5% attend at least one CR session. [104] Similar statistics 
demonstrating suboptimal rates of uptake are true across Europe and the US. 
[155, 156] Reasons for this underutilisation of CR in HF patients include lack of 
endorsement by physicians, which may be due to their perceived benefit of CR. 
[157] Other barriers to participation in and referral to CR include patient 
demographics such as age, lower socioeconomic status, distance to travel, and 
burden of comorbidities. [155-157] Therefore strategies are required to increase 
CR participation to ensure HF patients are accessing this important treatment 
for secondary prevention. Alternative models for CR such as telehealth, 
community- or home-based interventions have been shown to produce similar 
reductions in cardiovascular risk factors, with similar costs after myocardial 
infarction and coronary revascularisation, and may provide a different approach 
to widen participation in CR for HF patients. [158, 159] 
Rehabilitation Enablement in Chronic Heart Failure (REACH-HF) is a National 
Institute for Health Research (NIHR) funded research programme with the aim 
of developing and evaluating a health professional facilitated home-based self-
help manual CR intervention to improve self-care and HRQoL in people with HF 
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and their caregivers. [160, 161] It was developed with involvement of a local 
Patient and Public Involvement group consisting of HF patients and caregivers 
of people with HF. [162] Within the REACH-HF research programme there are 
two completed RCTs (both comparing REACH HF intervention (HF manual, 
Chair based exercise DVD, Caregiver resource and Progress tracker) plus 
usual care to usual care alone) – a full multicentre RCT in 216 patients (mean 
age 70 years, 22% female) with HFrEF with 12-months follow-up, [163] and a 
single centre pilot trial in 50 patients (mean age 73.9 years, 54% female) with 
HFpEF with 6-months follow-up. [164] In addition to a number of other 
outcomes these two trials collected 7-day raw accelerometry measured PA in all 
patients at baseline and follow-up time points. 
The findings of the pilot study support the acceptability of the REACH-HF 
intervention, and emerging evidence of the impact of exercise-based CR 
interventions in patients with HFpEF. Although the pilot study was not 
statistically powered to definitively assess the efficacy of the REACH-HF 
intervention, results were promising with a number of favourable patient 
outcomes including disease-specific HRQoL.  
The results of the full RCT in HFrEF patients showed clinically important 
improvements in disease specific HRQoL at 12 months follow-up with the 
REACH-HF intervention compared to usual care alone. REACH-HF was also 
associated with improved ratings of self-care maintenance, indicating greater 
engagement in activities such as monitoring weight and fluid retention, 
engaging in exercise and using a system to remember medication. However, no 
differences were seen in other secondary outcomes including accelerometer 
measured PA. Average daily PA outcomes reported utilised mg values for 
sedentary activities and MVPA based on healthy adults, therefore application of 




Lack of PA is a well-accepted risk factor of ill health in the general population. 
Maintenance of adequate PA is also a key recommendation for many chronic 
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disease populations, including HF. Although, often assessed in the past in 
larger population studies using self-report, a number of methods (including 
accelerometry) are now available to objectively assess PA levels. These 
methods have their relative pros and cons. PA measurement is complex across 
all populations, and as evidence shows, PA measurement in the elderly, and 
chronic disease populations involves additional challenges. In particular, 
accelerometer data reduction and analysis techniques such as cut-point and 
calibration studies that are based on samples of young healthy adults are likely 
to be inappropriate for use in HF populations, and may result in 
misinterpretation, misclassification or underestimation of PA levels of HF 
patients. 
To date, there has only been a small body of research on objectively assessed 
PA in HF patients. Well conducted studies, using improved, population specific 
PA assessment techniques are therefore needed to understand and clarify the 
PA patterns of this population, and the relationships between PA levels and 
patient level characteristics i.e. sociodemographics, exercise capacity and 
quality of life. A substantive body of RCT evidence shows that participation in 
exercise-based CR improves exercise capacity and HRQoL, and reduces risk of 
hospital admissions in people with HF. However, the impact of exercise-based 
CR on PA levels in HF remains uncertain. 
PA measurement in HF patients is under researched, and further work is 
needed to improve PA measurement methods, and understanding of PA levels 
in this population, and how exercise-based CR interventions can impact upon 
these levels.  
 
1.7 Aims of the thesis 
The overarching aim of this thesis is to contribute to the further knowledge and 
understanding on PA in people with HF and how exercise-based CR can impact 
this.  
The specific aims were to:  
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(1) Undertake a systematic review to assess the evidence as to whether 
participation in exercise-based CR increases PA levels of cardiac 
patients, including those with HF (Chapter 2), 
(2) Undertake an accelerometer calibration study and develop HF specific 
accelerometer intensity thresholds for MVPA and inactivity (Chapter 3),  
(3) Examine the PA levels of HF patients, and associations between 
baseline PA and patient-level factors including sociodemographics, 
exercise capacity, and HRQoL (Chapter 4), 
(4) Determine whether a home-based, self-help CR intervention improves 
PA levels of people with HF, and the sociodemographic, exercise 
capacity and HRQoL factors are associated with a change in PA level 
(chapter 5). 
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To undertake a systematic review and meta-analysis to assess the impact of 
cardiac rehabilitation (CR) on physical activity (PA) levels of patients with heart 
disease and the methodological quality of these studies.  
Methods 
Databases (MEDLINE, EMBASE, CENTRAL, CINAHL, PsychINFO and 
SportDiscus) were searched without language restriction from inception to 
January 2017 for randomised controlled trials (RCTs) comparing CR to usual 
care control in adults with heart failure or coronary heart disease (CHD) and 
measuring PA subjectively or objectively. The direction of PA difference 
between CR and control was summarised using vote counting (i.e. counting the 
positive, negative and non-significant results) and meta-analysis.  
Results 
Forty RCTs, (6480 patients: 5825 CHD, 655 HF) were included with 26% 
(38/145) PA results showing a statistically significant improvement in PA levels 
with CR compared to control. This pattern of results appeared consistent 
regardless of type of CR intervention (comprehensive vs. exercise-only) or PA 
measurement (objective vs. subjective). Meta-analysis showed PA increases in 
the metrics of steps/day (1423, 95% CI 757.07 to 2089.43, p<0.0001) and 
proportion of patients categorised as physically active (relative risk 1.55, 95% CI 
1.19 to 2.02, p=0.001). The included trials were at high risk of bias, and the 
quality of the PA assessment and reporting was relatively poor. 
Conclusion 
Overall, there is moderate evidence of an increase in PA with CR participation 
compared to control. High quality trials are required, with robust PA 
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measurement and data analysis methods, to assess if CR definitely leads to 
important improvements in PA. 
 
2.2 Introduction  
Physical activity (PA) is defined as any bodily movement produced by skeletal 
muscles resulting in energy expenditure beyond resting expenditure. [1] The 
current UK recommendation for PA in adults and older adults is ≥150 min of 
moderate intensity PA per week. [2] This is based on a number of systematic 
reviews and consensus statement, consistently identifying 150 min/week as 
providing considerable health benefits, including reduced all-cause mortality, 
reduced risk factors for chronic diseases, improved cardiovascular fitness and 
quality of life. [2, 3] This is also the standard PA recommendation for patients 
with cardiac disease by the British Association for Cardiovascular Prevention 
and Rehabilitation and the Scottish Intercollegiate Guidelines Network. [4, 5] 
The benefits of cardiac rehabilitation (CR) participation for those with coronary 
heart disease (CHD) and heart failure (HF) are well established and include 
reduced cardiovascular mortality, reduced risk of hospital admissions, improved 
exercise capacity and health-related quality of life. [6, 7] A key aim of CR is to 
increase total daily energy expenditure in addition to exercise capacity. [2] 
However, previous observational studies demonstrated that many patients with 
heart disease (pre-CR and post-CR) are failing to meet recommended daily PA 
levels [8, 9] and the extent that CR impacts on PA levels of patients remains 
unclear. 
While two systematic reviews to date have indicated inadequate evidence of an 
impact of CR participation on PA levels of patients with CHD, [10, 11] these 
studies have limitations. Neither included studies involving patients with HF nor 
attempted meta-analysis due to the heterogeneity of CR interventions. 
Therefore, an updated systematic review with an improved search strategy and 
broader population inclusion criteria is justified. 
The aim of this systematic review and meta-analysis of randomised controlled 
trials (RCTs) was twofold. First, to clarify the impact of CR participation on PA 
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levels of patients with CHD and HF. Second, to review the methodological 
quality of PA outcomes reported in these trials. 
 
2.3 Methods 
The protocol was registered on PROSPERO (CRD42017055137). We 
conducted and report this systematic review in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-analyse statement. [12] 
2.3.1 Search strategy and inclusion criteria 
Details of the search strategy and inclusion criteria are provided in appendix 
2.1. The full search strategy is provided in appendix 2.2. 
2.3.2 Data extraction and risk of bias assessment 
A standardised data extraction form was used to extract study characteristics, 
patient characteristics, intervention and control details, PA measurement 
method and outcome data at all follow-up time points. Multiple publications of 
the same study were assessed for additional data and presented as a single 
RCT (appendix 2.3). 
The Cochrane Collaboration’s tool for assessing risk of bias was used to assess 
the quality of included studies.[13] Data extraction and risk of bias assessment 
were initially completed by a single reviewer (GD) and then checked for 
accuracy by one other reviewer (MH, HD or RST). Disagreement was resolved 
by discussion. 
2.3.3 Data synthesis and meta-analysis 
Due to the wide range of PA metrics reported across studies, we first 
summarised the direction of PA results using a vote counting approach [13] 
(quantifying studies on the basis of their positive, negative or non-significant 
results). Given the wide range of PA measures, we decided against using 
standardised effect size for meta-analysis and instead conducted meta-analysis 
where two or more studies reported the same units of PA measurement. Meta-
analysis was completed on all follow-up time points apart from one outcome 
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measure (proportion of patients categorised as physically active) where there 
was sufficient data to separate into short-term (≤12 months post-CR) and long-
term (>12 months post-CR) follow-up. 
Given the clinical heterogeneity of the included studies, random-effects models 
were used to pool data. Statistical heterogeneity was assessed using the I2 
statistic. Binary outcomes for each study were pooled as relative risks (RR) and 
continuous outcomes as mean differences (MD). Meta-analysis results were 
reported as means and 95% CIs. A two-tailed p value of ≤0.05 was considered 
statistically significant. Analyses were performed in Review Manager (RevMan 
V.5.3, The Cochrane Collaboration) or Stata V.14. 
We explored the effect of various potential treatment effect modifiers by 
stratifying the vote counting results, that is, setting of CR (centre vs home 
based), patient group (CHD vs HF), publication date (pre-1990, representing the 
time of major changes in drug and device management of CHD and HF), dose 
of exercise intervention (dose=number of weeks of exercise training×average 
sessions/week×average duration of session in minutes. Dose ≥2000 units 
(median) vs dose <2000 units); objective versus subjective PA measures and 
method of PA statistical analysis. Studies lacking enough information to 
calculate dose were omitted from the analysis. 
 
2.4 Results 
2.4.1 Study selection 
Figure 2.1 summarises the screening process resulting in 47 publications 





Figure 2.1: Preferred Reporting Items for Systematic Reviews and Meta-
analyses flow chart of search process. 
 
2.4.2 Characteristics of included studies 
The 40 RCTs, all published in English, included a total of 6480 patients with 
cardiac disease (5825 CHD, 655 HF). A summary of study characteristics is 





Table 2.1: Summary of study characteristics 
Characteristic Number of studies 
(%) or Median (range) 
Multicentre RCT 10 (25) 
Exercise only 17 (42.5) 
CR location  
Home-based 10 (25) 
Centre-based 23 (57.5) 
Both 7 (17.5) 
Sample size 89.5 (19-1813) 
<50 10 (25) 
51-100 14 (35) 
>100 16 (40) 
Publication date  
1970-1979 1 (2.5) 
1980-1989 5 (12.5) 
1990-1999 12 (30) 
2000-2009 10 (25) 
2010-2017 12 (30) 
Study location  
Europe 25 (62.5) 
North America 10 (25) 
Asia/Australia 5 (12.5) 
Sex  
Male only 6 (15) 
Female only 1 (2.5) 
Both 32 (80) 
Not reported 1 (2.5) 
Age (years)* 58.3 (47-81) 
Diagnosis  
CHD 28 (70) 
HF 10 (25) 
Both 2 (5) 
Follow up (months) 12 (1.5-120) 
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* Median of study means 
 
2.4.3 PA measures reported 
In total, 28 studies measured PA using subjective approaches, 10 studies used 
objective methods and two studies used a combination of both. Across all 
studies, 45 different PA metrics were used (median 1.5, range 1–10). Details of 
individual study PA measurement methods including a summary is presented in 
appendix 2.5. 
2.4.4 Risk of bias assessment 
Risk of bias assessments for each study are summarised in figure 2.2. All 
studies were assigned high risk in blinding of participants and personnel due to 
the nature of CR. The most prevalent methodological issues were non-
adequate description of randomisation (25/40, 62.5%), allocation concealment 
(27/40, 67.5%) and blinding of PA outcome assessment (26/40, 65%). There 
was high risk of bias in 50% (20/40) trials for incomplete outcome data. Most 
trials were low risk for selective reporting (33/40, 82.5%), balanced groups at 





Figure 2.2: Quality appraisal. + (green), low risk of bias; ? (yellow), unclear risk 
of bias; − (red), high risk of bias. [40-59] 
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2.4.5 Impact of CR participation on PA levels 
Vote counting 
A total of 145 CR versus control PA comparisons were reported across all 
studies (appendix 2.6). Overall, 26% of results showed a statistically significant 
improvement in PA with CR (table 2.2). 
 
Table 2.2: Vote counting 
Direction of result  Number of results (%)    
PA in CR same as control (P>0.05) 100 (69%) 
PA in CR higher than control (P≤0.05) 38 (26%) 
PA in control higher than CR (P≤0.05) 2 (1%) 
PA difference between CR and control not clear 





The pattern of results was similar whether PA measurement was objective or 
subjective (appendix 2.7). The statistical methods used across the studies were 
varied. The majority reported a p value for between-group differences. 
Comparing the direction of results by statistical method showed a greater 
number of positive results reported when the p value for interaction time×group 
was used (appendix 2.8). As numbers were small, this is unlikely to be of 
significance. 
There was a higher proportion of non-significant results (86% vs 63%) and 
fewer positive results (10% vs 32%) in studies including patients with HF 
compared with studies with CHD (appendix 2.9). Removing the results from 
studies conducted prior to 1990 or those based on exercise frequency did not 






Table 2.3 shows an increased number of positive results with home-based CR 
interventions compared with centre-based interventions. Studies with a higher 
exercise dose also produced a slightly increased number of positive results 
compared with studies with a lower exercise dose (appendix 2.11). The pattern 
of results was similar when comparing studies of comprehensive CR to 
exercise-only CR studies (appendix 2.12). 
Table 2.3: vote counting – comparing centre based cardiac rehabilitation (CR) 




Five studies used mean steps/day as a measure of PA assessed by either 
pedometer [14–16] or accelerometer. [17, 18] Pooling results across studies 
showed compared with control, CR participation was associated with an 
 Number of results 








home based or 
RCT included 
both 
PA in CR same as 
control (P>0.05) 
 63 (77%) 22 (51%) 15 (75%) 
PA in CR higher than 
control (P≤0.05) 
15 (18%) 19 (44%) 4 (20%) 
PA in control higher 
than CR (P≤0.05) 
1 (1%) 0 1 (5%) 
PA difference 
between CR and 
control not clear (no 
P-value reported) 
3 (4%) 2 (5%) 0 
Total 82 43 20 
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increase in mean steps/day (1423, 95% CI 757.07 to 2089.43, p<0.0001; figure 
2.3) at short-term follow-up (median 3, range 1.5–12 months). With no evidence 
of statistical heterogeneity (I2=0%, p=0.845). 
 
 
Figure 2.3: Impact of cardiac rehabilitation on mean steps/day at short-term 
follow-up (median 3 months, range 1.5–12 months). CR, cardiac rehabilitation, 
PA, physical activity; WMD, weighted mean difference. 
 
Energy expenditure 
Energy expenditure (kcal/week) was estimated via questionnaire in three 
studies (median follow-up time 12 months, range 32 weeks–72 months). [19–
21] Meta-analysis showed that CR participation was associated with an 
increase in energy expenditure compared with control (878.4, 95% CI 433.83 to 
1323.01, p=0.0001). Test for statistical heterogeneity was significant (I2=70%, 
p=0.04). 
Sedentary time, light PA and moderate–vigorous PA (min/day) 
There was no impact on mean min/day spent sedentary or sitting between CR 
and control (−10.9, 95% CI −39.02 to 17.20, p=0.45; figure 2.4A) based on two 
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studies estimating this objectively via accelerometer [14, 18] and subjectively 
via International Physical Activity Questionnaire (IPAQ), [22] at 9 weeks follow-
up (median, range 6–12 weeks). There was no evidence of a difference in mean 
min/day spent in light intensity PA in CR compared with control (−6.6, 95% CI 
−45.09 to 31.92, p=0.74; figure 2.4B) based on two studies reporting this 
outcome via accelerometer [23] and IPAQ, [22] at 9.5 weeks follow-up (median, 
range 9–10 weeks). There was no difference in mean min/day spent in 
moderate–vigorous PA in CR compared with control (8.5, 95% CI −1.44 to 
18.44, p=0.09; figure 2.4C), measured via accelerometer [18, 23] and IPAQ, 
[22] at 9 weeks follow-up (median, range 6–10 weeks). 
 
 
Figure 2.4: Impact of cardiac rehabilitation on (A) min/day spent sedentary or 
sitting; (B) min/day spent in light intensity PA and (C) min/day spent in 
moderate–vigorous PA.  
 
Proportion of patients categorised as physically active (short-term follow-up ≤12 
months) 
CR increased the proportion of patients categorised as ‘physically active’, 
measured at short-term follow-up (median 6 months, range 0–12 months) 
across nine studies (RR 1.55, 95% CI 1.19 to 2.02, p=0.001; figure 2.5A). There 
was evidence of substantial statistical heterogeneity (I2=87%, p<0.00001). The 
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definition of ‘physically active’ varied across studies: that is, exercise frequency 
≥3×/week, [24] exercising ≥3×/week for 20 min, [25, 26] exercising 
>100 kcal/day, [27] average daily steps >7500,15 exercising for >1 hour/week, 
[28] regularly training (defined as either walking or cycling ≥30 min daily, sport 
activities once weekly or vigorous physical training) [29] and two studies did not 
provide any definition. [30, 31] 
 
 
Figure 2.5: Impact of cardiac rehabilitation on proportion of patients categorised 
as physically active measured at (A) short-term follow-up (≤12 months) and (B) 
long-term follow-up (>12 months).  
 
Proportion of patients categorised as physically active (long-term follow-up >12 
months) 
CR increased the proportion of patients considered physically active, measured 
at long-term follow-up (median 5 years, range 2–5 years) in three studies [28, 
30, 31] (RR 1.48, 95% CI 1.19 to 1.83, p=0.0003; figure 2.5B) with no evidence 
of statistical heterogeneity (I2=0.0%, p=0.96). 
Proportion of patients categorised as sedentary or not physically active 
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Five studies reported the proportion of patients considered sedentary, [29] 
exercising <4 hours per week [32] or undertaking no exercise, [24, 28, 33] at 12 
months (median, range 12–24 months) follow-up. There was a reduction in CR 
participants categorised as sedentary or not physically active (RR 0.76, 95% CI 




This systematic review of RCTs shows moderate evidence of an increase in PA 
with CR participation with 26% (38/145) of comparisons reporting a statistically 
significant result in favour of CR compared with control. This pattern of results 
appear consistent regardless of whether studies assessed PA using subjective 
or objective methods, or the CR intervention was comprehensive or exercise 
only. Studies involving patients with HF appeared less likely to have positive 
results in favour of CR. There was an increased proportion of positive results 
with higher doses of CR suggesting that higher doses of exercise training may 
be more effective in improving PA levels. Similarly, results suggest that home-
based interventions may be more effective in improving PA levels. 
Meta-analyses showed that CR participation compared with control is 
associated with an increase in some PA outcomes: steps/day at short-term 
follow-up, energy expenditure (kcal/week) at short-term follow-up, proportion of 
patients categorised as physically active both at short-term and long-term 
follow-up and reduced proportion of patients categorised sedentary or not 
physically active at short-term follow-up. CR was not shown to have a 
significant impact on minutes/day spent sedentary or in light or moderate-
vigorous PA at short-term follow-up. 
It remains uncertain if the mean increase of 1423 steps/day that we observed 
with CR is clinically meaningful. In patients with chronic obstructive pulmonary 
disease undergoing rehabilitation, the minimal clinically important difference 
(MCID) was calculated to lie between 600 and 1100 steps/day and resulted in a 
reduction in hospital admissions. [34] However, we know of no published MCID 
for patients with CHD or HF. 
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We believe there are two potential reasons why we saw improvements in some 
outcomes, but not others. First, categorising continuous PA data to PA 
categories (eg, sedentary, light moderate or vigorous) may have resulted in a 
loss of sensitivity to change. Second, some studies may have been susceptible 
to measurement bias as they used subjective PA measures. 
2.5.1 Comparison of findings to previous studies 
Our results build on previous systematic reviews [10, 11] that found some 
evidence to indicate that CR positively impacts on PA in patients with CHD, but 
little evidence in long term and recommended CR programmes place more 
emphasis on improving the long-term PA levels of patients. [10] Ter Hoeve et al 
concluded that centre-based CR was not sufficient to improve and maintain PA 
levels and suggested home-based CR programmes may be more successful; 
however, literature is limited in this area. [11] In accord with recent Cochrane 
systematic reviews of CR, [9, 10] the participating patients were relatively young 
(<60 years), predominantly male, with large differences in the programme 
location, duration, intensity, modality and length of follow-up. 
2.5.2 Strengths and limitations 
We believe this to be the first meta-analysis to assess the impact of CR on PA 
levels of patients with both CHD and HF. Strengths of this review include 
extensive literature searches, use of RCTs and inclusion of both subjective and 
objective PA assessment. Compared with the previous systematic reviews, we 
identified an additional 23 RCTs (2432 additional patients), 10 of which 
specifically involved patients with HF (655 patients). 
However, this review has limitations. With the wide range of PA outcomes 
reported across the studies, at various follow-up time points, we were limited in 
the extent of meta-analysis we were able to complete. That only small numbers 
of studies were suitable for inclusion in the meta-analysis, limits our ability to 
draw firm conclusions from these pooled results. Vote counting was done to 
give a quantitative overview of the results. However, this method has limitations: 
(1) large and small studies carry the same weight, (2) studies reporting multiple 
PA outcome results contribute more weight and (3) results from multiple 
outcomes within study may not be independent. Furthermore, judgements by 
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the authors on levels of PA were not based on national recommendations, 
leading to uncertainty about the clinical meaningfulness of PA improvements. 
Key issues raised in risk of bias assessments were insufficiently described 
randomisation and allocation concealment procedures, leading to difficulty 
rating the quality of the RCTs. Additionally, 65% of studies had unclear risk of 
bias with regard to blinding of outcome assessment. This is particularly 
important in PA measurement since awareness of being assessed may cause 
both the intervention and control group patients to alter their behaviour and 
increase their PA on assessment days, potentially introducing bias to results. 
Small study numbers meant we were unable to generate a funnel plot to assess 
potential publication bias. 
There were numerous limitations in approaches studies took to assessing PA. 
Where questionnaires were used, few had been evidently validated for use in 
cardiac populations. Self-report commonly considered the frequency of exercise 
sessions undertaken as opposed to overall PA per se. Self-reported measures 
of PA are less valid and reliable than direct measures in patients with CR, 
generally overestimating PA and relying on patient recall. [35] Despite 
accelerometers being the most commonly used objective PA measurement 
method, a variety of devices were used, with sensors placed at different body 
sites, and a wide range of outcome metrics reported across studies, limiting the 
ability to meta-analyse these data. Additionally, data handling methods were 
poorly reported; no studies adequately explained the minimum wear time 
requirement for inclusion in data analysis or data reduction techniques. Where 
accelerometer thresholds were used to estimate intensity, they were derived 
from studies in young, healthy adults which may mean the PA level is 
underestimated in patients with cardiac disease. [36] Resting metabolic rate in 
patients with cardiac disease has been previously demonstrated to be 
significantly lower (23%–36%) than the typically utilised value of 3.5 mL/kg/min, 
[37] which may have implications in underestimating energy expenditure during 
higher intensity activities. Therefore, researchers should consider using 
thresholds specifically established for patients with cardiac disease. 
There was inconsistency in statistical methods used across the studies. 
Baseline adjusted regression methods are recommended for analysis of RCTs. 
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[38] However, only 35% reported a p value that took the baseline PA level into 
account. Although many studies showed between group differences in fitness 
outcomes, 26% of results demonstrated a statistically significant difference in 
PA outcomes. This is likely because individual studies were often small and 
underpowered to detect small differences in PA. Only 13 (32%) of the included 
studies included formal sample size calculations and of these only 4 (31%) were 
based on PA outcomes. 
2.5.3 Implications for clinical practice and future research 
That our results showed no difference in PA outcomes in studies that employed 
comprehensive CR compared with exercise-only CR suggest that 
improvements in PA with CR are the result of exercise training rather than 
components of education and psychosocial interventions. Improved reporting of 
adherence and intervention fidelity would provide useful information to further 
understand the efficacy of comprehensive CR intervention components. 
Additionally, improvement in exercise capacity may not be directly related to 
increases in PA levels. CR programmes should consider supplementing their 
existing exercise-training intervention with interventions that specifically aim to 
increase PA level. For example, the ongoing PATHway I trial, where the basis 
of the CR intervention is PA promotion and the primary outcome is objectively 
measured PA level. [39] 
Further research is required to validate interventions that promote PA in cardiac 
populations. Furthermore, objective measurement of PA requires population-
specific calibration studies to establish intensity thresholds. The use of 
inconsistent PA measures and units made formal pooling of data problematic. 
We therefore recommend that future studies use objective measures of PA 
such as accelerometers, be statistically powered to detect small differences in 
PA, use appropriate data handling and analysis methods, and PA outcomes are 
reported in relation to national PA recommendations. Studies should assess PA 





This systematic review and meta-analysis provides moderate evidence of an 
increase in PA with CR participation compared with control. However, the 
included trials were at risk of bias, and the quality of PA assessment and 
reporting was relatively poor. It is unclear whether increases in PA with CR are 
clinically meaningful. Further high-quality trials are required to assess if CR 
leads to important improvements in PA, such as the UK recommended target of 
150 min of moderate intensity PA per week, especially in long term. 
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International guidelines for physical activity (PA) recommend at least 150 
minutes per week of moderate-to-vigorous PA (MVPA). There is yet to be 
consensus on the most appropriate way to categorise raw accelerometer data 
into behaviourally relevant metrics such as intensity, especially in chronic 
disease populations.  Therefore the aim of this study was to estimate 
acceleration values corresponding to inactivity and MVPA during daily living 
activities of patients with heart failure (HF), via calibration with oxygen 
consumption (VO2) and to compare these values to previously published PA 
intensity thresholds.   
Methods 
Twenty-one adults with HF (mean age 71±14 years) undertook a range of daily 
living activities (including laying down, sitting, standing and walking) whilst 
measuring PA via wrist- and hip-worn accelerometers and VO2 via indirect 
calorimetry. Raw accelerometer output was used to compute PA in units of 
milligravity (mg). Energy expenditure across each of the activities was 
converted into measured METS (VO2/resting metabolic rate) and standard 
METS (VO2/3.5 ml/kg/min). PA energy costs were also compared with 
predicted METS in the compendium of physical activities. Location specific 
activity intensity thresholds were established via multilevel mixed effects linear 
regression and receiver operator characteristic curve analysis. A leave-one-out 
method was used to cross-validate the thresholds. 
Results 
Accelerometer values corresponding with intensity thresholds for inactivity 
(<1.5METS) and MVPA (≥3.0METS) were >50% lower than previously 
published intensity thresholds for both wrists and waist accelerometers 
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(inactivity: 16.7 to 18.6mg versus 45.8mg; MVPA: 43.1 to 49.0 mg versus 93.2 
to 100 mg). Measured METS were higher than both standard METS (34-35%) 
and predicted METS (45-105%) across all standing and walking activities.  
Conclusion 
HF specific accelerometer inactivity and MVPA intensity thresholds are lower 
than previously published thresholds based on healthy adults, due to lower 
resting metabolic rate and greater energy expenditure during daily living 
activities for HF patients. 
 
3.2 Background 
Accurate monitoring of physical activity (PA) is increasingly important as 
exemplified by PA being a stated a key target in the lifestyle recommendations 
to heart failure (HF) patients. [1] Progressively, clinical trials are relying on 
accelerometers to objectively measure PA to investigate the relationship 
between PA and HF disease progression, [2] or to evaluate the effect of a PA or 
exercise programme in primary or secondary prevention in HF. [3] However, 
there is yet to be consensus on the most appropriate way to convert raw 
acceleration data into behaviourally relevant metrics, particularly in chronic 
disease populations.  
International PA recommendations for public health and cardiac patients are 
based on time spent in moderate-to-vigorous PA (MVPA). In order to derive this 
information from accelerometers, the raw data must be categorised into levels 
of intensity using thresholds or cut-points derived from calibration studies. 
Previous studies in HF patients have tended to use proprietary outcomes, 
‘activity counts’, and/or applied previously published intensity thresholds to 
express time spent in MVPA. [4-8] These proprietary outcomes and thresholds 
are typically based on calibration studies in young, healthy individuals. Applying 
these thresholds to HF patients assumes the energy cost for a given activity is 
the same for everyone, which may lead researchers to underestimate PA levels 
of people with HF due to the lack of consideration for an individual’s exercise 
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tolerance. [9] Therefore recent publications have called for population specific 
calibration studies. [9,10] 
We conducted a laboratory-based calibration study to estimate acceleration 
values for hip- and wrist-worn accelerometers corresponding to inactivity and 
MVPA in patients with HF, by calibrating with oxygen consumption (VO2) and 




A sample of 22 adults with HF were recruited from the Royal Devon and Exeter 
NHS Foundation Trust between March 2018 and October 2018. Inclusion 
criteria were adult (≥18 years) outpatients with a diagnosis of HF confirmed by a 
hospital specialist, New York Heart Association (NYHA) class I to III symptoms, 
who were able to give informed consent. Exclusions were: acute 
decompensated HF, contraindication to exercise testing or PA, resident in a 
long term care facility, unwilling or unable to travel to the research site, patients 
unable to understand the study information, and judged unable to participate for 
any other reason.  
The study protocol conforms to the 1975 Declaration of Helsinki, ethical 
approval was granted by Cambridge South Research Ethics Committee 
(18/EE/0019), and the trial registration ID is: NCT03659877. Participants gave 
informed consent prior to data being collected.  
3.3.2 Activities 
Participants attended the sports science laboratory at University of Exeter St 
Luke’s campus in the UK. They were asked to not eat or drink caffeinated or 
calorie containing foods or drinks prior to the visit which was scheduled in the 
morning, and instructed to take their medication as normal. The laboratory 
protocol consisted of a series of activities (listed in order of completion below), 
chosen based on previous calibration studies [7-8,11] and to be representative 
of daily living activities for HF patients, selected with the help of a local HF 
patient and public involvement group.  
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- Laying down on a bed for 30 minutes,  
- Sitting on the bed for 5 minutes, 
- Incremental shuttle walk test (ISWT) performed until stopping criteria 
met, [12-13] 
- Sitting watching TV for 5 minutes, 
- Standing washing & drying dishes for 5 minutes, 
- Sitting quietly for 5 minutes, 
- Walking at a pace perceived to be light for 3-5 minutes, 
- Walking at a pace perceived to be moderate for 3-5 minutes, 
- Light pace walk carrying 2x1.5kg shopping bags for 3-5 minutes.  
Resting metabolic rate (RMR) was measured during minutes 10-20 of a 30 
minute period laying down in low- or semi-Fowler’s position (as per patient 
preference). [14] Breakfast was then provided prior to any physical activities 
being performed. ISWT was performed to measure exercise capacity and 
gauge rating of perceived exertion (RPE) over the completed stages, which 
informed the light (RPE 11) and moderate (RPE 13) walking paces.  
Standardised instructions were given prior to the test, and no encouragement 
given throughout. [12-13] Stopping criteria were when the participant was too 
breathless to continue, or unable to maintain the required speed. 
The duration of each activity was chosen to optimise the likelihood of steady 
state metabolism being achieved. Patients unable to complete 5 minutes 
walking did a minimum of 3 minutes. At the end of the ISWT and each walking 
activity, participants were asked to sit and rest quietly until they felt ready to 
complete the next task. Other activities had a 1 minute transition period. 
Participants that used walking aids in their daily life, were allowed to do so 
throughout the activities as required. The patient visit lasted approximately 3 
hours in total. 
3.3.3 Measures 
Prior to the activities, weight was measured without shoes, to the nearest 0.1kg 
using an electronic scale (Seca, Hamburg, Germany), height was measured 
without shoes to the nearest 0.1cm using a stadiometer (Seca, Hamburg, 
Germany) and blood pressure was assessed using a manual 
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sphygmomanometer (Accoson, England). Body mass index was calculated 
using weight and height (kg/m2). 
Throughout each activity, participants wore 3 GENEActiv accelerometers 
(Activinsights, Kimbolton, UK); one on each wrist, secured using a watch strap; 
and on the waist, placed on the left iliac crest, secured using an elasticated 
waist band. GENEActiv accelerometers measure acceleration between -8g and 
8g, and recorded raw triaxial acceleration at 100Hz. The GENEActiv 
accelerometer has been validated for both hip- and wrist-worn measurement of 
PA, and to distinguish between inactivity, light PA, and MVPA in healthy adults. 
[15] 
VO2 was measured throughout each activity with a portable Oxycon mobile 
breath-by-breath ergospirometry system, (VIASYS Healthcare GmbH, 
Hoechburg, Germany). This system has been shown to be a reliable and valid 
method of measuring energy expenditure. [16] Standardised gas and volume 
calibration was performed within one hour before each participant visit 
according to manufacturer’s specifications. [17] The flow meter was calibrated 
automatically. VO2 was expressed in millilitres per kilogram per minute 
(ml/kg/min).  
Before starting any activities, participants were instructed on how to use the 
Borg 6-20 RPE scale, [18] which was reported during the last 30 seconds of 
each ISWT level and during the last minute of all other activities. 
3.3.4 Data reduction 
Immediately after testing was completed, the accelerometers and 
ergorespirometry system were removed and data were downloaded to a 
personal computer.  
Oxygen consumption data  
VO2 was averaged over minutes 10-20 of lying down, over the last 30 seconds 
of each stage of the ISWT, and over the last minute of all other activities. VO2 
data for each individual for each activity was converted into metabolic 
equivalents (METS) in two different ways; standard METS calculated using the 
standard formula (VO2/3.5ml/kg/min), and measured METS using each 
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individual participants measured RMR (VO2/RMR). Predicted METS for each 
activity were taken from the compendium of physical activities. [19] 
Accelerometer data  
GENEActiv data were downloaded using GENEActiv PC software (version 3.2; 
Activinsights, Kimbolton, Cambridge, UK) and averaged over 5 second epochs, 
which is considered adequate for reporting different activities. [20]  
Each axis (x, y, z) of the raw tri-axial data was multiplied by 1000 to transform 
the signals from g to milligravity units (mg), to ensure the subsequent 
accelerometer thresholds would be comparable to prior literature. Raw tri-axial 
data were then summarized into a single vector magnitude using three common 
approaches, which are described in table 3.1.  
As other studies have identified, at low magnitude of acceleration, ENMO 
returned a high frequency of 0’s, making it severely limited in classifying 
inactivity and light PA. [23] Therefore ENMO was excluded from further 
analysis.  
In line with the VO2 data, MAD and SVM values were averaged over minutes 
10-20 of lying down, the last 30 seconds of each ISWT stage, and the last 




Table 3.1: Details of the three data reduction approaches used in this study  
Data reduction approach Description Strengths/Limitations 
Gravity-subtracted sum of vector magnitudes 
(SVM) [19] 
𝑆𝑉𝑀 =  
1
𝑛
 × ∑ |√𝑥2 + 𝑦2 + 𝑧2 − 1000m𝑔 | 
Vector magnitude is calculated in 
each epoch and 1000mg is 
subtracted. When the 
accelerometer is static and the 
earth’s gravitation pull is the only 
acceleration, the result is 0. 
Gravity correction taken into account within the 
algorithm. 
Rotation invariant. 
The absolute value of negative vector 
magnitudes are used,  
Fewer studies have used this method, so 
comparability is more limited. 
Mean amplitude deviation (MAD) [25] 
𝑀𝐴𝐷 =  
1
𝑛
 ×  ∑ |𝑟𝑖 − 𝑟|̅     
Where;  
𝑟𝑖 =  √𝑥𝑖
2 + 𝑦𝑖
2 + 𝑧𝑖
2      
?̅? = 𝑚𝑒𝑎𝑛 𝑣𝑒𝑐𝑡𝑜𝑟 𝑚𝑎𝑔𝑛𝑖𝑡𝑢𝑑𝑒 𝑤𝑖𝑡ℎ𝑖𝑛 𝑡ℎ𝑒 𝑡𝑖𝑚𝑒 
Describes the typical distance of 
data points around the mean. 
Represents the mean value of the 
dynamic acceleration component.  
Gravity correction taken into account within the 
algorithm. 
Rotation invariant. 
Appears to account well for calibration error. 
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 𝑝𝑒𝑟𝑖𝑜𝑑 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 
Fewer studies have used this method, so 
comparability is more limited. 
Euclidean Norm Minus One (ENMO) [26] 
𝐸𝑁𝑀𝑂 = √𝑥2 + 𝑦2 + 𝑧2 − 1000m𝑔 
Vector magnitude is calculated in 
each epoch and 1000mg is 
subtracted. Negative ENMO 
values rounded to 0 
Gravity correction taken into account within the 
algorithm. 
Rotation invariant. 
More widely used in studies, and is the output 
from the only currently available open source 
accelerometer data processing package, 
GGIR. 
Sensitive to poor calibration. 
Negative values are rounded up to zero, 
hypothesised that this corrects for errors in 
subtraction in gravitational component.  
Studies shown that ENMO less sensitive at 
low levels of movement. 
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3.3.5 Data analysis 
Conservatively assuming a ROC AUC of 0.85 (based on lowest AUC previously 
reported, [7-8,11] and assumed null AUC of 0.5 (no association) at 90% power 
and 5% alpha, a minimum sample size of 18 patients was required. 
Based on methods used in previous calibration studies [7-8,11] we used a 
combination of receiver-operator characteristic (ROC) analysis and mixed 
effects regression model analysis methods to establish accelerometer 
thresholds for inactivity (<1.5 METS) and MVPA (≥3 METS). Because of the low 
exercise capacity of HF patients, a threshold for vigorous intensity was not 
generated. Data from the ISWT were not included in the threshold generation 
analysis due to the short interval times for each ISWT level, and the small 
numbers of participants that reached the latter stages.  
Correlations between SVM, MAD and METS were checked using Pearson’s 
correlation and interpreted according to Cohen’s effect size i.e. weak, r=0.1 to 
0.29; moderate r=0.3 to 0.49; strong r≥0.5. 
ROC analysis was performed using the ‘roctab’ and ‘roccomp’ STATA 
commands. The continuous MET values were coded into the following intensity 
categories: inactivity (<1.5 METS: yes/no), MVPA (≥3.0 METS: yes/no) to 
create binary indicators. The mg values that maximised the combination of 
sensitivity and specificity were selected as the threshold values. AUC values for 
each ROC curve calculated were defined as excellent (≥0.90), good (0.80-0.89), 
fair (0.70-0.79), poor (0.60-0.69) or failure (<0.60).  
Multilevel mixed effects linear regression modelled the accelerometer-derived 
mg values across the range of METS achieved during the different activities. 
This analysis was performed using the ‘xtmixed’ STATA command where METS 
was entered into the model as both a fixed and random effect. This allowed the 
‘mg against METS’ slopes and intercepts to vary between individuals. The 
resulting regression equation was used to calculate intensity thresholds for 
inactivity (<1.5 METS) and MVPA (≥3.0 METS). A different model was produced 
for each combination of ‘body location by ‘mg’ method’ separately.  
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Sensitivity analyses were undertaken to explore the impact of excluding 
participants that used a walking aid, as this may have affected accelerometer 
readings, and excluding washing up as an activity, as this involves high levels of 
wrist movement, but little waist movement. 
In order to validate the derived intensity thresholds a leave-one-out method was 
used. One observation was left out and used as the test dataset, and a 
multilevel mixed effects linear regression model was fitted and used to predict 
the left out observation, this was then repeated sequentially for all possible 
observations. A median split of the actual acceleration values and the predicted 
values were cross-tabulated to obtain a ‘percentage of correct predictions’.  
We applied both the derived thresholds and the Hildebrand thresholds to a 
baseline accelerometer measured PA data set of 247 HF patients recruited to 
two home-based cardiac rehabilitation randomised controlled trials, details of 
which are published elsewhere. [3,24] Cohen’s Κ was run to determine the level 
of agreement between the derived HF specific intensity thresholds and 
Hildebrand thresholds for classing patients as meeting current PA guidelines.  
Statistical analyses were performed using Stata (V.15.0; StataCorp, College 
Station, Texas, USA). Leave-one-out cross validation analysis was performed 
using the R programming language and environment (V3.6.1). All data are 
expressed as mean values and standard deviations unless otherwise stated. 
The level of significance was set at p<0.05. 
 
3.4 Results  




Table 3.2: Patient characteristics 
Characteristic N= 22 patients 
Mean ± SD unless 
otherwise stated 
Male (n, %) 17 (77) 
Age (years) 70.7 ± 14.1 
Body Mass Index (kg/m2) 28.1 ± 4.4 
LVEF (%) 
Reduced LVEF <40% (n, %) 
Mid-range LVEF 40-49% (n, %) 
Preserved EF ≥50% (n, %) 














Dilated cardiomyopathy (n, %) 14 (64) 
Ischaemic heart disease (n, %) 8 (36) 
ICD/CRT/Pacemaker (n, %) 13 (59) 
ACE/ARB/ARNI (n, %) 21 (95) 
Beta-blocker (n, %) 22 (100) 
MRA (n, %) 14 (64) 
Loop diuretic (n, %) 17 (77) 
Hypertension (n, %) 11 (50) 
Diabetes (n, %) 6 (27) 
COPD (n, %) 4 (18) 
Arthritis (n, %) 2 (9) 
AF (n, %) 11 (50) 
Stroke (n, %) 5 (23) 
Comorbidities (hypertension, 
diabetes, COPD, arthritis, AF, 















ISWT distance (m) 286.4 ± 190.6 
RMR (mL O2·kg-1·min-1) 2.67 ± 0.66 
Data presented as mean ± standard deviation or as number (percentage).  
LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; 
ICD, implantable cardioverter defibrillator; CRT, cardiac resynchronisation 
therapy; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; ARNI, angiotensin II receptor blocker neprilysin inhibitor; MRA, 
mineralocorticoid receptor antagonist; COPD, chronic obstructive pulmonary 
disease; AF, atrial fibrillation; ISWT, incremental shuttle walk test. 
 
3.4.1 Accelerometry and METS 
All participants completed all activities within the study protocol. All three 
accelerometers failed to record for one participant so they were omitted from 
analysis. For a second participant, the left wrist accelerometer failed to record, 
so only their right wrist and waist data was included.  
Accelerometer outputs (SVM and MAD), METS (standard, measured and 
predicted), and RPE scores for each of the activities are reported in table 3.3. 
For all activities, measured METS were 33-35% higher than standard METS. 
Similarly, measured METS were (7-105%) higher than the compendium 




Table 3.3: Mean (SD) accelerometer output via SVM and MAD calculations, METS calculated via measured and standard 
formula, and RPE score for each activity performed 































































































































Light pace walk 








































(average pace 2.2 
mph) 
Light pace walk 
carrying shopping bags 
(2 x 1.5kg) 




















SVM, sum of vector magnitude; MAD, mean amplitude deviation; METS, metabolic equivalents; RPE, rating of perceived 
exertion; ISWT, incremental shuttle walk test. 
*Measured METS = VO2 (ml/kg/min) measured during each activity / VO2 (ml/kg/min) measured at rest (resting metabolic 
rate). 
†Standard METS = VO2 (ml/kg/min) measured during each activity / 3.5 (ml/kg/min). 





Figure 3.1 shows the relationships between SVM and measured METS and 
MAD and measured METS for each participant at each accelerometer wear 
location. Accelerometer values increased in line with the increase in METS. 
Correlations between SVM and METS were strong (left wrist r=0.78, right wrist 
r=0.76, waist r=0.80). Correlation between left and right wrist MAD and METS 
was weak (left wrist r=0.18, right wrist r=0.28), and between waist MAD and 







Figure 3.1: Trellis plot showing acceleration values in mg vs intensity in METS 
for each activity and fitted regression lines, for SVM (blue) and MAD (orange), 
for (A) right wrist, (B) left wrist, (C) waist worn accelerometers. 
3.4.2 ROC curve analysis 
ROC analysis results are presented in appendix 3.6. GENEActiv 
accelerometers at all locations were able to discriminate between inactivity, and 
MVPA. SVM gave more precise discrimination across all three accelerometer 
wear locations, and both inactivity and MVPA (AUC=0.93 to 0.99) compared to 
MAD (AUC=0.61 to 0.97). All derived inactivity and MVPA thresholds were 
lower than the commonly used thresholds previously published at all wear 
locations. [7-8] 
3.4.3 Multilevel mixed effects regression analysis 
Table 3.4 shows the multilevel mixed effects regression model coefficients and 
constants, and the derived inactivity and MVPA intensity thresholds calculated 
by inputting 1.5 METS and 3.0 METS respectively. All derived thresholds for 
inactivity were much lower than the threshold for inactivity of 45.8 mg commonly 
applied to all populations. [8] Right wrist: SVM=13.3-18.6mg, MAD=14.2-
18.4mg. Left wrist: SVM=14.4-16.9mg, MAD=15.4-18.8mg. Waist: SVM=7.6-
11.1mg, MAD=1.0mg. 
Crucially, even the highest HF-derived MVPA threshold (49mg) is much lower 
than the MVPA threshold of 93.2mg or 100mg that are commonly applied to all 
populations. [7] Right wrist:  SVM=43.1-49mg, MAD=24.7-29.5mg. Left wrist: 
SVM=43.6-47.0mg, MAD=20.7-24.2mg. Waist: SVM=40.6-47.2mg, MAD=2.4-
2.6mg. MVPA thresholds did not differ by location (wrist or waist) for SVM, but 




Table 3.4: Mixed effect regression model coefficients, constants and resulting intensity thresholds for inactivity and MVPA with 
confidence intervals for SVM and MAD 
 Coefficient (95% CI) Constant (95%CI) Inactivity 
Threshold  
(<1.5 METS) (mg)  
(95% CI)† 
MVPA Threshold   
(≥3.0 METS) (mg)  
(95% CI)† 
SVM     
Right wrist     
All patients (n=21, obs=168) 17.9 (15.4 to 20.5)*** -8.3 (-14.2 to -2.3)** 18.6 (8.8 to 28.4) 45.5 (31.9 to 59.1) 
Excluded aided walking activity 
data‡ (n=21, obs=159) 
20.2 (17.6 to 22.9)*** -11.7 (-17.6 to -5.9)*** 18.6 (8.7 to 28.5) 49.0 (35.1 to 62.9) 
Excluded aided walking activity 
data and washing up activity 
data §(n=21, obs=138)  
19.8 (17.7 to 22.0)*** -16.4 (-19.9 to -
13.0)*** 
13.3 (6.7 to 19.9) 43.1 (33.3 to 52.9) 
Left wrist     
All patients (n=20, obs=160) 18.0 (15.5 to 20.5)*** -10.3 (-15.4 to -5.2)*** 16.7 (7.8 to 25.6) 43.6 (38.5 to 56.3) 
Excluded aided walking activity 
data‡ (n=20, obs=151) 
20.1 (17.7 to 22.5)*** -13.2 (-18.2 to -8.2)*** 16.9 (8.3 to 25.5) 47.0 (34.8 to 59.2) 
Excluded aided walking activity 
data and washing up activity 
data § (n=20, obs=131) 
19.9 (17.6 to 22.2)*** -15.5 (-19.6 to -
11.5)*** 
14.4 (6.8 to 21.85) 44.3 (33.2to 55.2) 
Waist     
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All patients (n=21, obs=168) 22.0 (18.3 to 25.7)*** -25.4 (-30.5 to -
20.2)*** 
7.6 (-3.1 to 18.4) 40.6 (24.3 to 57.0) 
Excluded aided walking activity 
data‡ (n=20, obs=159) 
22.9 (19.6 to 26.2)*** -26.6 (-31.7 to -
21.5)*** 
7.7 (-2.3 to 17.8) 42.0 (27.1 to 57.0) 
Excluded aided walking activity 
data and washing up activity 
data § (n=21, obs=138) 
24.0 (20.2 to 27.9)*** -24.9 (-29.5 to -
20.4)*** 
11.1 (0.78 to 21.49) 47.2 (31.0 to 
63.32) 
MAD     
Right wrist     
All patients (n=21, obs=168) 5.3 (2.5 to 8.0)*** 10.4 (3.1 to 17.8)** 18.3 (6.9 to 29.7) 26.2 (10.7 to 41.7) 
Excluded aided walking activity 
data‡ (n=21, obs=159) 
7.4 (4.5 to 10.3)*** 7.3 (-0.1 to 14.6) 18.4 (6.6 to 30.1) 29.5 (13.4 to 45.6) 
Excluded aided walking activity 
data and washing up activity 
data § (n=21, obs=138) 
7.0 (4.2 to 9.8)*** 3.7 (-2.6 to 10.0) 14.2 (3.6 to 24.8) 24.7 (9.9 to 39.5) 
Left wrist     
All patients (n=20, obs=160) 2.8 (0.3 to 5.2)* 14.6 (7.5 to 21.7)*** 18.7 (7.9 to 29.5) 22.8 (8.3 to 37.3) 
Excluded aided walking activity 
data‡ (n=20, obs=151) 
3.7 (1.0 to 6.3)** 13.3 (6.1 to 20.5)*** 18.8 (7.6 to 29.9) 24.2 (9.1 to 39.4) 
Excluded aided walking activity 
data and washing up activity 
data § (n=20, obs=131) 
3.5 (0.8 to 6.2)* 10.1 (3.2 to 17.0)** 15.4 (4.4 to 26.3) 20.7 (5.7 to 35.6) 
Waist     
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All patients (n=21, obs=168) 0.9 (0.7 to 1.2)*** -0.5 (-0.9 to 0.0) 1.0 (0.2 to 1.7) 2.4 (1.3 to 3.5) 
Excluded aided walking activity 
data‡ (n=21, obs=159) 
1.0 (0.8 to 1.2)*** -0.6 (-1.1 to -0.1)* 1.0 (0.2 to 1.8) 2.5 (1.4 to 3.6) 
Excluded aided walking activity 
data and washing up activity 
data § (n=21, obs=138) 
1.1 (0.8 to 1.3)*** -0.6 (-1.0 to -0.2)** 1.0 (0.3 to 1.7) 2.6 (1.5 to 3.6) 
MVPA, moderate-to-vigorous physical activity; SVM, sum of vector magnitudes; MAD, mean amplitude deviation; METS, 
metabolic equivalents 
†95% CI calculated using upper and lower bounds of coefficient and constant in formula. 
* p<0.05, ** p<0.01, *** p<0.001 
‡ Excluded walking activity data for n=3 patients using walking aids. § Excluded walking activity data for n=3 patients using 




3.4.4 Sensitivity analysis  
Two sensitivity analyses were performed (excluding walking data of patients 
who used walking aids, and walking data of patients who used walking aids, 
plus all washing and drying dishes data). Neither made considerable difference 
to the thresholds derived through ROC analysis or multilevel mixed effect 
regression analysis.  
3.4.5 Validation analysis 
Leave-one-out cross validation (appendix 3.7) of the multilevel models showed 
that the model fit for SVM at each wear location was acceptable but appeared 
to under predict at high PA and MET levels. Proportion of correct predictions 
were high (right wrist: 96%; left wrist: 99%, waist: 95%). Models using MAD 
performed less well with lower proportions of correct predictions (right wrist: 
69%; left wrist: 64%; waist: 87%).  
Cohen’s Κ test showed 63% agreement (95% CI 57% to 69%, Κ= 0.19, 
p<0.001) between HF specific and adult intensity thresholds in classification of 
patients meeting PA guidelines. [7] 
 
3.5 Discussion  
This is the first study to derive HF specific accelerometer intensity thresholds for 
time spent inactive and in MVPA. Intensity thresholds corresponding to inactivity 
were much lower than those previously published based on young healthy 
adults. [8] Sedentary time is defined as a combination of sitting or reclining and 
low energy expenditure during waking hours. [25] The time spent below 1.5 
METS measured by wrist worn accelerometry can only measure inactivity, and 
not the specific posture required to be defined as sedentary time, therefore we 
use the term inactivity. Although less investigated than MVPA, inactivity 
thresholds of <50mg or <40mg have been previously proposed for GENEActiv 
accelerometers. [8, 26-27] This suggests the possibility that researchers using 
generic intensity thresholds are concluding that HF patients are more inactive 
when they may actually be engaging in light intensity activities. 
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Similarly, accelerometer thresholds corresponding to MVPA were much lower 
than those derived from other calibration studies both in healthy adults and 
older adults. [7,10] Applying intensity thresholds developed in younger, healthier 
populations to HF patients assumes the energy cost for a given activity is the 
same for everyone, with no consideration for an individual’s exercise capacity. 
[9] In line with previous studies, we showed HF patients require greater energy 
expenditure to complete walking and self-paced daily living activities, where 
METS calculated using measured RMR were higher than METS calculated 
using the standard RMR estimate of 3.5 ml/kg/min [28-31]. Additionally, 
measured METS were higher than the predicted METS from the compendium of 
physical activities. [19] Often, self-reported PA measures use the compendium 
to inform activity estimates and it is also used to prescribe PA. [32-33] This 
clearly highlights the limitations of using existing MET tables to estimate the 
time HF patients spend in MVPA.  
The average RMR for this sample of HF patients was 2.67 ml/kg/min, 24% less 
than the standard 3.5 ml/kg/min, consistent with RMRs reported previously in 
older adults,[28] and HF patients. [30] The application of standard RMR for MET 
calculations is common, including in previous calibration studies, [7-8] however 
several studies have shown the inaccuracy of using estimated RMR in elderly 
and clinical populations including HF patients. [28, 30-31] Although the 
mechanism for decreased RMR in HF patients is currently unknown, decline 
with increasing NYHA class has been shown, and may be influenced by 
changes in skeletal muscle physiology associated with a reduced cardiac output 
in HF. [30] It may be argued that our lower RMR is due, to some extent, to 
being measured whilst supine, rather than sitting, however we measured supine 
RMR in line with current best practices. [12]  
3.5.1 Data reduction and analysis techniques 
We explored 3 data reduction approaches for generating a single value of 
acceleration from the x, y, z axes. We found that ENMO returned a high 
frequency of 0’s across all activities, which has been observed by others, [23] 
and therefore excluded it from further analysis. SVM had stronger correlations 
with METS, produced higher AUC values in the ROC analysis, and returned 
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better model fit predictions in the leave-one-out cross validation analysis 
compared to MAD.  
ROC analysis was less robust than multilevel mixed effect regression analysis 
when using MAD, with poor-fair AUC for wrist accelerometers. This may be due 
to the dichotomisation of MET data in the ROC analysis, which leads to a loss 
of statistical power, whereas the absolute MET values are used in the multilevel 
mixed effect regression analysis. Furthermore, the multilevel mixed effect 
regression correctly accounts for the clustering of measures within individuals 
which ROC analysis does not.  
Therefore we recommend studies measuring PA levels in HF patients use the 
thresholds derived using SVM and multilevel mixed effect regression for all 
patients, i.e. inactivity (right wrist: 18.6mg, left wrist: 16.7mg, waist: 7.6mg) and 
MVPA (right wrist: 45.5mg, left wrist: 43.6, waist: 40.6mg). 
3.5.2 Strengths and limitations 
Strengths of this study include the use of both wrist- and waist-worn 
accelerometers with known reliability and validity, comparison of multiple data 
reduction algorithms, and comprehensive data analysis of raw acceleration data 
captured at a high sampling frequency. We were thus able to generate HF 
specific intensity thresholds, enabling more accurate differentiation between 
inactivity, and MVPA behaviours of HF patients. In contrast to previous 
calibration studies we have individually measured RMR, and used this to more 
accurately measure METS for each activity for each individual. [7-8]. We 
selected representative HF patients from a hospital clinic, who were 
heterogeneous in exercise capacity and age, factors known to affect PA 
measurement, [10-11,28] and determined activities with the assistance of a HF 
Patient and Public Involvement group to represent typical daily living, with the 
majority of PA and exercise from walking and household activities.  
We recognise that this study has some limitations. It was based on small, 
single-centre sample of HF patients, therefore we are unable to determine how 
the thresholds may vary between NYHA classes. In addition, it is difficult to 
determine whether HF medications taken by the patients (100% patients taking 
β-blockers) influenced VO2 or heart rate. Attempting to apply a single threshold 
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to all within a population may not be possible since individual capacities vary. 
[34] Employing a threshold or cut-point technique to derive PA metrics from 
accelerometers may not be as accurate as newer techniques such as machine 
learning that are being explored in public health studies. [35-36] However, whilst 
PA recommendations are based on classes of PA intensity rather than specific 
behaviours, these techniques are still pragmatic to use until consensus is 
reached.  
3.5.3 Implications and future research 
We have developed a new approach that better captures PA in HF patients 
using accelerometry. Our results suggest that application of previously 
published intensity thresholds based on calibration studies of adults without 
chronic disease potentially risks underestimation and misclassification of PA in 
HF patients. Larger studies, using our approach are now required to clarify PA 
levels in the various severity levels of HF, taking account of comorbidity. We 
suggest power calculations should take into account the small numbers of 
patients that reach the latter stages of the ISWT to ensure spread of patients 
fitness levels represented.  
This study also has important implications for PA and exercise prescription. It is 
vital both the patient and the clinician are aware of the PAs that will count as 
MVPA and benefit the patient, as prescribing activities that are too intense may 
lead to decreased motivation and adherence to PA guidelines or CR. [37] Our 
results show that any walking activity, including at a slow speed, would be 
sufficient for HF patients to accumulate minutes of MVPA.  
 
3.6 Conclusions  
HF specific accelerometer intensity thresholds for both inactivity and MVPA 
were substantially lower (<50%) than previously published and commonly used 
intensity thresholds. Using cut-points or intensity thresholds based on 
calibration studies of younger, healthy adults assumes energy expenditure is 
the same for everyone, regardless of an individual’s exercise capacity. We 
demonstrated that HF patients require more energy to perform typical daily 
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living activities, including walking and household activities, with higher 
measured MET values compared to METS calculated using assumed RMR, or 
METS predicted from the compendium of physical activities. We thereby 
demonstrate that the application of generic PA thresholds may result in a 
misclassification and underestimation of the true amount of MVPA undertaken 
by HF patients.   
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Chapter 4: Factors associated with objectively assessed physical activity 




To determine the level of objectively measured moderate-to-vigorous physical 
activity (MVPA) in patients with heart failure (HF), and to assess the association 
between MVPA and patient sociodemographic, exercise capacity, and health 
status factors.  
Methods 
Baseline MVPA data was available in 247 HF patients with 7-day wrist-worn 
accelerometry from two randomised controlled trials. Associations between 
MVPA and patient sociodemographic, exercise capacity, and health status 
factors were assessed using univariate and multivariable linear regression 
models.   
Results 
247 patients (28% female, mean age 71±10 years) with HF with reduced 
ejection fraction (n=198) and preserved ejection fraction (n=49) were included in 
the analysis. Average MVPA was 283.3 min/week and ranged widely from a 
minimum of 0 mins/week to maximum of 2626.7 mins/week (standard deviation: 
404.1 mins/week). 111 (45%) of patients had a level of PA that met current 
guidelines of at least 150 minutes/week of MVPA. Multivariable regression 
showed patient’s age, body mass index, employment status, smoking status, 
New York Heart Association class, NT-proBNP and exercise capacity to be 
strongly associated (p<0.001) with the level of MVPA (p<0.001). 
Conclusion 
Whilst 45% of HF patients had objectively measured levels of MVPA that met 
current PA recommendations, we observed a wide range in the level of MVPA 
across this patient sample. As a number of factors were found to be associated 
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with MVPA our findings provide important information for future interventions 
aiming to increase MVPA in HF patients.  
 
4.2 Introduction 
There are numerous benefits of regular physical activity (PA) that persist across 
the life course, including prevention and management of chronic disease, 
prolonging functionality and increasing health-related quality of life [1]. To 
achieve these health benefits, it is recommended that adults perform at least 
150 minutes per week (i.e. ≥30 minutes/day over 5 or more days per week) of 
moderate-to-vigorous PA (MVPA) [1].  
A small number of studies to date have quantified the PA levels of HF patients 
and consistently report daily MVPA levels much lower than the recommended 
30 minutes [2-5]. Some studies have reported that HF patients undertake on 
average as little as 1 minute of MVPA per day [2-5]. However, these previous 
studies are limited by small sample sizes (N<100), [2-4] and/or reliance on self-
report measures of PA, [5] which have been shown to be less reliable than 
objective measures [6]. Moreover, studies that did use objective PA methods 
are based on proprietary algorithms that assess levels of MVPA from data in 
healthy adults [2-4].  
The aims of this study were to: (1) determine the level of objectively measured 
PA and MVPA in HF patients using HF-specific intensity algorithms and (2) 
assess the association between MVPA and patient sociodemographic, exercise 
capacity, and health status factors. 
 
4.3 Methods 
4.3.1 Study design 
This study used baseline data pooled from two randomised controlled trials of a 
home-based cardiac rehabilitation intervention for HF patients (REACH-HF): a 
single centre study in patients with HF with preserved ejection fraction (HFpEF) 
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(ISRCTN78539530) and a multicentre study in patients in HF reduced ejection 
fraction (HFrEF) (ISRCTN86234930) [7-10].  
Both trials were conducted in accord with the principles of the Declaration of 
Helsinki and ethical approval was granted by the East of Scotland Research 
Ethics Service (15/ES/0036) [9] and by the North West Lancaster Research 
Ethics Committee (14/NW/1351) [10]. 
4.3.2 Study participants 
Participating HF patients were recruited from primary and secondary care 
settings in five UK centres (Birmingham, Cornwall, Dundee, Gwent, and York) 
between January 2015 and February 2016 [9-10]. A total of 266 patients 
completed the baseline visit, 216 with HFrEF (defined as left ventricular ejection 
fraction <45%) and 50 with HFpEF (defined as left ventricular ejection fraction 
≥45%). The patients were aged ≥18 years and had a confirmed diagnosis of HF 
on echocardiography or angiography within the last 6 months [7-8]. A full list of 
trial inclusion and exclusion criteria are provided in appendix 4.1.  All study 
participants provided written informed consent. 
4.3.3 Data collection 
Medical history, demographics, blood test, and exercise capacity 
During their baseline clinic visit the following categories of data were collected: 
(1) medical history, i.e. comorbidities, New York Heart Association (NYHA) 
class, HF aetiology, concomitant HF medication and presence of implantable 
cardiac devices;  (2) sociodemographic information i.e. age, ethnicity, weight, 
employment status, and smoking status; (3) blood sample was taken for 
measurement of N-terminal Brain Natriuretic Peptide (NT-proBNP); (4) health 
outcome questionnaires – i.e. disease-specific health-related quality of life 
assessed by Minnesota Living with Heart Failure Questionnaire, and the Health 
Related Quality of Life (HeartQoL) questionnaire; psychological wellbeing using 
the Hospital Anxiety and Depression Scale questionnaire; generic health-related 
quality of life using the EQ-5D-5L questionnaire; and Self-care of HF Index 
questionnaire; (5) exercise capacity assessed by an incremental shuttle walk 
test (ISWT) – the ISWT was performed twice with at least 30 minutes rest 
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between the tests, administered by the PI or research nurse. Standardised 
instructions were given to patients, and no encouragement was given 
throughout the test [7-8]. The peak distance (m) walked in either of the two tests 
was recorded. 
Physical Activity – Accelerometry 
At baseline visit, patients were also provided a GENEActiv triaxial 
accelerometer (GENEActiv, Activinsights, Kimbolton, Cambridge, UK) and 
instructed to wear the accelerometer on their non-dominant wrist for 7 days 
during waking and sleeping hours [9-10]. Monitors were returned using postage-
paid envelopes. Data were downloaded using GENEActiv PC software (version 
3.2; Activinsights, Kimbolton, Cambridge, UK) and analysed in R (R Core Team, 
Vienna, Austria) using the GGIR software package (version 1.5-18, http://cran.r-
project.org). Initial processing included autocalibration, the detection of 
abnormally high values and non-wear [11-12]. Data were averaged over 5 
second epochs and Euclidean Norm Minus One was used to quantify the 
acceleration related to movement registered and was expressed in units of 
milligravity (mg) [13]. The Euclidean norm (magnitude) of the 3 raw signals 
minus 1000mg, with negative numbers rounded to zero was calculated using 
the following formula:  
√𝑥2 + 𝑦2 + 𝑧2 − 1000𝑚𝑔 
Non-wear was determined over 60 minute windows using 15 minute 
increments, and was apparent when 2 of the 3 axes had a data range <50 mg 
and a standard deviation  <13 mg [14]. To be included in analysis patients were 
required to have ≥16 hours per day and ≥7 days of wear. The first seven days 
that met the criteria were used for analysis.  
For each patient, the following PA metrics were calculated: (1) minutes per 
week of MVPA, (2) whether patients meet the PA recommendation of 
≥150 minutes of MVPA per week, (3) average daily PA levels (over all days, 
weekdays only, and weekend days only) broken down into minutes of inactivity, 
light PA, and MVPA. These metrics were calculated using both bouted PA i.e. 
periods of PA sustained for at least 10 minutes where accelerometer readings 
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lie above the intensity threshold (with a 20% allowance for values to fall outside 
the threshold) and unbouted i.e. PA accumulated in bouts of any length. 
These metrics were calculated using HF population specific accelerometer 
intensity thresholds for inactivity of 16.7mg (left wrist) and 18.6mg (right wrist) 
and MVPA of 43.6mg (left wrist) and 45.5mg (right wrist). These intensity 
thresholds were determined by a recent calibration study in 21 HF patients with 
concurrently assessed acceleration values and directly measured oxygen 
uptake across a range of activities of daily living [15]. We considered the 
potential effects of application of HF specific intensity thresholds which were 
derived using an alternative data reduction method (SVM rather than ENMO), 
and concluded that the difference in the calculated PA patterns would be 
minimal, and would not affect the conclusions of the study.  
4.3.4 Statistical analysis 
Descriptive statistics were used to summarise patient characteristics and levels 
of PA. Continuous variables are presented as means and standard deviations 
(SD) and discrete variables presented as counts or percentages.  
Univariate linear regression analysis was conducted to examine the association 
between MVPA in minutes/week and each group of potential predictor variables 
(i.e. medical history/sociodemographics, exercise capacity, health status 
outcomes) separately. Univariate logistic regression was used to examine the 
association with these groups of variables and the binary outcome of whether 
patients meet PA guidelines or not. Variables were selected for multivariable 
analysis if there was statistical evidence of (p<0.15) of their association in 
univariate analysis.  
Three multivariable PA regression models were developed for both MVPA in 
minutes/week and binary outcome of meeting PA guidelines or not: (1) model 1 
– medical history sociodemographic variables only, (2) model 2 - exercise 
capacity and health status variables only, and (3) model 3 - medical history 
sociodemographic and health and disease status variables that were identified 
as statistically significant (p<0.05) in models 1 and 2. Checks and diagnostics 
were performed for model assumptions, residuals, multicollinearity (variance 
inflation factor) and influential observations (Cook’s distance). Akaike 
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information criterion and R2 values (proportion of variance explained) were used 
to inform model comparison and selection. We performed two groups of 
sensitivity analyses: (1) including the patients previously excluded with high 
residuals and Cook’s distances and (2) MVPA was recalculated without the 
requirement for PA to be in bouts of at least 10 minutes (unbouted). 
Statistical analyses were performed using Stata (V.15.0; StataCorp, College 
Station, Texas, USA). 
 
4.4 Results 
Of the 266 patients who completed baseline visits, 247 were included in the 
analysis (see table 4.1). Overall, patients had a mean age of 70.9 years and 
were predominantly male (72%) and NYHA class I to III (99%). Alongside 
differences in medications, HFpEF patients were more likely to be older and 
female, have higher BMI, live alone, have hypertension, chronic renal 
impairment, arthritis and COPD, have lower generic health-related quality of life 
(EQ-5D-3L) Hospital Anxiety and Depression Scale depression scores 
depression, and self-care maintenance scores, and lower ISWT distance. Four 
patients had missing accelerometer data, and 15 patients were excluded due to 
inadequate accelerometer wear time (<7 days of wear with ≥16 hours per day).  
Apart from a higher proportion in employment (26 vs 13%, p=0.01), excluded 




Table 4.1: Sociodemographic characteristics and disease and health status 
factors at baseline of patients included in the analysis. N (%) unless otherwise 
stated 









Mean (SD) age (years) 70.9 (10.4) 70.1 (10.7) 74.3 (8.0)** 
Female sex 70 (28) 43 (22) 27 (55)*** 






Employment status    
     Retired 199 (81) 153 (77) 46 (94) 
     In employment or self-
employment 







Ethnic origin    
     White 236 (96) 187 (94) 49 (100) 
     Other 11 (4) 11 (6) 0 (0) 
NYHA class    
     I 40 (16.2) 38 (19) 2 (4) 
     II 147 (59.5) 117 (59) 30 (61) 
     III 59 (23.9) 42 (21) 17 (35) 
     IV 1 (0.4) 1 (1) 0 (0) 
Median (IQR) LVEF (%) 35 (30-44) 34 (25-38) 62 (58-64)*** 
     LVEF <45% 114 (46) 144 (73) 0 (0) 
     LVEF>45% 







Time since HF diagnosis 
(years) 
     <1 
     1-2 
















Live alone 66 (27) 44 (22) 22 (45)** 
Current smoker 14 (6) 10 (5) 4 (8) 
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Cause of heart failure    
     Ischaemic 115 (47) 91 (46) 24 (49) 
     Non-ischaemic 116 (47) 93 (47) 23 (47) 
     Unknown/Not classified 16 (6) 14 (7) 2 (4) 
Trial site    
     Truro 
     Gwent 
     Birmingham 
     York 
















Comorbidities    
     Diabetes mellitus 59 (24) 44 (22) 15 (31) 
     Myocardial infarction 70 (28) 61 (31) 9 (18) 
     Hypertension 113 (46) 82 (41) 31 (63)** 
     Stroke 29 (12) 26 (13) 3 (6) 
     Asthma 28 (11) 20 (10) 8 (16) 
     Chronic renal 
impairment 
45 (18) 32 (16) 13 (27)* 
     Arthritis 107 (43) 77 (39) 30 (61)** 
     Atrial fibrillation or atrial 
flutter 
118 (48)  99 (50) 19 (39) 
     COPD 27 (11) 17 (9) 10 (20)* 
     Depression 61 (25) 46 (23) 15 (31) 
Median (IQR) Number of 
comorbidities 
3 (2-5) 3 (2-5) 4 (3-6) 
Medication    
     ACE inhibitor/ARB 220 (89) 182 (92) 38 (78)* 
     Aldosterone antagonist 118 (48) 109 (55) 9 (18)*** 
     Anticoagulant 114 (46) 96 (48) 18 (37) 
     Beta blocker 194 (79) 163 (82) 31 (63)** 
     Digoxin 39 (16) 33 (17) 6 (12) 
     Loop diuretic 170 (69) 127 (64) 43 (88)** 
     Nitrate 38 (15) 24 (12) 14 (29)** 










Mean (SD) ISWT (m) 
(N=232) peak 
230.4 (150.8) 245.3 (147.7) 171.9 
(150.4)** 
Mean (SD) MLHFQ overall 32.1 (23.8) 30.9 (23.1) 36.9 (26.2) 
 Mean (SD) HADS    
     Anxiety 5.6 (4.4) 5.6 (4.3) 5.8 (4.8) 
     Depression 4.8 (3.5) 4.5 (3.3) 5.8 (4.0)* 
Mean (SD) HeartQoL 
global 
1.8 (0.78) 1.8 (0.74)  1.5 (0.87) 
Mean (SD) EQ-5D-3L 0.70 (0.26) 0.73 (0.24) 0.58 (0.30)*** 
Mean (SD) SCHFI    
     Maintenance 54.5 (15.8) 55.8 (15.6) 49.0 (15.3)** 
     Management 40.7 (22.5) 41.8 (23.6) 38.0 (19.6) 
     Confidence 62.7 (24.3) 63.6 (24.3) 59.2 (24.1) 
SD, standard deviation; IQR, interquartile range; BMI, body mass index; NYHA, 
New York heart association; HF, heart failure; HFrEF, heart failure with reduced 
ejection fraction; HFpEF, heart failure with preserved ejection fraction; LVEF, 
left ventricular ejection fraction; NT-proBNP, NT-pro-brain natriuretic peptide; 
COPD, chronic obstructive pulmonary disease; ACE, Angiotensin-converting 
enzyme; ARB, angiotensin II receptor antagonist; ISWT, incremental shuttle 
walk test; MLHFQ, Minnesota living with heart failure questionnaire; HADS, 
hospital anxiety and depression scale; SCHFI, self-care of heart failure index. 






4.4.1 Level of PA in HF patients 
The average level of MVPA across the HF patients was 283.3 mins/week. 
MVPA ranged widely across the study population from minimum of 0 mins/week 
to maximum of 2626.7 mins/week (standard deviation: 404.1 mins/week).  A 
total of 111 (45%) patients had a level of PA that met current guidelines of 150 
minutes/week of MVPA. Daily PA of HF patients categorised by intensity, days, 
and bout rule is reported in table 4.2. Patients undertook 40.5 ± 57.7 mins/day 
bouted MVPA and 175.9 ± 86.4 min/day unbouted MVPA averaged across all 
days of the week. Unbouted MVPA levels were higher during the week days 
compared to weekend days (p<0.001), but bouted MVPA levels did not differ. 
Levels of bouted and unbouted light PA were higher during weekdays than 
weekend days (p<0.001) and both bouted and unbouted inactivity levels were 
higher at the weekend than during the week (p<0.001). 
Table 4.2: Mean (SD) PA mins/day of different intensity (inactivity, Light PA, 
MVPA) over all days, weekend days and week days 
 All Days Weekend Days Week Days 
Bouted* 
Inactivity 1199.6 (145.7) 1214.5 (150.4) 1193.6 (150.9)*** 
Light PA 200.0 (108.0) 187.9 (114.1) 204.8 (112.2)*** 
MVPA 40.5 (57.7) 37.6 (58.7) 41.6 (60.5) 
Unbouted† 
Inactivity 1075.1 (110.1) 1089.3 (115.7) 1069.4 (113.1)*** 
Light PA 189.0 (46.8) 183.0 (50.9) 191.4 (48.4)*** 
MVPA 175.9 (86.4) 167.7 (86.6) 179.1 (89.2)*** 
PA, physical activity; MVPA, moderate-to-vigorous physical activity. 
*Bouted: activity accumulated in continuous 10 minute duration 
†Unbouted: activity accumulated in any duration 
*** p<0.001 t-test weekend days vs week days 
 
Table 4.3 summarises the characteristics and reported MVPA levels of HF 
patients in this study and across previous HF studies. Daily MVPA levels of the 
HF patients in the present study are higher than the majority of PA levels 
reported in previous studies [2-5]. 
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Mean age 62±14 years 
71% male 
NYHA I-II 60% 
NYHA III 40% 
Accelerometer – SenseWear 
Pro3 Armband worn for 2 
consecutive weekdays 




Median age 74 (range 61-
85) years 
65% male 
NYHA not reported 
Modified 7 day physical 
activity recall questionnaire 
(self-report) 
Accelerometer – Actiheart 
worn for 7 consecutive days 
Not reported (self-
report) 








HFpEF N=53  
Median age 75 (IQR 66-81) 
years 
58% male 
NYHA I-II 75% 
NYHA III 23% 
HFrEF N=16 
Accelerometer – SenseWear 
Mini Armband worn for 4 
consecutive days 
HFpEF – median 12 
(first quartile-third 
quartile 6-30) mins/day 
HFrEF – median 36 
(first quartile-third 




Median age 72.5 (IQR 63-
81) years  
81% male 
NYHA I-II 75% 






Mean age 68.6 ± 9.6 years 
50% male 
NYHA I 6% 
NYHA II 59% 
NYHA III 34% 
NYHA IV 1% 
Non-validated (self-report) 
question “What has the 
subject’s usual pattern of 
exercise been during the past 
2 weeks?” for 3 categories of 
activity (heavy, medium, 
light) 
Not reported 11% 
Present study  N=247 
Mean age 70.9 ± 10.4 
years 
72% male 
NYHA I 16% 
NYHA II 60% 
NYHA III-IV 24% 
Accelerometer – GENEActiv 
worn for 7 consecutive days 
mean 40.5 ± 57.7 
min/day 
45% 
HF, heart failure; PA, physical activity; MVPA, moderate-vigorous physical activity; HFpEF, heart failure with preserved 
ejection fraction; HFrEF, heart failure with reduced ejection fraction.  




4.4.2 Predictors of PA in HF patients 
MVPA minutes per week 
Univariate analyses 
Appendix 4.2 shows the results of the univariate linear regressions between 
MVPA (min/week) and the sociodemographic, exercise capacity and health 
status factors. MVPA (min/week) was positively (p<0.05) associated with cause 
of HF, smoking history, ISWT distance, HEART QoL global and physical scores, 
and overall EQ-5D-3L score. PA was negatively (p<0.05) related to age, body 
mass index (BMI), employment status, NYHA class I-III, NT-pro-BNP, living 
alone, living with child >18 years, diabetes, number of comorbidities, number of 
cardiorespiratory-metabolic comorbidities, taking loop diuretics, Minnesota 
Living with Heart Failure Questionnaire overall, physical and emotional scores 
(where lower scores indicate better QoL), and Hospital Anxiety and Depression 
Scale depression scores. Variables that were closely related to MVPA 
(0.05<p<0.15) included living with a parent, osteoporosis, angina and taking 
nitrates.  
Multivariable analyses   
In model 1: NYHA class I-III, age, BMI, smoking history and employment status 
were all included in the final model as significant contributors, and the model 
accounted for 30% of the observed variance in MVPA (table 4.4). Two patients 
were removed from multivariable analysis due to having both high residual 
(e=2178, e=2040) and Cook’s distance (D=0.07, D=0.15). 
In model 2: ISWT distance was the only significant contributor and explained 
27% of the observed variance in MVPA (table 4.4). Two patients identified with 
high residual (e=2288, e=2182) and Cook’s distance (D=0.17, D=0.14) were 
removed from the analysis.  
In model 3: two patients removed with high residual (e=2202, e=2141) and 
Cook’s distance (D=0.10, D=0.14). ISWT distance, age, BMI, and smoking 
history remained as significant contributors and accounted for 36% of the 
variance in MVPA (table 4.4).  
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The variance inflation factor ranged from 1.1-1.2 across the three models 
indicating a low level of multicollinearity (variance inflation factor >5 indicates a 
level high correlation that may be problematic for modelling).  
Including the patients with high residuals and Cook’s distances decreased the 
R2 across all three models, and resulted in the removal of employment status in 
model 1, and NYHA class being replaced by smoking status in model 3. 
Running a model containing all variables with p<0.15 from the univariate 
analysis produced findings consistent to model 3. Analysis with unbouted (< 10 
minutes in duration) MVPA data, which decreased R2 across all models, and 





Table 4.4: Comparison of multivariable linear regression models to predict minutes/week PA.  
Multivariable model Variables included in 
model (p<0.05) 
Unstandardized beta 






Adjusted R2  
(p-value) 






-133.06 (-196.85 to -69.26) 
-13.36 (-17.25 to -9.47) 
-13.50 (-20.06 to -6.94) 
84.41 (19.49 to 149.32) 
-40.94 (-81.66 to -0.22) 















2. Exercise capacity 
and  health status 
ISWT peak 
constant 
1.2 (0.94 to 1.46) 















0.84 (0.57 to 1.11) 
-10.55 (-14.39 to -6.71) 
-11.17 (-17.54 to -4.80) 
-65.09 (2.11to -128.07) 













PA, physical activity; NYHA, New York heart association; BMI, body mass index; NT-proBNP, NT-pro-brain natriuretic peptide; 
ISWT, incremental shuttle walk test. 




MVPA meeting PA recommendations 
Univariate analyses 
Appendix 4.3 shows the results of the univariate logistic regressions between 
meeting PA guidelines and the sociodemographic, exercise capacity and health 
status factors. The association between meeting PA guidelines was statistically 
significant with age, BMI, employment status, NYHA class I-III, NT-proBNP, 
living alone, living with partner, diabetes, number of comorbidities, number of 
cardiorespiratory-metabolic comorbidities, taking anticoagulants, taking loop 
diuretics, ISWT distance, Minnesota Living with Heart Failure Questionnaire 
overall, physical and emotional scores, Hospital Anxiety and Depression Scale 
depression scores and overall EQ-5D-3L. Variables that were closely related to 
meeting PA guidelines (0.05<p<0.15) included cause of HF and trial site. 
Multivariable analyses 
In model 1: NYHA class I-III, NT-proBNP level, age, and BMI were statistically 
significant contributors included in the model (table 4.5). One patient with high 
residual (e=5.96) was removed.  
In model 2 (exercise capacity and health status variables), only ISWT distance 
was included in the model, all patients were included in this model (table 4.5).  
In model 3 (overall model with all variables identified in models 1 and 2), ISWT 
distance and NT-proBNP level were the only significant variables included in the 
model (table 4.5), all patients were included in this model.  
Sensitivity analysis 
Including the patient previously excluded with high residuals and Cook’s 
distances in model 1, which made no difference to the included variables, but 
decreased the pseudo R2. Running a model containing all variables p<0.15 
made no difference to the included variables but decreased the pseudo R2.  
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Table 4.5: Comparison of multivariable logistic regression models to predict meeting PA guidelines.  
Multivariable model Variables included in 
model (p<0.05) 













0.39 (0.23 to 0.66) 
1.00 (1.00 to 1.00) 
0.96 (0.93 to 0.99) 
0.93 (0.88 to 0.98) 

















1.01 (1.00 to 1.01) 













1.01 (1.00 to 1.01) 
1.00 (1.00 to 1.00) 









PA, physical activity; NYHA, New York heart association; BMI, body mass index; NT-proBNP, NT-pro-brain natriuretic peptide; 
ISWT, incremental shuttle walk test. 





We found that some 45% of HF patients had objectively assessed levels of 
activity that meet current recommendation of at least 150 minutes per week of 
MVPA. HF patients undertook an average of 283.3 min/week MVPA. However, 
the level of MVPA across patients ranged widely from a minimum of 0 
mins/week to a maximum of 2626.7 mins/week. Results also showed that HF 
patients have higher levels of MVPA and light PA, and lower levels of inactivity 
during the week compared to the weekends. 
Our results differ somewhat from the majority of previous studies reporting very 
low levels of MVPA in HF patients [3-5]. However, these previous studies have 
relied on less accurate methods of measuring PA intensity, either using self-
reported measures, or categorising accelerometer measured PA intensity using 
thresholds derived from studies of healthy adults. In this study, we used recently 
developed HF specific accelerometer intensity thresholds for MVPA to 
determine MVPA levels of HF patients. Using HF population specific 
accelerometer intensity thresholds provides a more accurate estimation of PA 
intensity as the increased energy cost of physical activities and limited exercise 
tolerance of HF patients are taken into account. Were we to have used the 
standard thresholds [16-17], it would have been concluded that HF patients 
undertook 33.2 ± 74.1 mins/week MVPA, and only 19 (8%) of patients met PA 
guidelines of 150 minutes of MVPA/week. 
The three multivariable linear regression models, and three multivariable logistic 
regression models revealed that lower PA levels were associated with older 
patients, those with higher BMI, patients who were unemployed, higher NYHA 
classes, current smokers, higher NT-proBNP levels, and lower ISWT peak 
distances.  Since PA has been shown to have stronger associations with 
mortality in HF patients than measures of physical fitness [18], these variables 
may be useful for clinicians to identify those patients for whom PA promoting 
interventions may be most beneficial, and to tailor the information, PA and 




Our results build upon previous studies that showed PA is associated with a 
number of HF patient clinical characteristics [18, 21-25]. Previous studies have 
also shown that patients with lower PA levels had a higher burden of 
comorbidities [18]. In our univariate analyses, we found that apart from 
diabetes, the presence of other comorbidities in isolation were not associated 
with PA level. However, the total number of comorbidities was significantly 
associated with PA level. We found that the number of cardiorespiratory and 
metabolic comorbidities was associated with PA whereas the number of 
physical and musculoskeletal was not associated with PA. We also confirm that 
reduced PA is moderately associated with reduced exercise capacity in HF 
patients, with ISWT peak distance giving the highest univariate R2 value. 
4.5.1 Strengths and limitations 
Our study has a number of strengths. We believe this to be the first study 
objectively assessed PA levels of HF patients using accelerometry and HF-
specific intensity thresholds, That PA is measured and reported using a range 
of methods and metrics makes direct comparison across studies difficult [26]. It 
is common practice to estimate levels of MVPA from accelerometer data using 
previously reported PA intensity thresholds, or proprietary, private algorithms 
from commercially available activity monitors [15-17, 27]. However, these 
thresholds and algorithms are based on studies using young, healthy adults, 
therefore may not be applicable to chronic disease or elderly populations [15, 
28]. As HF patients have limited exercise capacity, the energy cost of physical 
activities are higher, [15, 29] so applying these intensity thresholds risks 
misclassification of PA of HF patients, which is highlighted by our previous 
comment on MVPA conclusions, had we used the standard intensity thresholds. 
Using improved MVPA assessment methods, with HF specific intensity 
thresholds as a potentially more accurate measure in this patient population 
should provide more precise understanding of the relationships between 
sociodemographics, exercise capacity, and health and disease status factors 
and PA levels of HF patients. This study also benefits from a relatively large HF 
patient sample from two clinical trials and recruited from a number of sites 
across UK [9-10]. 
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Our study also has some limitations. Because of tolerability, dose of medication 
was not optimized in all patients. Although each of the multivariable models 
identified factors with significant associations with PA, over 50% of the variance 
in MVPA mins/week remained unexplained. Studies have identified motivation, 
exercise self-efficacy and fear of PA to be barriers to PA in HF patients although 
these were not assessed in this study [30-31]. Sedentary time has been shown 
to be a risk factor for poor outcomes in cardiac rehabilitation participants 
independent of PA level [32]. Inclusion of heart rate data has also been shown 
to improve accuracy of energy expenditure estimation [33]. Future studies may 
consider measurement of these additional factors in order to improve PA 
prediction models. 
Although our study sample size was larger than previously reported studies of 
PA levels in HF patients and associations with various factors in HF [18, 25], the 
frequency count of some of the demographic variables was low such as ethnic 
minorities, presence of some comorbidities and taking particular medications. 
Given the cross-sectional nature of this study, the associations found between 
PA and sociodemographics, exercise capacity and health status factors cannot 
be implied to be causal. Longitudinal studies of objectively assessed PA in HF 
patients using population specific accelerometer intensity thresholds are 
needed to confirm the results of the present study. 
 
4.6 Conclusions 
Almost half of the HF patients in this study had objectively assessed levels of 
MVPA that met current PA recommendations of at least 150 minutes per week 
of MVPA. However, we also found the level of MVPA to range widely across 
patients in our study. Patients were less inactive and performed more PA during 
the week compared to the weekend. Multivariable regression analyses showed 
that patient age, BMI, employment status, NYHA class I-III, current smoking 
status, NT-proBNP level, and ISWT peak distance to be strongly associated 
with the PA levels of HF patients. These factors may be useful to help inform 
clinicians and researchers how best to target subgroups of HF patients who 
could most benefit from interventions to increase their PA. Future accelerometry 
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studies of PA in chronic disease populations need to consistently apply 
population specific thresholds when estimating MVPA. 
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Chapter 5: effect of home-based cardiac rehabilitation (REACH-HF) on 
objectively assessed physical activity in people with heart failure: pooled 




To quantify the impact of home-based cardiac rehabilitation (CR) on objectively 
assessed physical activity (PA) of heart failure (HF) patients and to explore the 
extent by which patient characteristics are associated with a change in PA.   
Methods 
PA data from two randomised controlled trials of a home-based CR intervention 
(REACH-HF) plus usual care versus usual care alone (control) were pooled 
across a total of 247 HF patients. Objective PA was assessed via GENEActiv 
triaxial accelerometer for 24-consecutive hours for 7 days at baseline (pre-
randomisation), post-intervention (4 months) and final follow-up (6-12 months).   
Results  
There was no difference in PA between REACH-HF and control groups in 7-day 
PA levels post-intervention or at final follow-up. At final follow-up there was 
evidence of an increase in weekday moderate-to-vigorous PA (MVPA) (10.9 
mins/day, 95% CI: -2.94 to 24.69), and light PA (26.9 mins/day, 95% CI: -0.05 
to 53.8) and decrease inactivity (-38.31 mins/day, 95% CI: -72.1 to -4.5) in 
favour of REACH-HF. Factors associated with an increase in PA from baseline 
to final follow-up were baseline MVPA, incremental shuttle walk test (ISWT) 
distance, and HADS anxiety score, and living with a child >18 years (p<0.05). 
Living with a parent was associated with a decrease in MVPA (p<0.05). 
Conclusion 
Whilst participation in the REACH-HF home-based CR intervention did not 
increase overall weekly activity, week day PA levels were increased and period 
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of inactivity reduced. CR programmes and related research need to focus on 
the importance improving levels of objectively assessed PA of people with HF. 
 
5.2 Introduction 
Physical activity (PA) has numerous health benefits for heart failure (HF) 
patients including reduced HF mortality and HF hospitalisation, and improved 
quality of life [1-3]. Current PA guidelines recommend 150 mins/week 
moderate-to-vigorous PA (MVPA) or the equivalent of 30 mins/day on 5 or more 
days/week [4, 5]. 
Traditionally, cardiac rehabilitation (CR) interventions have prioritised increasing 
exercise capacity rather than PA behaviour, and evidence that CR increases PA 
toward recommended levels is lacking [6]. To date, only a small number of 
studies have assessed the impact of CR on PA levels in HF patients, mainly 
using self-report measures that are known to be prone to over-reporting.[7] HF 
specific accelerometer intensity thresholds for categorising PA intensity from 
raw accelerometer data have recently been developed, taking into account the 
lower resting metabolic rate and requirement for greater energy expenditure 
during PA in people with HF.[8] Due to the wide range of health benefits 
associated with increased PA, further studies examining the impact of CR on 
levels of MVPA in HF patients are required using more objective, population 
specific PA measurement techniques.  
Home-based programmes are increasingly being used to promote the 
availability and uptake of CR.[9] The primary aim of this study was to assess the 
impact of home-based CR programme (Rehabilitation Enablement in Chronic 
Heart Failure (REACH-HF))[10-13] on objectively measured PA using HF 
specific accelerometer thresholds for estimating intensity. In addition we also 
explored the patient level characteristics associated with a change in PA level.   
 
5.3 Methods 
5.3.1 Study design 
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This study used data pooled from two controlled trials that randomised HF 
patients 1:1 to a home-based CR intervention consisting of a HF manual, chair 
based exercise DVD, caregiver resource and progress tracker plus usual care 
(REACH-HF group) to usual care alone (control group), stratified by site and N-
terminal Brain Natriuretic Peptide (NT-proBNP) (ISRCTN78539530 and 
ISRCTN86234930). Details of these trials are presented elsewhere.[10-13] 
Ethical approval was granted for the two trials by East of Scotland Research 
Ethics Service (15/ES/0036) and the North West Lancaster Research Ethics 
Committee (14/NW/1351).  
5.3.2 Participants 
A total of 266 HF patients (216 HF with reduced ejection fraction (HFrEF), 50 
HF with preserved ejection fraction (HFpEF)) were recruited and completed the 
baseline visit between January 2015 and February 2016, from primary and 
secondary care settings in five UK centres (Birmingham, Cornwall, Dundee, 
Gwent and York). Full inclusion and exclusion criteria are published 
elsewhere.[12-13] In summary, eligible participants were aged ≥18 years with a 
confirmed diagnosis of HF on echocardiography, radionuclide ventriculography 
or angiography within the last 6 months. All participants provided written 
informed consent.  
5.3.3 Data collection 
PA data were collected via accelerometry on three occasions; at baseline (pre-
randomisation), post-intervention (4 months) and final follow-up (6-12 months). 
The final follow-up visit varied between the two trials (6 months for HFpEF 
patients, and 12 months for HFrEF patients) and have therefore been combined 
for this study.   
During the baseline visit, the following data were collected: past medical history 
(i.e. comorbidities, New York Heart Association (NYHA) class, concomitant 
medication), sociodemographic information (i.e. age, ethnicity, employment 
status, smoking status), NT-proBNP measurement via blood sample, exercise 
tolerance via incremental shuttle walk test (ISWT), and health outcome 
questionnaires i.e. disease-specific health related quality of life (HRQoL) using 
the Minnesota Living with Heart Failure Questionnaire (MLHFQ), and the Health 
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Related Quality of Life (HeartQoL) questionnaire; psychological wellbeing using 
the Hospital Anxiety and Depression Scale (HADS) questionnaire; generic 
HRQoL using the EQ-5D-5L questionnaire; and Self-care of HF Index 
questionnaire (SCHFI). 
Physical activity – accelerometry   
At the clinic visits, participants were provided with and instructed to wear a 
GENEActiv triaxial accelerometer (GENEActiv, Activinsights, Kimbolton, 
Cambridge, UK) for 24-consecutive hours for 7 days. Accelerometers were 
returned to the clinical trials unit using postage-paid envelopes. Data were 
downloaded using GENEActiv PC software (version 3.2; Activinsights, 
Kimbolton, Cambridge, UK) and processed in R (R Core Team, Vienna, Austria) 
using the GGIR software package (version 1.5-18, http://cran.r-project.org). 
Initial processing included autocalibration, and detection of abnormally high 
values and non-wear.[14-15] Data were averaged over 5 second epochs and 
Euclidean Norm Minus One (ENMO) was used to quantify the acceleration 
related to movement registered and expressed in milligravity units (mg) using 
the following formula.[16] 
√𝑥2 + 𝑦2 + 𝑧2 − 1000𝑚𝑔 
Once the raw accelerometer data was processed, HF specific accelerometer 
intensity thresholds (inactivity: 16.7mg (left wrist), 18.6mg (right wrist), MVPA: 
43.6mg (left wrist), 45.5mg (right wrist)) were applied to calculate the average 
minutes per day spent inactive, in light PA and MVPA, over all days, weekend 
days and week days. These thresholds were established by a recent 
accelerometer calibration study in 21 HF patients.[8] Average weekly MVPA 
was used to calculate the proportion of patients meeting current PA guidelines. 
For the primary analysis these metrics were calculated using bouted data, i.e. 
sustained periods of 10 minutes or more where accelerometer data lies above 
the intensity threshold (with a 20% allowance for values to fall outside the 
threshold) in line with current National PA recommendations.[4,5] For 
secondary analyses, these metrics were calculated using unbouted data, i.e. 
allowing PA to be accumulated in bouts of any duration. 
5.3.4 Statistical analysis 
151 
 
Descriptive statistics were calculated as means and standard deviations or 
counts and percentages unless otherwise stated.  
Data from final follow-up were used for primary analysis in line with the primary 
end-points of the two trials.[12-13] The intervention effects (i.e. REACH-HF vs 
control) on average min/day PA (inactivity, light PA and MVPA) over all days, 
week days and weekend days were examined using linear regression analysis, 
adjusting for baseline PA (inactivity, light PA or MVPA respectively), treatment 
group and trial stratification variables  (NT-proBNP, centre). Similarly, 
intervention effects on the proportion of patients meeting PA guidelines was 
examined using logistic regression. These analyses were repeated at post-
intervention follow-up, and using unbouted PA data for secondary analyses. 
Linear regression was used to investigate the baseline sociodemographic (e.g. 
age, sex, ethnicity), medical history (e.g. NYHA class, medication), ISWT and 
health status variables (e.g. HRqOL) associated with change in MVPA, 
adjusting for baseline MVPA treatment group and trial stratification variables 
(NT-proBNP, centre).  
Variables with statistical evidence of univariate association with change in 
MVPA (p<0.15) were selected for entry into a series of multivariable regression 
models to establish which variables were independently and most strongly 
associated with change in PA at final follow-up and post-intervention, mutually 
adjusting for trial stratification variables, baseline MVPA and treatment group.  
Model 1 – sociodemographic and medical history variables only, model 2 – 
exercise capacity and health status variables only, and model 3 – 
sociodemographic, medical history, exercise capacity and health status 
variables identified as significant (p<0.05) predictors in models 1 and 2. Checks 
and diagnostics were performed for model assumptions, residuals, 
multicollinearity (variance inflation factor) and influential observations (Cook’s 
distance). AIC and R2 values were used to inform model comparison and 
selection. 
Statistical analyses were performed using Stata (V.15.0; StataCorp, College 





247 patients had accelerometer data at baseline which met the criteria for 
inclusion in analysis. Post-intervention, 198 patients were included, and at final 
follow-up 173 patients were included in the analysis (figure 5.1). Patients were 
predominantly male (72%), had a mean age of 70.9 ± 10.4 years, and majority 
NYHA II (60%), full baseline characteristics are described in table 5.1. PA levels 
did not differ between HFrEF and HFpEF patients at any time point (data not 
shown). 
 
Figure 5.1: Participant flow diagram 
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Table 5.1: Patient characteristics at baseline. Data are presented as N(%) 





Mean (SD) Age (years) 70.5 (10.0) 71.3 (10.7) 
Female Sex 40 (33) 30 (24) 




















Ethnicity (white vs other) 7 (6) 4 (3) 
NYHA class 
   NYHA I 
   NYHA II 









Time since HF diagnosis 
   0 years 
   1 year 









Cause of HF 
Ischaemic 
Non-ischaemic 









Mean (SD) LVEF (%)  38.4 (14.7) 38.1 (15.5) 
Mean (SD) NT-proBNP (pg/ml) 1288.3 (1794.3) 1364.4 (1602.1) 
Living alone 32 (26) 34 (27) 
Living with partner 79 (65) 79 (63) 
Living with child>18 7 (6) 10 (8) 
Living with child<18 3 (2) 2 (2) 
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   Angina 
   Diabetes  
   MI 
   Hypertension 
   Osteoporosis 
   Stroke 
   Asthma 
   Chronic back pain 
   Chronic renal impairment  
   Arthritis 
   Atrial fibrillation 
   COPD 
   Depression 
































   Angiotensin II receptor 
antagonist 
   ACE inhibitor 
   Aldosterone antagonist 
   Anticoagulant 
   Beta blocker 
   Digoxin 
   Ivabradine 























   Nitrate 
   Thiazide diuretic 
1 (1) 3 (2) 
Type of HF (HFrEF vs HFpEF) 24 (20) 25 (20) 
Mean (SD) ISWT (peak 
distance, m)  
241.9 (157.1) 219.1 (144.2) 
Mean (SD) MLHFQ   
     Overall 33.5 (24.5) 30.7 (23.0) 
     Physical 17.3 (11.8) 16.1 (11.6) 
     Emotional 7.7 (7.7) 7.1 (7.0) 
Mean (SD) HADS   
     Anxiety 5.3 (4.5) 5.9 (4.4) 
     Depression 4.8 (3.6) 4.8 (3.4) 
Mean (SD) HeartQoL   
     Global 1.8 (0.8) 1.8 (0.8) 
     Physical  1.6 (0.8) 1.6 (0.8) 
     Emotional 2.1 (0.9) 2.1 (0.9) 
Mean (SD) EQ-5D-5L  0.7 (0.3) 0.7 (0.3) 
Mean (SD) SCHFI   
     Maintenance 56.0 (16.1) 53.0 (15.4) 
     Management  42.0 (24.7) 39.6 (20.4) 
     Confidence 61.9 (25.2) 63.6 (23.4) 
REACH-HF: Rehabilitation enablement in chronic heart failure; SD: standard 
deviation; BMI: body mass index; NYHA: New York Heart Association; HF: 
heart failure; LVEF: left ventricular ejection fraction; NT-proBNP: N-terminal 
proB-type natriuretic peptide; MI: myocardial infection; COPD: chronic 
obstructive pulmonary disease; HFrEF: heart failure with reduced ejection 
fraction; HFpEF: heart failure with preserved ejection fraction; ISWT: 
incremental shuttle walk test; MLHFQ: Minnesota living with heart failure 
questionnaire; HADS: hospital anxiety and depression scale; SCHFI: self-care 






5.4.1 Intervention analysis 
The average change in daily MVPA (over all 7 days) at final follow-up  in the 
REACH-HF group was 4.0 mins/day, but varied greatly (minimum -91.2, 
maximum 291.7, SD 51.5 min/day). The control group average MVPA change 
at final follow-up was -5.1 mins/day (min -135.7, max 173.2, SD 34.2 min/day). 
No between group differences were seen in PA changes over all days or 
weekend days (table 5.2). However, an increase in at least light intensity, 
bouted PA on weekdays and a decrease in weekday inactivity (mins/day) was 
seen in the REACH-HF group with the reverse found in the control group 
(between group differences in favour of REACH-HF: light PA: 26.87 (95% CI -
0.05 to 53.78), p=0.05, inactivity: -38.31 (95% CI -72.13 to -4.5), p=0.03).  
In terms of prevalence of meeting PA guidelines, no differences were found 
between REACH-HF and control group at final follow-up (table 5.3). There was 
an increase in unbouted weekday MVPA and a decrease in weekday inactivity 
in the REACH-HF group, with the reverse found in control group, (between 
group differences showing a trend in favour of REACH-HF (MVPA: 15.18 (95% 
CI -0.32 to 30.67), p=0.06; inactivity: -21.25 (95% CI -43.24 to 0.75), p=0.06; 
appendix 5.1). 
At post-intervention follow-up, the average change in daily MVPA (over all 7 
days) in the REACH-HF group was 1.7 mins/day (minimum -76.9, maximum 
177.7, SD 26.4 min/day). In the control group average MVPA change was 2.0 
min/day (minimum -96.3, maximum 150.6, SD 33.1 min/day). There were no 
significant differences between REACH-HF group and control for all PA 
intensities, days (all, weekend or week), and bouted or unbouted PA, or 
proportion of patients meeting PA guidelines (appendices 5.2-5.4).   
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Table 5.2: Intervention effects on PA outcomes at final follow-up 
 Baseline Final follow-up Δ to final follow-up Between group 
difference (mean, 


































































-24.77 (-56.69 to 7.16) 
p=0.13 















































8.27 (-27.01 to 43.55) 
p=0.64 

















































-38.31 (-72.13 to -4.5) 
p=0.03 
REACH-HF: Rehabilitation enablement in chronic heart failure; SD: standard deviation; MVPA: moderate-to-vigorous physical 
activity; PA: physical activity 




Table 5.3: Intervention effects on proportion of patients meeting PA guidelines at final follow-up 
 Baseline Final follow-up OR (95% CI) p-value 
REACH-HF 
 (n, N, %) 
Control  
(n, N, %) 
REACH-HF 
(n, N, %) 
Control 
(n, N, %) 
Bouted 
Proportion meeting guidelines 
 
42, 80, 53% 
 
45, 93, 48% 
 
43, 80, 54% 
 
39, 93, 42% 
 
0.43 (0.16 to 1.14) p=0.09 
Unbouted 
Proportion meeting guidelines 
 
80, 80, 100% 
 
93, 93, 100% 
 
79, 80, 99% 
 
93, 93, 100% 
 
- 




5.4.2 Univariate regression analysis 
Appendix 5.5 shows the associations between baseline sociodemographic, 
clinical and behavioural patient variables and change in MVPA at final follow-up. 
Older patients were more likely to show a decrease in MVPA (p<0.05), whereas 
patients living with a child >18 years, with greater ISWT distance, and higher 
HADs anxiety score were more likely to increase their MVPA (p<0.05).  
Post-intervention, presence of diabetes and SCHFI maintenance scores at 
baseline were associated with a decrease in MVPA (p<0.05), whereas 
individuals with greater ISWT distance at baseline were more likely to increase 
their MVPA (p<0.05; appendix 5.6).  
5.4.3 Multivariable regression analysis 
Table 5.4 shows the multivariable prediction models at final follow-up. In model 
1: baseline MVPA and living with a parent was associated with a decrease in 
MVPA and living with a child aged >18 years was associated with an increase 
in MVPA. This model accounted for 15% of the variance in change in MVPA. 
Three patients were removed with high residual (e=211.5, e=258.3 and 
e=182.0) and Cook’s distance d=0.35, d=0.39 and d=0.04). In model 2: baseline 
MVPA was associated with a decrease in MVPA, and ISWT distance and HADS 
anxiety score were associated with an increase in MVPA. This model accounted 
for 9% of the variance in MVPA change. In model 3: ISWT distance, living with 
a child aged over 18 years, and HADS anxiety score were strongly associated 
with an increase in MVPA, and living with a parent and baseline MVPA were 
associated with a decrease in MVPA. The model explained 15% of the variance 
in MVPA change at final follow-up. 
Multivariable models to predict change in MVPA post-intervention are presented 
in appendix 5.7. In model 1: living with a parent was associated with an MVPA 
increase, and baseline MVPA and presence of diabetes with an MVPA 
decrease. This model explained 10% of the variance in MVPA change. In model 
2: baseline MVPA was associated with a decrease in MVPA, and ISWT 
distance was most strongly associated with an increase in MVPA. The model 
accounted for 10% of the variance in MVPA change. In model 3: living with a 
parent and ISWT distance were associated with MVPA increases, and baseline 
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MVPA and presence of diabetes were strongly associated with MVPA 
decrease. This model accounted for 14% of the variance in MVPA change. 
Variance inflation factor ranged from 1.06 – 1.18 across the 6 models indicating 




Table 5.4: Comparison of multivariable models to predict change in minutes/day MVPA at final follow-up.  
Multivariable model Variables included 
in model (p<0.05) 
Unstandardized beta 














Live with parent 
Live with child >18 
constant 
-4.03 (-12.19 to 4.12) 
-0.15 (-0.22 to -0.09) 
-0.28 (-3.0 to 2.45) 
-6.58 (-17.27 to 4.10) 
-41.81 (-72.96 to -10.67) 
16.04 (0.05 to 32.02) 

















2. Exercise capacity 








-6.72 (-19.81 to 6.37) 
-0.20 (-0.31 to -0.09) 
0.13 (-4.34 to 4.60) 
-7.39 (-25.08 to 10.30) 
0.07 (0.02 to 0.11) 
1.90 (0.41 to 3.38) 
























-8.37 (-21.13 to 4.38) 
-0.21 (-0.33 to -0.10) 
-0.11 (-4.47 to 4.25) 














Live with child >18 
HADS anxiety 
Live with parent 
constant 
0.08 (0.03 to 0.12) 
30.48 (5.92 to 55.04) 
1.89 (0.44 to 3.33) 
-52.60 (-100.16 to -5.05) 











MVPA: moderate-to-vigorous physical activity; BNP 2000: NT-proBNP above or below 2000 pg/ml; ISWT: incremental shuttle 
walk test; HADS: hospital anxiety and depression score 





We believe this to be the first analysis of randomised controlled trial data of a 
CR intervention (REACH-HF) objectively assessing  PA levels of people HF 
using intensity thresholds  specifically developed for HF. Compared to control, 
participation in REACH-HF had  no impact on daily PA levels when averaged 
over the 7 days of the week. However, separating weekend and weekdays 
revealed important different patterns in the PA response. Average weekday PA 
levels showed a consistent trend where MVPA and light PA increased, and 
inactivity decreased in the REACH-HF group. Over weekend days, the reverse 
appeared to be true, with an increase in inactivity and decrease in PA. 
As some 45% of patients in the REACH-HF trials were already meeting UK PA 
guidelines at baseline (based on bouted data), it may be that there was a ceiling 
effect, where those already physically active would have difficulty further 
improving upon MVPA levels, making small changes in PA difficult to pick up 
statistically. This has often been the case in other CR trials.[6] Our findings also 
suggest that the REACH-HF participants compensated for increased PA during 
the week by being less active at the weekend. Understanding of the behavioural 
effects of a home-based CR intervention could provide a key target for clinicians 
to encourage patients to increase PA and reduce inactivity at the weekend as 
well as during the week, which could lead to more marked increases in overall 
weekly PA levels. 
5.5.1 Regression analysis 
Given the large variation in PA differences from baseline up to final follow-up in 
MVPA, we were interested to investigate potential factors associated with a 
change in MVPA. Living with a parent, presence of diabetes, baseline MVPA 
and ISWT distance, living with a child >18 years and baseline HADS anxiety 
score were closely associated with a change in MVPA up to 12 months follow-
up. Only baseline ISWT distance was consistently associated with an increase 
in MVPA across both follow-up time points. This finding suggests that 
individuals with higher exercise tolerance may find it easier to increase their PA 
levels. Our results also showed that particular living situations of the patient had 
a strong association with PA change (living with a parent or child >18 years), 
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which may indicate involvement of family members is associated with PA 
behaviour change and self-care of HF patients.[19] Understanding the factors 
associated with change in PA with CR intervention could potentially enhance 
development of tailored interventions targeting particular sub-groups where a 
change in PA is either more or less likely to occur.  
Although some studies have shown that PA levels are associated with a 
number of factors including age, BMI, exercise capacity and disease severity in 
HF patients, these have been limited by cross-sectional design that do not 
measure within-person PA change. [20-22] Therefore it is difficult to compare 
our results to other HF or chronic disease studies.  
5.5.2 Strengths and limitations 
This study has a number of strengths. Firstly, the objective measurement of PA, 
and robust and rigorous accelerometer data processing and analysis. Literature 
reporting accelerometer measured PA in HF patients with CR intervention is 
limited, especially in large, representative samples. The use of population 
specific intensity thresholds provides a more reliable estimate of PA levels of 
HF patients, compared to application of commonly used thresholds based on 
healthy adults.[8] However, we acknowledge that these are based on a small 
heterogeneous sample of patients, and is not a perfect method. Application of a 
single threshold for MVPA to a population will always lead to a proportion of 
patients PA being misclassified due to heterogeneity in exercise tolerance. 
Therefore further studies are required to find an alternative approach. 
This study highlights the benefit of extracting more detailed PA data, looking 
beyond a single PA metric (i.e. average weekly MVPA), and considering within-
week differences in PA patterns. Looking at the unbouted data also provides 
useful information in HF patients as performing continuous bouts of exercise for 
10 minutes or more may be challenging with limited exercise tolerance. 
However, in increasing granularity, statistical power is reduced and future 
studies should consider this in sample size calculations. Future studies could 
also consider the distribution of PA both between- and within-days in HF 
patients, since research has shown that afternoon and evening PA decreases 
with increasing age.[23] This could inform future intervention development, 
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targeting inactive periods throughout both the week and the day best placed for 
PA modification. 
As this was an exploratory study, multiple repeated independent tests were 
conducted comparing treatment groups, and between baseline predictors and 
change in MVPA. Given the dangers of multiple testing, which may have led to 
increased Type 1 errors, our results must be treated with caution. In addition, 
variables associated with MVPA change were inconsistent across the two 
follow-up points and explained only a small proportion (10-15%) of the variance 
in MVPA change and combining the final follow-up data sets from 6 and 12 
months may have introduced variation to the data. Whilst the sample size was 
sufficient for this exploratory study, some of the frequency counts of variables 
included in the multivariable models were low. Further studies using objective 
PA assessment are needed in order to clarify the impact of exercise-based CR 




This pooled analysis of randomised controlled trials shows that participation in a 
home-based CR intervention has no impact objectively measured on 7-day PA 
of HF patients but did appear to increase weekday PA levels.   
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Chapter 6: Discussion 
Exercise-based CR is considered a key element in the management of HF with 
strong evidence of improvements in patient exercise capacity and health-related 
quality of life and reduction in the risk of hospitalisation. [1] In addition, exercise-
based CR seeks to increase PA levels so that HF patients meet the national PA 
recommendations of at least 150 minutes per week of MVPA. [2, 3] With 
developments in PA measurement technology in recent years, there has been 
an increasing shift away from self-reported, subjective measures of PA that are 
prone to recall and social desirability bias, towards objective measures of PA. 
Accelerometry has become the most widely used objective method, with wrist-
worn devices often used in large population assessment studies, due to minimal 
burden to participants and high levels of precision and adherence. [4] 
Accelerometers do not directly measure PA, but acceleration, and estimates of 
PA levels are based on the relationship between accelerometer values and PA 
intensity. 
Studies measuring PA levels of HF patients with accelerometers have 
consistently reported HF patients have low levels of PA. [5-7] but are limited by 
small sample sizes and use of proprietary accelerometer algorithms. [5, 6] 
Proprietary accelerometers use closed, commercially owned algorithms to 
transform the raw data into units of activity, such as activity counts, which 
complicates comparison and interpretation of results across studies using 
different brands of accelerometer. Although more reliable than self-report, 
another fundamental limitation of previous studies of PA measurement is that 
they have applied thresholds of acceleration to estimate PA intensity based on 
studies of healthy adults rather than HF-specific populations. [7] Given the 
limitations in physical function of patients with HF compared to healthy adults, 
these previous accelerometry studies are at high risk of misclassifying and 
underestimating HF patient PA levels. [8] Reliable and accurate classification of 
PA levels in HF patients, is needed to not only determine the impact of 
interventions (such as exercise-based CR) on the PA levels of participants but 
also to quantify the potential associations of PA with patient health outcomes, 
such as HRQoL.  
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The overarching aim of this thesis was to contribute to the further knowledge 
and understanding of PA in people with HF, and how exercise-based CR can 
impact this.  
The specific aims were to:  
(1) Undertake a systematic review to assess the evidence as to whether 
participation in exercise-based CR increases PA levels of cardiac 
patients, including those with HF (Chapter 2), 
(2) Undertake an accelerometer calibration study and develop HF specific 
accelerometer intensity thresholds for MVPA and inactivity (Chapter 3),  
(3) Examine the PA levels of HF patients, and associations between 
baseline PA and patient-level factors including sociodemographics, 
exercise capacity, and health-related quality of life (Chapter 4), 
(4) Determine whether a home-based, self-help CR intervention improves 
PA levels of people with HF, and the sociodemographic, exercise 
capacity and HRQoL factors associated with a change in PA level 
(chapter 5). 
This discussion chapter presents: (1) an overview of the key findings of each of 
the empirical chapters 2, 3, 4 and 5, (2) discussion of the overarching strengths 
and limitations of the research work undertaken (3) an overview of clinical and 
policy implications of the results, and (4) identification of directions for future 
research in this field. 
 
 6.1 Overview of the findings  
Systematic review of exercise-based CR  
This study (presented in chapter 2) which built upon two previous reviews [9, 
10] identified forty RCTs comparing exercise-based CR to control (usual care or 
no CR) which measured pre- and post-CR PA levels of 6480 patients (655 HF 
and 5825 CHD). Only 25% (38/145) of reported comparisons reported 
statistically significant increases in PA in favour of CR over control. However, 
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meta-analyses of studies showed participation in CR was associated with an 
increase in some of the PA outcomes i.e.  steps/day (1423 steps, 95% CI 757.1 
to 2089.4, p<0.001) and energy expenditure (878.4 kcal/week, 95% CI 433.8 to 
1323.0, p=0.0001) at short term follow-up, proportion of patients categorised as 
physically active both at short and long term follow-up (short term: RR 1.55, 
95% CI 1.19 to 2.02, p=0.001; long term: RR 1.48, 95% CI 1.19 to 1.83, 
p=0.0003), and reduced proportion of patients categorised sedentary or not 
physically active at short term follow-up (RR 0.76, 95% CI 0.61 to 0.95, p=0.02). 
The study concluded that there was moderate evidence to support that CR 
positively impacts PA levels of patients with CHD and HF compared to control. 
Increases appeared to be consistent regardless of whether studies used 
subjective or objective measures of PA and improvements appeared to be the 
result of the exercise training component of PA rather than the education or 
psychosocial elements of the intervention. [11] 
However, the review identified few studies that fully characterised the 
frequency, intensity and duration of PA undertaken. This study highlighted the 
need for a more complete characterisation of PA and HF specific methods for 
measuring PA, in order to make firm conclusions and determine whether PA 
improvements are clinically meaningful.  
Accelerometer calibration study to develop HF specific intensity thresholds 
This study (presented in chapter 3) sought to determine the accelerometer 
threshold values that correspond to ‘inactivity’ (<1.5 METS) and ‘MVPA’ (≥3.0 
METS) in patients with HF during daily living activities with direct assessment of 
oxygen consumption.  
Twenty-one patients with HF were included in the analysis out of 22 recruited. 
Patients had a mean age of 71 years, were majority male (77%), and NYHA 
class II (82%). The HF specific intensity thresholds identified for inactivity were 
(right wrist: 18.6mg (95% CI 8.8 to 28.4mg), left wrist: 16.7mg (95% CI 7.8 to 
25.6mg), waist: 7.6mg (95% CI -3.1 to 18.4mg)) and MVPA (right wrist: 45.5mg 
(95% CI 31.9 to 59.1mg), left wrist: 43.6 (95% CI 38.5 to 56.3mg), waist: 
40.6mg (95% CI 24.3 to 57.0)). These values are much lower than previously 
published and frequently applied thresholds based on healthy adults i.e. 
inactivity: wrist 45.8mg, waist 46.9mg; MVPA: wrist 93.2mg, waist 68.7mg. [12, 
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13] It was shown that HF patients had lower mean resting metabolic rate than 
the assumed metabolic rate used in standard MET calculations (2.67 vs 3.5 
ml/kg/min) and required more energy to perform daily living activities. For 
example, walking at any speed or perceived effort level constituted a moderate 
intensity (≥3 METS) activity for the majority of patients. This study demonstrates 
the problem of applying accelerometer thresholds derived from healthy 
population studies to patient populations such as HF who typically have low 
exercise capacity. Doing so can result in misclassification of PA intensity, and 
underestimation of PA levels and proportions of patients meeting PA 
recommendations. This study demonstrated that a ‘one size fits all’ approach to 
acceleration cut point methods is not appropriate in HF patients. [8]  
Secondary analysis of REACH-HF trials: level and predictors of baseline PA  
Using the accelerometer thresholds determined in chapter 3, this study (chapter 
4) sought to assess the PA levels of HF patients and then to examine the 
sociodemographic, exercise capacity and health status outcomes associated 
with MVPA levels. The study used data from the two RCTs of a home-based 
CR intervention (REACH-HF). [14, 15] A total of 247 patients were included with 
mean age 70.9 years, 72% male, 99% NYHA I-III. Almost half (45%) of the 
patients were found to meet current PA recommendations of 150 minutes per 
week of MVPA at baseline. However, MVPA ranged widely across the patients 
from 0 to 375.2 minutes per week. Multivariable regression analyses showed 
that patient age, BMI, employment status, NYHA class, smoking status, NT-
proBNP level, and ISWT peak distance were each strongly associated (P<0.05) 
with baseline MVPA levels of patients with HF.  
Secondary analysis of REACH-HF trials: intervention effect and on PA  
Using the data from the REACH-HF trials and the HF-specific PA intensity 
thresholds (chapter 3), this study (chapter 5) sought to determine whether a CR 
intervention improved PA levels of people with HF, and the sociodemographic, 
exercise capacity and health status outcome predictors of change in PA level. 
No differences in PA levels at post-intervention follow-up at any PA intensity, 
days (all, weekend or week) and bouted or unbouted PA data were found 
between REACH-HF compared to control group. However, at final follow-up 
there was evidence of an increase in weekday light PA (26.9 mins/day, 95% CI: 
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-0.05 to 53.8, p=0.05) and a decrease in inactivity (-38.31 mins/day, 95% CI: -
72.1 to -4.5, p=0.03), in favour of the REACH-HF group. Over weekend days, 
the reverse appeared to be true, with an increase in inactivity and decrease in 
PA.  
PA differences from baseline up to final follow-up in the REACH-HF group 
varied greatly from -91.2 to 291.7 mins/day. Multivariable regression analyses 
showed that baseline ISWT distance and HADS anxiety score, baseline MVPA 
levels, presence of diabetes and living with a parent or child >18 years were 
associated with a change in PA. However, these factors were inconsistent 
across the two follow-up time points, and only explained a small percentage 
(10-15%) of the variation in PA change.  
 
6.2 Strengths and limitations 
The strengths and limitations specific to the four studies above are presented 
within each of the respective chapters. There were some important overarching 
strengths and limitations of the research work undertaken and presented in this 
thesis – (1) systematic and comprehensive approach, (2) use of accelerometry 
and data reduction methods, (3) calibration study methods; (4) generalisability 
of study population samples.  
(1) Systematic and comprehensive approach 
An overarching strength of this thesis was its focus on the understanding of PA 
in people with HF, and how exercise-based CR can impact this. The thesis was 
planned with each of the four linked research studies that build upon and feed 
into the next. For example, the systematic review highlighted several limitations 
to the evidence base such as the poor quality of PA measurement with 
considerable variation in the adopted PA assessment techniques and PA 
metrics reported. This warranted the subsequent calibration study to develop 
HF specific acceleration values for estimating the time spent in different PA 
intensities. The HF-specific accelerometer intensity thresholds were then 
applied to the REACH-HF data set to provide valuable information regarding the 
objectively measured PA levels of a large, representative sample of HF patients 
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prior to exercise-based CR and the sociodemographic, exercise capacity and 
health status variables closely associated with PA levels. Finally, bringing 
together all the findings of the previous studies to determine whether a home-
based CR intervention impacts the PA levels of HF patients, and what 
sociodemographic, exercise capacity and health status factors at baseline may 
predict a change in PA. 
Rigorous methods were used in each research stage. The systemic review 
(chapter 2) was conducted and reported in line with Cochrane guidelines and 
Preferred Reporting Items for Systematic Reviews and Meta-analyses 
statement [16, 17] ensuring systematic and transparent methods of searching, 
screening and data extraction. After extensive literature searches, only RCTs 
with control groups involving usual care or no exercise were included to ensure 
high quality evidence, and methodological quality was assessed using the 
Cochrane risk of bias tool [16]. This study provides a comprehensive summary 
of the evidence base for exercise-based CR on PA levels of patients with HF 
and CHD and is the first meta-analysis in this area. In chapter 3, novel HF 
population specific accelerometer intensity thresholds were developed after 
multiple data reduction and analysis techniques were explored in order to find 
the best model fit, and validation analysis performed to check the performance 
of the derived intensity thresholds. This then enabled accurate quantification of 
PA levels and investigation into the factors associated with PA in a cohort of HF 
patients in chapter 4, and detailed assessment of the impact of a home-based 
CR programme (REACH-HF [14, 15]) on the PA levels of HF patients compared 
to usual care control in chapter 5. In both chapters 4 and 5 statistical model 
checks and diagnostics were performed along with sensitivity analyses in order 
to obtain the best model fit for the data. 
(2) Use of accelerometry and data reduction methods  
A strength of the linked nature of the research studies in this thesis was the 
consistent use of accelerometer technology, i.e. GENEActiv accelerometer 
devices (chapters 3-5) and comprehensive, robust and transparent data 
processing and analysis techniques. As noted in the systematic review, 
although accelerometery data have been reported in previous CR intervention 
studies, inconsistency in data processing methods, choice of intensity 
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thresholds and researcher decisions regarding device wear time criteria, 
location and outcome metrics make comparisons across studies challenging. 
GENEActiv devices have known reliability and validity and allow acceleration 
data captured at a high sampling frequency in its raw format. [18, 19] Devices 
that produce raw acceleration values offer researchers increased opportunity for 
development of new and innovative data processing techniques and facilitate 
the comparison between studies. GENEActiv accelerometers have been shown 
to be comparable to other accelerometer brands that also produce raw data. 
[20, 21] The use of the open source R package GGIR also facilitates 
transparent data processing. Accelerometer data collection, processing, 
reduction and analysis techniques used in chapters 3-5 were comprehensive, 
and reported according to best practice papers [22, 23], ensuring reproducibility 
and transparency, as consensus on gold standard methodology, particularly in 
chronic disease populations is yet to be established. [24] 
However, accelerometers are not without limitations. Accelerometers are unable 
to accurately distinguish activities that require upper body effort (i.e. carrying a 
load). This was demonstrated in the calibration study, where measured MET 
values for walking whilst carrying shopping bags were slightly higher than 
walking at the same pace without carrying any load, whereas accelerometer 
values were lower (table 3.2). In addition to this, accelerometers are not able to 
distinguish walking on an incline from walking on a flat surface, or walking up 
flights of stairs, each of which requires greater energy expenditure [25]. 
Accelerometer placement location on different parts of the body also impacts 
measurement accuracy, and it is not clear which placement location provides 
the best recording of whole-body movement. For example, activities requiring 
large amounts of upper body movement whilst stationary are challenging to 
capture with a single accelerometer, as demonstrated by the washing up activity 
of the calibration study, where the wrist accelerometer values were much higher 
(recording values similar to walking), than the waist worn accelerometer (table 
3.2). A single accelerometer will also be unable to accurately capture other 
activities such as non-ambulatory forms of locomotion i.e. driving or cycling, and 
swimming. [26] However, the majority of HF patients’ PA will tend to consist of 
walking and household activity, which both wrist- and hip-worn GENEActiv 
accelerometers have been proven to be accurate at measuring. [18, 19]  
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Within the calibration study (chapter 3), multiple data reduction algorithms were 
explored. SVM, MAD and ENMO [18, 27, 28] are commonly used methods to 
summarise raw triaxial accelerometer data into a single vector magnitude. It 
was found that ENMO was not suitable for further analysis because of the low 
level of movement performed by the HF patients, which led to a large amount of 
0s returned for activities. The data reduction method that performed best in the 
calibration study was SVM, thus the derived accelerometer thresholds were 
SVM based. GGIR was then used in the two secondary analyses of chapters 4 
and 5 to process the accelerometer data of participants. GGIR is designed for 
use with ENMO, and not SVM. However, there is currently no universally 
accepted method for data reduction, analysis and presentation of accelerometer 
outcome data in chronic disease populations. [29, 30] Since other comparable 
intensity thresholds are based on ENMO, and GGIR is currently the only openly 
available processing package for accelerometer data, the accelerometer data 
was run through GGIR the same way for consistency.  
(3) Calibration study methods 
The calibration study methods were informed by studies undertaken by 
researchers in the field of public health, who have identified that cut-points or 
intensity thresholds for adults may not be applicable in elderly populations. [31, 
32] Although there is a large literature base for accelerometer validation and 
calibration studies in children and healthy adults, very few accelerometer 
calibration studies have been undertaken in chronic disease populations and 
none in patients with HF, therefore there have been calls for studies in this area 
[33]. 
The thresholds were developed using robust data reduction and analysis 
methods, after multiple techniques were explored in order to obtain the best 
model fit, and individual resting metabolic rate was measured and used to 
calculate the metabolic cost of physical activities, in contrast to previous 
calibration studies. [12, 13] Leave-one-out cross validation analysis was used to 
validate the derived intensity thresholds. This statistical approach demonstrated 
that the models fit was generally acceptable but performed less well at higher 
PA and MET levels. In an attempt to maximise the applicability of the laboratory 
based activities to daily life, the daily living activities selected for the protocol 
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were determined with the assistance of a HF patient and public involvement 
group as activities they typically undertake on a day to day basis, and that 
would make up the majority of their overall daily PA.  
It is acknowledged that this study has methodological limitations, which are 
common among all laboratory calibration studies. The study is limited by a small 
heterogeneous sample recruited from a single centre. In addition, the physical 
activities were undertaken in a laboratory rather than free living conditions.  
Laboratory based studies can only include a narrow range of specific activities, 
whereas in a free living scenario many more activities are undertaken that may 
look similar to laboratory based activities in terms of raw acceleration, but may 
in fact be entirely different behaviours with different intensities. Overall, these 
limitations mean that the derived cut-points may only be applicable to the small 
sample of patients performing the specific activities undertaken as part of the 
protocol. 
The key challenge with this methodological approach to categorising 
accelerometer measured PA intensity is the substantive level of between 
subject variability in METS and accelerometer values in populations with 
compromised resting metabolic rate and exercise tolerance. [31-34] Multiple 
studies have shown that application of the various available cut-points and 
intensity thresholds for adults and children to the same sample results in largely 
discrepant conclusions as to the volume of MVPA undertaken, and prevalence 
of meeting PA recommendations. [33-40] When both the HF specific and adult 
intensity thresholds for MVPA were applied to the REACH-HF patient data set 
significantly different conclusions regarding PA levels of the patients was found 
depending on the threshold used (i.e. 45% patients met PA guidelines using the 
HF specific thresholds vs 8% using the adult thresholds) with 63% agreement 
using Cohen’s K test (95% CI 57% to 69%, Κ= 0.19, p<0.001). However, 
application of a single cut point based on small, heterogeneous samples 
performing laboratory-based activities will always fail to generalise to the entire 
population performing free living activities.  
A downside of the ability to develop new and innovative techniques with raw 
accelerometry data, is that it has led to considerable methodological 
inconsistencies in research, and consensus regarding best practice methods 
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has yet to be reached, which means data harmonization is still a challenge. 
Studies in public health have shifted towards more advanced statistical methods 
such as machine learning. [41, 42] These methods move beyond intensity 
classification, and enable researchers to identify specific behaviours. However, 
because national PA recommendations are based on PA intensity, cut-point 
methods are still used in epidemiological and interventional studies, [7, 43] 
despite knowledge that this may not be appropriate. [8] Therefore, even with 
limitations in terms of the level of precision, intensity classification via calibration 
studies remains useful until a better solution is agreed upon.  
(4) Generalisability of study population samples 
A limitation common to each of the studies that make up this thesis is their 
limited sample size that can limit the generalisability to the wider HF population. 
Many of the studies included in the systematic review and meta-analyses had 
small samples recruited from a single centre, and an average patient age of 58 
years, lower than the national average of patients undertaking CR (centre 
based 65 years, home based 67 years), and much lower than the mean age of 
HF patients at diagnosis in the UK of 77 years. [44, 45] Individual studies were 
often underpowered to detect small differences in PA, with only 4 of the studies 
including formal sample size calculations based on PA outcomes. 
The calibration study presented in chapter 3 is limited by a small heterogeneous 
sample recruited from a single centre. The patient sample of 21 was small in 
comparison to some previous calibration studies [12, 13] and heterogeneous. 
However, power calculations suggested a minimum sample size of 18 patients. 
Nevertheless, this limits our ability to draw firm conclusions, in particular 
regarding how disease severity may influence the accelerometer values relating 
to MVPA, since few patients at higher NYHA class (i.e. III-IV) were included in 
the study. Due to the limitations of PhD budget, timeline and logistics the 
sample was chosen for convenience. The patients included in the calibration 
study were comparable to the REACH-HF patients in terms of age and 
comorbidities, however the REACH-HF patients performed better in their 
baseline ISWT.  
Although the study samples of the multicentre REACH-HF studies are larger 
and more representative of the wider HF population, [12, 13, 46-52] the 
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frequency counts of some of the predictors such as ethnic minorities, presence 
of particular comorbidities and taking particular medications were low, and few 
patients classified as NYHA class IV were included, limiting generalisability. In 
chapter 5, it was demonstrated how aggregating PA behaviour into a single 
metric, i.e. average weekly MVPA, can mask other important associations in PA 
data. Increasing the granularity of the data in order to observe differences in 
weekend and weekday PA, provided valuable information about the ways in 
which exercise-based CR can impact PA behaviour. However, the limited 
sample size in the REACH-HF data set, combined with the increased 
granularity of the PA data meant the analysis may be underpowered. The 
results should also be interpreted with some degree of caution as multiple 
repeated tests were conducted. 
 
6.3 Implications for practice and policy 
The findings presented in this thesis have several important implications for 
both clinical practice and healthcare policy relating to two broad topics – (1) 
practice of PA assessment, and (2) implications for CR practice.  
(1) PA assessment 
Accelerometer PA measurement in chronic disease populations is under-
researched and consensus regarding the most appropriate and accurate way to 
measure PA in chronic disease populations is urgently required. The calibration 
study presented in chapter 3 aimed to develop an improved approach to 
categorising PA intensity in HF patients and provide a signal to clinicians and 
researchers that thresholds for moderate intensity based on healthy adults are 
not appropriate for application in HF patients. In line with many previous studies 
reporting low PA levels of HF patients which used accelerometer intensity 
thresholds based on healthy adults, [5-7] application of the Hildebrand 
thresholds [12, 13] to the REACH-HF data set led to the conclusion that 8% 
(9/247) of patients met PA recommendations. In contrast, application of the HF 
specific thresholds derived for MVPA in the calibration study concluded that 
45% (111/247) of patients met PA recommendations, with an average daily 
MVPA of around 40 minutes. The HF specific thresholds for MVPA were lower 
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than the Hildebrand thresholds for inactivity, which demonstrates how 
application of thresholds based on healthy adults risks misclassification of PA 
intensity of HF patients. Despite the limitations of this method detailed in the 
previous section, it is suggested that researchers measuring PA levels of HF 
patients with raw accelerometers use these thresholds until a better method is 
published. 
Chapter 5 demonstrated the value of taking a more in-depth and detailed 
analysis approach with accelerometer data. Simply considering a single 
aggregated PA outcome such as overall weekly minutes of MVPA may mask 
important associations, preventing further understanding of how exercise-based 
interventions could be working, or not working. The analysis of the REACH-HF 
cohort revealed differences in PA patterns between days, i.e. more PA and less 
inactivity during the week compared to weekends. There is also evidence in 
older adults that with increasing age, PA tends to be compressed into the 
morning, with increased inactivity during the afternoons and evenings, [53] 
supporting the recommendation for accelerometer data to be studied in greater 
detail. Increasing the granularity of the data, however, decreases the statistical 
power of the analyses, therefore sample size calculations for future studies 
should reflect this. Researchers should carefully consider the PA outcome 
metrics of interest to be extracted from the raw data, and how best to present 
these data. 
Conventionally, in line with National PA recommendations for MVPA to be 
accumulated in bouts of at least 10 minutes, accelerometer data is usually 
processed and reported in terms of bouts. [3] The most common bout criteria 
used in accelerometer data processing are bouts of 10 minutes or more above 
the threshold for MVPA with an 80% allowance (i.e. allowing for up to 2 minutes 
of acceleration values to be below the threshold). In the United States and UK, 
updated PA recommendations have recently been developed, removing the 
need for PA to be accumulated in bouts of a minimum duration, informed by 
emerging research showing that PA of any bout length has significant health 
benefits. [3, 52] Current methods for defining bouts of PA based on intensity are 
potentially flawed, for example a 20 minute bout of PA at an accelerometer 
value just below the threshold for moderate intensity would not be classed as 
MVPA, whereas 8 minutes (allowing for up to 2 minutes interruption) at a value 
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just over the threshold for moderate intensity would count as MVPA, despite the 
former PA accumulating a greater volume. Since some HF patients limited 
exercise capacity restricts them from being able to perform extended bouts of 
continuous PA, PA of all durations is also useful to report, as in chapters 4 and 
5 of this thesis. Researchers may uncover interesting relationships or data 
trends in intermittent PA that would not be seen if only sustained PA (10 
minutes) is reported. Other authors support this, stating that researchers should 
consider sample characteristics when investigating PA accumulated in bouts of 
varying durations [34].  
(2) Implications for CR practice 
The findings of the systematic review and meta-analysis (chapter 2) and the 
secondary analysis of the REACH-HF individual patient data set (chapter 5), 
provide evidence that exercise-based CR can have a modest positive impact on 
PA levels of HF patients. These findings, in conjunction with other recent 
individual patient data meta-analyses and an updated Cochrane review [55-57] 
continue to support the class 1A recommendation for CR in HF. [58] Therefore, 
one of the key implications for practice is that we should continue to encourage 
HF patient participation in CR, whether it be a centre- or home-based 
intervention as recommended by the updated NICE guidelines [1]. 
Traditionally CR programmes have focussed on aerobic exercise training with 
the main aim to increase exercise capacity rather than PA promotion. Whilst 
increases in exercise capacity can be achieved with CR programmes as short 
as 4 weeks, [55] increases in PA may require a long-term change in behaviour 
and habits of the patient. Across all the studies in this thesis, the close 
relationship between exercise capacity and PA level has been evident. For 
example, REACH-HF patients who achieved a greater ISWT distance at 
baseline were more likely to be physically active at baseline, but also more 
likely to increase their PA levels up to 12 months follow-up. In its current format, 
we have shown modest positive influences of CR on PA levels of HF patients. 
But with studies demonstrating the close relationships between PA and key 
measures of exercise capacity and HF severity, and some indicating that PA 
levels are more important than exercise capacity in relation to mortality [46-51] 
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CR programmes may need to adapt, placing greater emphasis on increasing 
PA levels in the long term specifically.  
In addition to a greater focus of CR on PA levels, there may be benefits to gain 
from simplifying the PA advice given to HF patients. A key target of CR is for 
patients to meet current National PA recommendations for adults and older 
adults of 150 minutes per week of MVPA. It is important to note that these 
current PA guidelines have been developed based predominantly on self-
reported measures of PA. [1] The calibration study presented in chapter 3 
showed that for the majority of participating HF patients, any walking activity, 
even walking at a pace perceived by the patient to be light, constituted a 
moderate intensity PA (≥ 3 METS). Given this finding, clinicians may consider 
encouraging patients simply to walk more, not necessarily aiming to reach any 
particular speed, or effort level, as this is likely to have significant health 
benefits [43]. The interventional analysis presented in chapter 5 showed that the 
REACH-HF intervention increased weekday PA, thereby decreasing weekday 
inactivity, whereas the opposite appeared to be true at the weekend. This may 
present a tangible target for clinicians and CR professionals to encourage 
patients to increase PA both during the week and the weekend; making a 
conscious effort not to compensate for exercise by sitting. A simple message of 
sit less, move more, every day, could be easier for patients to understand and 
implement into their lifestyle in the long term, and may lead to more marked 
increases in overall PA levels and reduction in sedentary time rather than a 
message that focuses on 150 minutes or more per week of PA at a minimum of 
moderate intensity [43].  
This approach has also been suggested by other researchers, since cardiac 
patients have been observed to have consistently high levels of sedentary time 
regardless of whether the patient was entering, completing or long removed 
from a CR programme [59]. Freene and colleagues [60] recently reported that 
participation in a 6 week hospital-based CR programme did not affect 
accelerometer measured time spent in MVPA or sedentary behaviour despite 
increases in self-reported MVPA, but did improve time spent in light intensity PA 
along with exercise capacity. In this study, thresholds for activity intensity based 
on healthy adults were applied, so where an improvement in objectively 
measured light intensity PA is seen, this may in fact be MVPA if population 
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specific thresholds had been applied. Nevertheless, the authors conclude that 
alternative approaches to increasing PA should be considered such as sit less, 
move more, which this thesis supports for HF patients. Studies in the context of 
public health also suggest that the approach of ‘sit less, move more’ may be a 
better alternative. Ekelund et al. [43] showed that higher levels of total PA, 
regardless of intensity, and less time spent sedentary are associated with 
reduced risk of all-cause mortality in middle aged and older adults in a non-
linear dose-response relationship. However, this study was cross-sectional in 
design, and so changes in PA over time and their effect on mortality and other 
health outcomes remain unclear. [61]  
The cross-sectional study reported in chapter 4 identified a number of 
sociodemographic, exercise capacity and health factors that are closely 
associated with PA levels of HF patients prior to intervention. Lower levels of 
PA were associated with patients who: were older, had a higher BMI, were 
unemployed or retired, had a higher NYHA class, were current smokers, had a 
higher NT-proBNP level or walked less distance on their ISWT. These factors 
may be important for clinicians and researchers to inform development of 
interventions and target specific subgroups of HF patients who could benefit 
most from PA interventions.  
Chapter 5 presents the sociodemographic, exercise capacity and health status 
variables that were related to a change in PA level up to 12 months follow-up. 
The variables that were closely associated with a change in PA level were 
baseline ISWT distance, HADS anxiety sore, presence of diabetes, and living 
with a parent or child >18 years. However, these associations were inconsistent 
across the two follow-up time points, and the multivariable regression models 
only explained a small amount of the variance in PA change. Nevertheless, 
since this is the first study to investigate the patient characteristics associated 
with changes in PA level, these results provide an early indication to potential 
subgroups of patients who may require more or less intensive intervention in 
order to maximise intervention efficacy.  
 
6.5 Future research directions 
185 
 
The research studies undertaken in this thesis identified a number of areas for 
future research.  
 (1) Accelerometer measured PA intensity 
Objective, accelerometer measured PA and sedentary behaviour is likely to 
remain a feature of CR and HF trials as technology becomes more advanced 
and devices become less expensive. Therefore, until consensus is reached on 
the gold standard, criterion measure of PA, continued improvements are 
needed in the methods used to extract the clinically meaningful information 
researchers require from raw accelerometer data, specifically in chronic disease 
populations such as HF patients. It is essential that we measure PA accurately 
in order to further examine the relationships between PA and various health 
outcomes and assess the effectiveness of CR interventions.  
Multiple data reduction methods to extract a single accelerometer value from 
the raw triaxial data were explored within the calibration study. ENMO was 
found to return a high number of 0 values and so was excluded from further 
analysis. This has been found previously, [28] and it seems likely that in 
populations where a large proportion of activity is at low intensity, ENMO may 
be an inappropriate method for calculating a single accelerometer value from 
multi-axis devices. GGIR is the only open source, freely available raw 
accelerometer processing package, which at present can only return ENMO 
values. Therefore, caution is advised for future studies using this method in HF 
populations, until a solution to this is agreed upon. A data reduction method 
more appropriate for use in populations where the majority of physical activities 
are a low intensity should be explored in greater depth. In addition, new open 
access code that has a user defined summary measure of acceleration is 
required. 
In accordance with the findings in this thesis for HF patients, studies in older 
adults have shown that application of accelerometer thresholds for adults may 
not be applicable. [35, 36, 62] Although an improved method of estimating 
absolute PA intensity specifically in the HF population has been developed as 
described in chapter 3, calibration studies are limited in their ability to generalise 
to a wider population than the small sample used. Future studies should ensure 
recruitment of the often underrepresented HF groups, i.e. NYHA classes III-IV, 
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HFpEF patients, and also accounting for the smaller number of patients that 
reach the latter stages of the ISWT so that a range of fitness levels are also 
represented. Power calculations to inform the appropriate sample size will 
enable researchers to examine potential differences between NYHA classes.  
In the field of PA and public health, there has been a shift towards machine 
learning based methods for device calibration and validation in order to 
measure PA and sedentary behaviour more accurately. Machine learning based 
modelling is a more advanced statistical method, which utilises artificial 
intelligence to automatically learn and improve from experience. This enables 
the ability to capture nonlinearities and complex relationships in raw 
accelerometry data in order to identify thresholds without the need for 
laboratory-based calibration studies. [41, 42] It provides opportunities beyond 
identifying the intensity of PA, to also predict the type of activity and energy 
expenditure. [41] An advantage of this method is the use of the raw acceleration 
data, with no need for reduction into a single summary measure of acceleration 
in epochs. However, Farrahi et al. [41] recently performed a systematic review 
of machine-learning approaches to calibration and validation of accelerometers 
and showed that the capability of machine learning based models to generalise 
to independent populations in free living settings still remains a challenge, 
without consensus on a gold standard, criterion measure. The heterogeneity of 
previous studies, and wide-ranging parameters and methodological decisions 
that affect the model results made it difficult to provide recommendations on the 
optimal parameters, and consensus remains in question. Nevertheless, studies 
applying these advanced methods in HF populations are also required to further 
understand PA levels in this population, and how they differ from healthy adults. 
While PA recommendations remain based on estimates of PA intensity based 
on single values of acceleration, there will be difficulty in accurately classifying 
what ‘moderate intensity’ is for an entire population, particularly in a population 
of people with compromised but very heterogeneous exercise capacity such as 
HF patients. Using absolute, fixed accelerometer thresholds or cut-points to 
define intensity will always misclassify the relative intensity of PA for a given 
person, due to heterogeneity of capacity within a population. One solution is to 
calculate individualised intensity thresholds, relative to the individual’s exercise 
capacity. A small number of previous studies have investigated relative intensity 
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thresholds in other populations (i.e. healthy adults, healthy older adults and 
postmenopausal women), demonstrating the strong influence of exercise 
capacity on the inter-individual variability in accelerometer values and resulting 
relative activity thresholds [63-67]. Common among all the findings of these 
studies is the increased accuracy of PA level estimations using relative intensity 
thresholds compared to absolute thresholds. For example, Shrack et al., [67] 
using a combination of heart rate and accelerometer measurement, compared 
relative to absolute cut-points to assess PA levels of older adults. Data showed 
that time spent in MVPA, relative to the individual, contradicted the general 
consensus that older people are less active, after considering the changes in 
physiology, functional ability and subclinical burden. Future studies need to 
perform multiple maximal and submaximal exercise tests, in order to determine 
measures such as VO2 max, lactate threshold and heart rate reserve to inform 
individualised relative accelerometer thresholds. However, such detailed 
exercise protocols may be challenging and burdensome for patients. These 
methods would also be expensive and time consuming limiting their applicability 
to larger scale surveillance studies. Nevertheless, improved methods for 
capturing the frequency, intensity, duration and type of PA in HF patients would 
provide more accurate estimates and further understanding of PA levels in this 
population, and requires additional investigation. 
Studies in public health are also now beginning to investigate whether lower 
intensities of PA have health benefits, with results suggesting light intensity PA 
is inversely associated with all-cause mortality risk and cardiometabolic health, 
independent of confounders including age and MVPA. [43, 68, 69] Since a 
single accelerometer threshold was applied to estimate intensity in this 
population-wide study, it may be that relative MVPA has been detected rather 
than light intensity PA. The same may also be true of HF patients, however until 
we are better able to categorise accelerometer measured PA intensity in this 
patient group, the health benefits of PA at differing intensities remain unclear.  
As outlined in the previous section, the increasing popularity of commercially 
available fitness trackers, activity monitors and smart watches that provide 
consumers with an abundance of health information including daily step counts, 
heart rate, and activity intensity could prove to be useful tools in CR 
interventions, providing patients with goals and targets, and providing 
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immediate feedback. However, these commercial devices will be limited by 
proprietary algorithms to measure the different PA metrics, which will limit 
comparability with other PA measurement methods such as raw 
accelerometers. However, since their popularity is increasing, and the next 
generation of HF patients are very likely to be more technologically adept, 
validation studies will be required before they can be used in clinical practice. 
(2) Alternative PA metrics 
National PA guidelines are primarily based on self-reported PA data, and 
recommendations for HF patients are the same as for healthy adults. Alongside 
intensity, PA can also be categorised according to frequency, duration, type, 
and pattern. There are now a wealth of opportunities to explore new 
subcategories of data, or physiologically meaningful patterns of behaviour, 
which may prove to be better indicators of overall PA, and show stronger 
associations with health outcomes. As accelerometer derived PA outcome 
metrics evolve, becoming less influenced by individual or population specific 
characteristics, they could be used to inform new PA guidelines, both for the 
general population, and specifically for CR participants including those with HF. 
[70]  
Whilst emerging studies have suggested that PA of light intensity also has 
benefits, with a curvilinear relationship between PA and health outcomes, [43, 
68, 69, 71] results presented within this thesis have shown that the application 
of a single accelerometer threshold to determine PA intensity across a 
population is not appropriate, and for some within the population, PA labelled as 
light intensity may in fact be at least moderate intensity and vice versa. 
Therefore, it may be that a measure of overall PA, which is not subject to 
categorisation based on intensity is more appropriate. This, theoretically, would 
also overcome the need for multiple cut-points and calibration studies for 
different subpopulations such as age categories and different chronic disease 
groups. For example, the UK Biobank and Whitehall II studies [7, 72] report 
overall ENMO as a PA metric. However, this single value currently has little 
clinical meaning, and is difficult for those not familiar with accelerometer data to 
understand. Future research using an overall PA metric should aim to 
189 
 
determine the value at which associations with health outcomes such as 
mortality, which would aid understanding with a reference or target value.  
In addition to this, exploring differences in the duration of bouts of PA, i.e. 
sustained activity versus intermittent activity in HF patients may provide 
important additional information. Since longer, sustained bouts of aerobic 
activity may be more difficult for the less fit HF patients, or those with HFpEF to 
achieve, [73] this may offer an alternative target for PA interventions. For 
example, a patient at the start of an exercise-based intervention may accrue 
intermittent activity in very short bouts, requiring lots of breaks, but by the end of 
the intervention is able to complete a longer continuous bout of activity. Would 
this have health benefits if the patient is not necessarily completing a greater 
volume of PA overall? Melin et al. [74] explored accelerometer measured 
walking patterns in HF patients and found that variability in PA (characterised by 
low walking speed and frequent pauses) had an additive value over and above 
exercise capacity in a prognostic model. Studies should therefore explore 
differences in activity bout durations, and their association with health outcomes 
in HF patients.  
Since accelerometers assess PA continuously with a time stamp, within- and 
between-day patterns of how PA is accrued can be monitored. Chapter 5 
demonstrated the value of looking at PA data in more detail, and showed a 
trend for both MVPA and light intensity PA to increase only during the week with 
REACH-HF intervention. Other studies have identified a diurnal pattern of PA in 
older, non-working populations with a mid-morning peak and gradual decline 
with age in activity in afternoon and evening activity. [53] Understanding these 
types of patterns of PA behaviour in HF patients, who experience higher levels 
of fatigue than the general population, may help to identify potential windows 
throughout the day where PA modification will be best placed. Further research 
is needed here, and measures of within- and between-day variability in PA 
accrual should be explored.  
Identifying alternative PA metrics based on duration, timing, or type of PA as 
well as intensity, and their relationships with health outcomes in HF patients, 
may enable researchers to determine an ideal ‘dose’ of PA, or prescriptions 
similar to medications. As many previous studies have been observational or 
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cross sectional in design, larger, longitudinal studies are required. Researchers 
should also ensure sample sizes are large enough to detect differences in the 
PA data, especially when the outcome measures of interest are more granular.   
(3) CR interventions 
There has been a large increase in the volume of studies measuring PA level as 
a secondary outcome of RCTs of CR over recent years, as PA and sedentary 
time have become key targets of CR. [2] However, much like the field of public 
health, the primary challenge facing researchers is developing effective, 
sustainable and cost-effective interventions to generate long term PA behaviour 
change to successfully reduce rehospitalisation, and improve HF patient’s 
symptoms and quality of life. Traditionally, the exercise training element of CR 
intervention has focussed on increasing functional exercise capacity (VO2) as 
the key target. Major benefits of increased PA levels in HF patients, 
independent of exercise capacity include improvements in quality of life, and 
reductions in all-cause mortality, HF mortality, and HF hospitalisation.  [75-77] 
In addition, many HF patients are not keen to undergo tests of maximal exercise 
capacity such as cardiopulmonary exercise tests on treadmills or bicycle 
ergometers and may be more amenable to PA measurement via accelerometer 
[78]. Although the results of the studies presented in this thesis have shown 
how closely associated exercise capacity (measured via ISWT) and PA levels 
are, it appeared the fitter patients at baseline were more likely to increase their 
PA levels with REACH-HF intervention. However, it is the less fit, and less 
active patients that may need to be targeted for more intense intervention, as 
these patients will have the most to gain from increasing their PA. Therefore, 
more intense interventions specifically tailored or targeted at those with lower 
PA levels could be explored. 
New models of CR intervention that specifically target PA levels of participants 
are emerging. The PATHway I trial which has now completed recruitment for a 
multicentre pilot RCT, proposes an internet-enabled and sensor-based home 
exercise platform for individualised CR, where PA promotion is the basis of the 
intervention, and objectively measured PA level is the primary outcome. [79] 
Other such trials would provide valuable longitudinal data to further 
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understanding of the ways in which CR intervention can impact PA levels in 
patients with HF.  
Although exercise-based CR effects appear to be consistent regardless of 
delivery method (i.e. centre vs home based), research should continue to 
pursue alternative modes of delivery in order to improve CR uptake in HF 
patients (in the UK, less than 20% of patients discharged from hospital after HF 
diagnosis are offered CR, and less than 5% attend at least one session of CR 
[50]), and in line with NICE guidelines that recommend a ‘personalised, 
exercise-based CR programme in a format and setting that is easily accessible’. 
[1] One such potential mode of delivery is through mobile or electronic health, 
which includes internet based interventions, mobile applications or various 
wearable devices. Potential benefits of this mode of delivery include access to 
the intervention at any location, at any time, which allows programmes to be 
more tailored to fit into the individual’s lifestyle and overcomes barriers of face-
to-face contact. [80] It may be that these home-based mobile interventions are 
more suitable for increasing daily PA than structured group exercise 
programmes as it is easier to implement into daily life. There is increasing 
evidence that these types of health interventions are feasible, acceptable and 
can support lifestyle modification in those with CHD, however use of these 
interventions to increase PA levels of those with HF is yet to be investigated 
thoroughly, and there is concern that some of these interventions have been 
developed with little theoretical underpinning, or poor description of the 
behaviour change techniques utilised. [80, 81]  Future studies investigating the 
integration of theoretically informed, mobile or internet technology applications 
and their impact on increasing HF patient participation in CR and improving PA 
levels are warranted.  
Buys et al. have shown that cardiac patients express interest for technology 
enabled home-based CR. [82] PA technology continues to develop rapidly, and 
availability and popularity of commercially available wearable activity monitors 
or fitness trackers are increasing, even within clinical research. [83] Popular 
devices include Fitbits, Garmin, Misfit, Apple and Polar, and commonly contain 
sensors such as pedometers, accelerometers and photoplethymography (to 
estimate heart rate). [83] ter Hoeve et al. [84] found that the addition of 
pedometer-based, face-to-face group counselling sessions to a standard CR 
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programme increased daily step counts and time spent in prolonged MVPA. 
Advances in device quality offer both researchers and patients new 
opportunities with access to an abundance of PA information which may be 
useful tools in CR interventions. Although these devices are limited by 
proprietary algorithms for converting the raw data into meaningful PA units, and 
often only display a limited set of PA metrics on the device or associated mobile 
app, they may be useful for enhancing the delivery of PA and CR interventions, 
facilitating activity tracking, goal setting and feedback. [85] Thorough validation 
of these newer devices would be required however, especially in chronic 
disease populations such as elderly HF patients with multiple morbidities. [45]  
In addition to development of new, accessible and PA focussed models of CR 
intervention, chapter 2 of this thesis identified there is a paucity of studies 
reporting PA outcomes over the long-term, therefore studies with long term 
follow-up of a year or longer are also required. Furthermore, patients with more 
severe symptoms of HF, i.e. NYHA class IV have been greatly 
underrepresented in the studies that make up this thesis, so conclusions as to 
whether accelerometer thresholds for MVPA and inactivity differ across the 
different NYHA classes remains unknown, along with associations between PA 
level and other factors in the more severely limited patients. This is also true of 
the majority of HF and CR research, and studies including underrepresented 
groups such as older, NYHA class IV, HFpEF patients have been called for. [55]  
 
6.6 Conclusions  
Maintaining PA levels is important to the health of patients with chronic disease 
including HF. Nevertheless, objective measurement of PA in these groups 
remains under researched. The body of research presented in this thesis 
provides new and important information in this field including: (1) improved 
methods for the objective and reliable assessment of PA in chronic disease and 
HF specifically; (2) better understanding of the PA levels of HF patients and (3) 
how exercise-based CR interventions can impact upon PA in HF patients.   
Overarching research limitations included small patient samples and therefore 
the potentially limited generalisability of findings to the wider HF population. 
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There are also major limitations in accelerometer calibration methods, both 
within this thesis and in the wider field of research, with a lack of consensus on 
the gold standard method of measuring PA intensity in chronic disease 
populations.  
HF patients should continue to be encouraged to participate in exercise-based 
CR, and clinicians and practitioners are urged to refocus CR to enhance PA 
rather than simply improving exercise capacity. New modes of delivery such as 
internet based and technology enabled interventions should be explored to 
assess their impact on both CR uptake and changes in levels of PA. 
Researchers and clinicians should also explore the possibility of moving beyond 
a single PA metric, which could inform intervention design (i.e. identifying and 
targeting inactive periods throughout the day or week), and provide alternative 
goals for interventions beyond increasing weekly MVPA. Research into PA 
measurement in HF patients should follow the developing sophisticated 
methods being explored by public health researchers, ensuring that HF patients’ 
PA measurement continues to improve, and patients’ PA behaviour is not 
misclassified. Further research is required towards identifying a better solution 
and consensus on the best methodological approach to extracting behaviourally 
meaningful metrics from raw accelerometer data. 
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A search strategy was developed in consultation with information specialists 
experienced in systematic review searching. The following databases were 
searched from inception to January 2017 for relevant RCTs: MEDLINE, 
EMBASE, CENTRAL, CINAHL, PsychINFO and SportDiscus. A copy of the full 
strategy is provided (appendix 2.2). We also undertook supplementary searches 
of the following catalogues for grey literature (i.e. publications beyond the 
control of commercial publishers): EThOS, Open Grey, Zetoc and PQDT; trial 
registries: ClinicalTrials.gov, The WHO International Clinical Registry Platform 
(ICTRP), UK Clinical Trials Gateway, ISRCTN registry; forward and backward 
citation checking and searched the reference lists of included studies and 
previous systematic reviews.[14,15]. 
A single reviewer (GD) initially screened the titles and abstracts and discarded 
clearly irrelevant studies. Full papers were checked for inclusion by two 
reviewers (GD and MH, HD or RST) and disagreements about inclusion of 
studies were resolved by discussion. 
Inclusion criteria 
Studies were eligible if they fulfilled the following criteria: 
 Design: RCT 
 Study population: adults with heart failure or CHD (including myocardial 
infarction, revascularisation or stable angina).  
 Intervention: CR, defined as structured exercise or PA programme alone 
or in combination with education and psychosocial interventions – in any 
setting (home, centre or community based). 
 Control: usual care that did not include a structured exercise programme. 
 Outcomes: PA measured objectively (e.g. accelerometer, pedometer) or 
subjectively (e.g. interview, questionnaire). We included studies that 
used amount of exercise undertaken as an acceptable proxy of PA. 




Appendix 2.2  
Search strategy for MEDLINE database 
Database(s): Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 
1946 to Present  
Search Strategy: 
# Searches Results 
1 exp Heart Failure/ 113505 
2 ((heart or cardiac or myocardial or ventricular) adj5 failure).ti,ab. 165648 
3 "congestive heart failure".ti,ab. 37916 
4 ((right-sided or left-sided or diastolic or systolic) adj5 failure).ti,ab. 6991 
5 exp Myocardial Ischemia/ 432299 
6 (myocard* adj5 isch*mi*).ti,ab. 50649 
7 exp Heart Diseases/ 1109082 
8 (((heart or coronary) adj5 disease) or CHD or CAD).ti,ab. 258469 
9 ("ischemic heart disease" or "ischaemic heart disease" or IHD).ti,ab. 33856 
10 "acute coronary syndrome".ti,ab. 16465 
11 ((myocard* or heart) adj5 infarct*).ti,ab. 187996 
12 (atherosclerosis or arteriosclerosis).ti,ab. 119767 
13 ("percutaneous coronary intervention*" or PCI).ti,ab. 31306 
14 angioplasty.ti,ab. 42533 
15 exp Myocardial Infarction/ 175310 
16 stent*.ti,ab. 85371 
17 exp Angina Pectoris/ 46071 
18 angina.ti,ab. 52590 
19 "angina pectoris".ti,ab. 19708 
20 "stable angina".ti,ab. 7629 
21 revasculari*.ti,ab. 53414 
22 exp Coronary Artery Bypass/ 52957 
23 exp Myocardial Revascularization/ 92398 
24 ("coronary artery bypass graft" or "coronary artery bypass surgery" or CABG).ti,ab. 26816 
25 
1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 
19 or 20 or 21 or 22 or 23 or 24 
1456929 
26 exp Rehabilitation/ 193650 
27 rehabilitat*.ti,ab. 140077 
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28 exp Sports/ 170759 
29 sport.ti,ab. 22280 
30 exertion.ti,ab. 14324 
31 exp Exercise/ 168685 
32 exercise.ti,ab. 232301 
33 
((lifestyle or life-style or risk factor) adj3 (intervent* or program* or modification or change* or 
treatment* or therap*)).ti,ab. 
25424 
34 
((physical or exercise or fitness) adj5 (training or therap* or intervent* or program* or 
treatment* or prescription)).ti,ab. 
96583 
35 (aerobic adj3 (training or exercise or activit*)).ti,ab. 13005 
36 exp "Physical and Rehabilitation Medicine"/ 23492 
37 "cardiac rehabilitation".ti,ab. 5131 
38 "heart rehabilitation".ti,ab. 24 
39 "cardio* rehabilitation".ti,ab. 431 
40 telerehabilitation.ti,ab. 433 
41 telemedicine.ti,ab. 8069 
42 telecare.ti,ab. 580 
43 (prescribed adj2 (exercise or activity)).ti,ab. 649 
44 
26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 
42 or 43 
719391 
45 exp Motor Activity/ 270112 
46 "physical activity".mp. 90007 
47 "physical inactivity".mp. 6506 
48 "activity level".mp. 10982 
49 ((habitual or leisure or daily) adj3 activity).mp. 15283 
50 ((lifestyle or life-style) adj2 (activ* or behaviour* or behavior*)).mp. 6433 
51 exp "Activities of Daily Living"/ 66589 
52 "activit* of daily living".mp. 74413 
53 (habitual adj3 exercise).mp. 533 
54 (exercise adj2 (habit* or participation)).mp. 2571 
55 (adherence adj2 exercise).mp. 1045 
56 (sedentary adj2 (behaviour or behavior or time)).mp. 4821 
57 "energy expenditure".mp. 23370 
58 "risk factor".mp. 175935 
59 acceleromet*.mp. 12894 
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60 pedomet*.mp. 2434 
61 IPAQ.mp. 774 
62 (step adj2 count*).mp. 1283 
63 walk*.mp. 108945 
64 ((direct or indirect) adj2 calori*).mp. 7768 
65 
(MVPA or "moderate-vigorous physical activity" or "moderate to vigorous physical 
activity").mp. 
4455 
66 ("doubly labelled water" or "doubly labeled water").mp. 1436 
67 "activity monitor".mp. 1265 
68 
45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 
61 or 62 or 63 or 64 or 65 or 66 or 67 
657045 
69 exp Randomized Controlled Trial/ 508365 
70 ("randomised controlled trial" or "randomized controlled trial").mp. 530710 
71 "controlled clinical trial".mp. 110323 
72 "clinical trial".mp. 710202 
73 "controlled trial".mp. 540481 
74 69 or 70 or 71 or 72 or 73 961974 
75 25 and 44 and 68 and 74 3707 
76 
limit 75 to (("young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and 
adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or 
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Appendix 2.4: Characteristics of included studies 





CHD – stable angina 
N=62 (intervention 33, control 
29) 
Age: Intervention 62±7, 
control 65±8 years 
Sex: Intervention 21%, 
control 24% female 
Ethnicity: not reported 
Exercise only 
Home-based 
Duration: 250 days (mean), ≥5 
sessions/ week, ≥30 mins/ session  
Intensity: approx. 70% maximal 
capacity.  
Modality: Exercise bike, allowed to 
replace cycling with other aerobic 
training twice per week. 








CHD – MI 
N=171 (intervention 81, 
control 90) 
Age: Intervention: 55.3±6.6, 
control: 57.1±6.6 years 
Sex: Intervention 14%, 
control 16% female 
Ethnicity: not reported 
Comprehensive rehabilitation - 
Exercise, counselling and social 
measures 
Centre-based 
Duration: 3 months, 2 
sessions/week, 30 mins/session  
Intensity: 90% maximum HR at 
exercise tolerance test. 
Modality: Ergometer cycling, 




resistance training. Supervised by 
physiotherapist. 





CHD – AMI 
N=110 (intervention 57, 
control 53) 
Age: Intervention 52.1±1.3, 
control 52.7±1.3 years 
Sex: not reported 
Ethnicity: not reported 
Comprehensive rehabilitation - 
Exercise, relaxation technique and 
information reinforcement 
Centre-based 
Duration: 4 weeks, 2 sessions 
/week. Intensity not described.  
Modality: Pulse monitored, group 










Intervention group:  
NYHA II/III (n=10/14) 
LVEF 26±10. Control group: 
NYHA II/III (n=11/12) 
LVEF 27±11 
N=48 (intervention 25, control 
23) 
Age: Intervention: 70±6, 
control: 71±9 years 
Sex: Intervention 25%, 
Exercise only 
Centre-based 
Duration: 3 months, 2 
sessions/week, 60 mins/session  
Intensity: Borg RPE 12-13 and/or 
Category ratio scale, dyspnoea 2-
3. 
Modality: peripheral muscle 
training, aerobic exercise on 
ergometer cycle and balance 
exercises. Resistance training 
Asked to continue 
with their usual lives. 
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control 28% female 
Ethnicity: not reported 







CHD – AMI 
N=168 (intervention 87, 
control 81) 
Age: Intervention: 62.2, 
control: 61.9 years (SD not 
reported) 
Sex: Intervention 25%, 
control 25% female 
Ethnicity: not reported 
Comprehensive rehabilitation - 
Exercise and education 
Centre-based 
Duration: 10-12 weeks, 2-3 
sessions/week, 40 mins/session. 
Intensity: not reported 
Modality: interval training, cycling 
and jogging. Supervision not 
reported.  
Usual care 






NYHA II/III (37(62%)/23(38%) 






N=60 (home intervention 20, 
hospital intervention 20, 
control 20) 
Age: Home: 65.5 (35-82), 
Comprehensive rehabilitation - 
Exercise and some education on 
symptoms of unstable HF 
Home-based or centre-based 
Duration: 8 weeks, 2 
sessions/week, 60 mins/session. 
Intensity: 40-60% HRR, or 12-13 
Borg RPE 
Modality: Aerobic exercise, circuit 
training. 
Resistance exercise not included. 




Hospital: 71.2 (59-85), 
Control: 61.4 (39-79) 
Sex: 15% female 
Ethnicity: not reported 
physiotherapist, home group given 
DVD and physiotherapist contact 





CHD – MI 
N=70 (gym intervention 28, 
home intervention 12, control 
30) 
Age: Gym: 52±8, Home: 
55±7, Control: 54±8 years 
Sex: 0 female 
Ethnicity: not reported. 
Exercise only 
Centre-based or home-based 
Duration: 8 weeks, gym group 3 
sessions/week and 60 
minutes/session, home group 7 
sessions/week and 40 
minutes/session. 
Intensity: 70-85% peak HR 
attained during cycle testing. 
Modality: Gym group – 
calisthenics, walking, jogging and 
stationary cycling. Home group – 
stationary cycling. Resistance 
training not included. 
No exercise training 




CHD – stable angina 
N=94 (intervention 48, control 
46) 
Age: Intervention 66.27±8.35, 
control: 66.20±10.06 years 
Comprehensive rehabilitation – 
education on secondary 
prevention of CHD and goal 
setting for PA, diet, managing 
emotions and smoking. 




Sex: Intervention 29%, 
control 22% female 
Ethnicity: Intervention 92% 
white British, 8% other, 
Control: 91% white British, 
9% other. 
Home-based – online program 
Duration: 6 weeks, encouraged to 
log into program 3-4 times per 
week. 
Intensity: not reported. 
Modality: individualized tailored 
goals focussed on exercise, 







CHD – CABG 
N=201 (intervention 93, 
control 78) 
Age: Intervention: 54±6, 
Control: 54±6 years 
Sex: 0 female 
Ethnicity: not reported 
Comprehensive rehabilitation - 
exercise, education, relaxation 
training and psychosocial 
Centre-based 
Duration: 8 months, 
sessions/week and time/session 
not described 
Intensity: 70% HR achieved during 
exercise test 
Modality: floor and swimming pool 
gymnastics, cycle ergometer, 
swimming and ball games, 













CHD – MI, CABG and severe 
stable angina 
N=80 (intervention 40, control 
40) 
Age: 51 (range 35-60) 
Sex: 0 females 
Ethnicity: not reported 
Exercise only 
Centre-based 
Duration: 6 months, 2 
sessions/week, 90 
minutes/session 
Intensity: Not reported 
Modality: Gymnastics, jogging and 
sports such as volleyball, soccer 
and hockey. No resistance training 
included. Supervised by 
cardiologist. 
Home rehabilitation – 












Intervention group: NYHA 
class II 45%, NYHA class III 
55%, LVEF 22±8. 
Control group: NYHA class II 
29%, Class III 71%, LVEF 
25±10 
N= 33 (intervention 17, 
control 16) 
Age: Intervention: 67±7, 
Control: 64±10 years 
Exercise only 
Centre-based 
Duration: 6 months, 3 
sessions/week, goal of 30 
minutes/session 
Intensity: Borg RPE 12-13 
Modality: Initially rode a Schwinn 
Aerdyne bike, gradually introduced 
to walking on a treadmill. Final 
exercise program consisted of 15ft 
on bike and 30ft on treadmill. 




Sex: Intervention 0, control 
21% female 
Ethnicity: Intervention: Black 
73%, White 27%, Control: 
Black 71%, White 29% 







CHD – MI or cardiac surgery 
patients 
N= 40 (intervention (1) – 11, 
intervention (2) – 15, control - 
14) 
Age: 57±11.3  
Sex: 30% female 
Ethnicity: not reported 
(1) Comprehensive rehabilitation – 
exercise and education 
(2) Education only 
Hospital based 
Duration: 5 weeks, 3 
sessions/week, 30 
minutes/session. 
Intensity: 70-80% maximum HR 
response 
Modality: not described. 




et al. 1989 
Finland 
Multicentre RCT 
CHD – AMI 
N=375 (intervention 188, 
control 187) 
Age: <65 years 
Sex: 25% female 
Ethnicity: not reported 
Comprehensive rehabilitation – 
exercise, education (smoking, 
dietary and physical activation 
advice) and psychosocial 
discussions 
Centre-based 
FU by patients own 
doctors and did not 






Duration: 3 months, 
sessions/week and 
minutes/session not described. 
Intensity: not described 
Modality: not described. 
Supervised exercise in one centre 
only. 
Hambrecht 




CHD – Stable angina 
N=88 (intervention 45, control 
43) 
Age: Intervention: 53±6, 
control 54±7 years 
Sex: 0 females 
Ethnicity: not reported 
Exercise only 
Initially hospital based, then home-
based 
Duration: 12 months, 7 
sessions/week, <30 
minutes/session. 
Intensity: 75% VO2 max HR 
Modality: cycle ergometer and 
group training (jogging, 
calisthenics and ball games). 
Resistance training not included. 
Hospital exercise was supervised, 
home exercise was not.  
1 week on ward, 
received instructions 
about necessity of 
regular physical 
activity and ways of 
lowering fat 
consumption. Then 
received usual care 
from private 
physician. 





CHD – CABG Exercise only 




N=65 (home exercise 17, 
group exercise 28, control 
20) 
Age: Control: 63±6, Home 
exercise: 56±11, Group 
exercise: 58±8 years 
Sex: 25% female 
Ethnicity: not reported 
Duration: 12 weeks, 5 
sessions/week, 30-40 minutes 
exercise/session (90 minutes 
supervised group sessions) 
Intensity: 70-100% peak heart rate 
during treadmill test, and 13-15 
Borg RPE scale. 
Modality: walking, stationary 
cycling or similar. Resistance 
training not included. Group 
sessions only were supervised.  





CHD – post PCI 
N=105 (intervention 54, 
control 51) 
Age: Intervention: 48 (range 
31-63), Control: 47 (range 
26-63) years 
Sex: Intervention 17%, 
control 4% female 
Ethnicity: not reported 
Comprehensive rehabilitation - 
Exercise, education and 
psychosocial support 
Home-based 
Duration: 12 months, 
sessions/week and 
minutes/session not described 
Intensity: moderate, RPE guided. 
Modality: Walking program with 
graded increase in frequency in 
duration of exercise. No resistance 
Standard care and 
telephone follow up 
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training. Clinician made 3 home 
visits and monthly telephone calls.  




CHD – ACS 
N=65 (intervention 32, control 
33) 
Age: Intervention: 58±8, 
Control: 59±9 years 
Sex: Intervention 19%, 
control 24% female 
Ethnicity: not reported 
Comprehensive rehabilitation – 
pedometer based programme, 
exercise (daily step target), 
education regarding PA, and 
psychosocial support 
Home-based 
Duration: 12 months, 
sessions/week and 
minutes/session not described. 
Intensity: moderate according to 
Borg RPE scale 
Modality: walking. Resistance 
training not included, and exercise 
unsupervised.  
Usual care (no 
restriction to go to 
centre based CR or 








CHD – MI 
N=116 (intervention 53, 
control 63) 
Age: Intervention: 55, 
Control: 57.6 years (SD not 
reported) 
Exercise and education 
Centre and home-based 
Duration: 6 months, 1 
session/week plus home exercise, 
120 minutes/session (60 mins 
exercise). 




Sex: Intervention 13.2%, 
control 12.7% female 
Ethnicity: not reported 
Modality: bicycle ergometer and 
calisthenics. Resistance not 






CHD - Ischaemic heart 
disease 
Heart attack – 74%, Angina – 
50% 
N=171 (intervention 85, 
control 86) 
Age: Intervention: 61.4±8.9, 
Control: 59.0±9.5 years 
Sex: intervention 19%, 
control 19% female 
Ethnicity: Intervention group - 
NZ Maori – 7%, Pacific – 6%, 
Asian – 9%, NZ 
European/other – 78% 
Control group - NZ Maori – 
8%, Pacific – 6%, Asian – 




Duration: 24 weeks, at least 5 
sessions/week, at least 30 
mins/session 
Intensity: moderate to vigorous 
Modality: aerobic based activity, 
resistance training not included. 
No supervision. 
Usual care with 
encouragement to be 
physically active and 
attend a cardiac club 
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N=50 (intervention 25, control 
25) 
Age: 55.0 ± 10 years 
Sex: 0 females 
Ethnicity: not described 
Comprehensive rehabilitation - 
Exercise, education and diet 
Centre-based 
Duration: 1 month, 5 cycling and 
14 walking sessions/week, 30 
mins per cycling session, 45 
minutes per walking session 
Intensity: 60-80% HRR and work 
rate, 12-14 RPE Borg Scale 
Modality: walking and indoor 
cycling. No resistance training. 
Supervised by physician or 
medical resident. 
Usual care 





CHD – First MI 
N=100 (intervention 50, 
control 50) 
Age: Intervention: 53.2, 
Control: 54.8 years (SD not 
reported) 
Sex: intervention 10%, 
control 22% female. 
Ethnicity: not reported 
Comprehensive rehabilitation - 
exercise, lifestyle counselling  
Centre-based 
Duration: 2 years, 2 
sessions/week, reducing to 1 
session/week from month 2 
onwards. 60 mins/session 
Intensity: not reported 
Modality: heart targeting aerobic 




included. Supervised by program 






CHD – CABG 
N=91 (intervention 43, control 
43) 
Age: Intervention: 60±7.1, 
Control: 59±8.1 years 
Sex: intervention 7%, control 
12% female 
Ethnicity: not reported 
Comprehensive rehabilitation – 
exercise, education (focussed on 
key areas of CVD risk) and 
psychologist led support 
Centre-based 
Duration: 12 months, 6 weekly 
meetings, which began between 4 
and 8 weeks following hospital 
discharge and booster sessions at 
8 months and 1 year post 
baseline. 3 hours/session 
Intensity: not described 
Modality: Stretching, calisthenics, 
cycle ergometer and walking. 
Resistance training not included. 
Supervised by physiotherapist and 
registered nurse.  
Standard medical 






CHD – AMI 




Duration: 8 weeks, 3 




Age: Intervention: 54.8 ± 
10.6, Control: 58.6 ± 10.7 
years 
Sex: intervention 14.9%, 
control 17.8% female 
Ethnicity: not reported 
Intensity: 70-85% maximal heart 
rate achieved in the exercise test 
Modality: Aerobic exercise, cycle 
ergometer or treadmill. No 
resistance training. Supervised 
exercise.  





N=48 (intervention 28, control 
20) 
Age: Intervention: 56.1 ± 7.5, 
Control: 59.8 ± 9.1 years 
Sex: intervention 5%, control 
21% female 
Ethnicity: not reported 
Comprehensive rehabilitation - 
exercise, stress management, 
psychosocial support, education 
and diet 
Centre-based 
Duration: 5 years, up to 6 
sessions/week, at least 30 
mins/session 
Intensity: 50-80% of max heart 
rate achieved during treadmill test 
or age-adjusted maximum. 
Modality: Aerobic exercise, 
typically walking. No resistance 





Norway CHD – AMI, UAP, PCI or 
CABG 
Comprehensive rehabilitation – 






N=197 (intervention 98, 
control 99) 
Age: Intervention: 54 ± 8, 
Control: 55 ± 8 years 
Sex: intervention 19%, 
control 16% female 
Ethnicity: not reported 
cessation, physical activity 
counselling, risk factor 
management, psychosocial 
management and health 
education. 
Centre-based 
Duration: 2 years, 2 
sessions/week, 1 hour/session 
Intensity: First 6 weeks: 11-13 
Borg RPE scale. Following 9 
weeks: 13-15 Borg RPE scale. 
Modality: dynamic endurance 
training. Resistance training not 
included.  Supervised by 
physiotherapist for first 15 weeks, 
then encouraged to exercise at 
home alone or in organised groups 




CHD – MI and PCI 
N= 223 (intervention 115, 
control 108) 
Age: Intervention: 56.7 ± 9.0, 
Control: 56.0 ± 9.0 years 
Exercise only 
Home-based (internet) 
Duration: 6 months, daily activity, 
minutes/session not reported 




Sex: intervention 15.7%, 
control 13.9% female 
Ethnicity: not reported 
Modality: not described, not 
supervised. 





CHD – First MI 
N= 42 (intervention 22, 
control 20) 
Age: Intervention: 54.3 ± 
10.8, Control: 57.0 ± 7.6 
years 
Sex: intervention 10%, 
control 27.8% female 
Ethnicity: not reported 
Exercise only 
Centre-based 
Duration: 8 weeks, 3 
sessions/week, 55 mins/session 
Intensity: 65-75% maximal heart 
rate achieved during exercise test. 
Modality: Aerobic exercise, cycle 
ergometer or treadmill. No 









NYHA class II/III 
Intervention group: LVEF 
27.9 ± 8.3% 
Control group: LVEF 26 ± 7% 
N= 77 (intervention 44, 
control 33) 
Age: 59.8 ± 9.3 years 
Sex: Intervention 20%, 
control 31% female 
Exercise only 
Home and centre based 
Duration: 26 weeks, at least 4 
sessions/week (2 home, 2 centre), 
home sessions 11 minutes, centre 
sessions 1 hour 
Intensity: Cycle ergometer: 50% of 
maximum short-term exercise 
performance determined by steep 




Ethnicity: not reported home training programme: >70% 
peak HR measured during steep 
ramp test. 
Modality: Aerobic interval training 
(stationary running or cycle 
ergometer), with strength, flexibility 
and coordination exercises. 
Resistance training included. 





Multicentre RCT  
CHD – MI 
N=258 (intervention 1: 88, 
intervention 2: 86, control: 
84) 
Age: Intervention 1: 55.6±9.3, 
Intervention 2: 56.3±8.3, 
Control: 57.1±7.3 years 
Sex: <20% female in each 
group 
Ethnicity: >80% Caucasian in 
each group 
Intervention 1 – exercise only, 
intervention 2 – Comprehensive 
rehabilitation – exercise, education 
sessions and teaching-counselling 
Home-based 
Duration: 3 months, 2 sessions per 
week, reducing to 1 once patient 
has returned to work. Minutes per 
session not described 
Intensity: progressive, no further 
information 
Conventional 




Modality: Calisthenics and 
walking. Resistance training not 
included. No supervision. 





CHD (some HF patients) – 
ACS 
N=101 (intervention 50, 
control 51) 
Age: Intervention: 71 ± 3.9, 
Control: 71 ± 4.7 years 
Sex: Intervention 18%, 
control 22% female 
Ethnicity: not reported 
Exercise only 
Centre-based 
Duration: 3 months, 3 
sessions/week, 50 mins/session 
Intensity: (1) ≥50% based on the 
relation between maximal heart 
rate and maximal oxygen uptake 
for at least 40 minutes 
(2) ≥80% of estimated maximal 
oxygen uptake during three 
periods of 3-4 minutes engaging 
large muscle groups for training 
the central circulation 
Modality: Aerobic exercise, group 
training. Strength training also 
included. Supervised by 
specialised physiotherapist 
Usual care – 









CHD – stable angina 
N= 40 (intervention 20, 
control 20) 
Exercise only Usual care 
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Age: Intervention: 53 (range 
45-60), Control: 51 (range 
37-60) years 
Sex: 0 female 
Ethnicity: not reported 
Home-based, with weekly centre-
based sessions early on in the 
programme 
Duration: 1 year, 7 sessions/week, 
11 minutes/session 
Intensity: progressive, no further 
information. 
Modality: calisthenics, no 
resistance training. Initial in-
hospital sessions supervised by 








N=28 (intervention 16, control 
12) 
Age: Intervention: 64 ± 9, 
Control: 62 ± 11 years 
Sex: 100% female 
Ethnicity: Intervention group:  
Caucasian 94%, Native 
American, Alaskan 6%, 
Hispanic 0%, African 
American 0%, Other 0% 
Comprehensive rehabilitation – 
exercise, cooking classes, stress 
management, group discussions 
Centre-based 
Duration: 24 months, daily 
sessions, then at least 3 
sessions/week, 1 hour/session. 
Intensity: Individually prescribed 






Caucasian 83%, Native 
American, Alaskan 0%, 
Hispanic 8%, African 
American 0%, Other 8% 
Modality: Aerobic exercises or 
walking, no resistance training 









Intervention group: LVEF – 
23.9 ± 9.4%, NYHA class II/III 
– 56/44%. Control group: 
LVEF – 27.6±6%, NYHA II/III 
– 63/37% 
N= 34 (intervention 18, 
control 16) 
Age: Intervention: 58.6 ± 
12.1, Control: 58.6 ± 10.6 
years 
Sex: intervention 33%, 
control 19% female 
Ethnicity: not reported 
Exercise only 
Centre-based 
Duration: 3 months, 2 
sessions/week, 1 hour/session 
Intensity: Individually prescribed 
target heart rate (resting HR + 
(60% difference between resting 
and maximal HR) 
Modality: Aerobic exercise, 
predominantly cycling, walking and 
games. No resistance training 




special advice for 
activities 






LVEF ≤60%, mean not 
reported. 
Comprehensive rehabilitation - 
Exercise and education (nutrition,  
medication, disease management 
and monitoring symptom changes 






NYHA class – Intervention 
2±0, Control 2.13±0.13. 
N= 19 (intervention 9, control 
10) 
Age: Intervention: 69 ± 4.44, 
Control: 70 ± 4.05 years 
Sex: intervention 33.3%, 
control 50% female) 
Ethnicity: 100% white. 
and disease status 
Home-based 
Duration: 12 months, 3 
sessions/week, >15 mins/session. 
Intensity: not reported 
Modality: Aerobic exercise, 
treadmill. No resistance training 





home visits and 
follow-up phone 
calls. 





CHD – MI 
N=128 (intervention 64, 
control 64) 
Age: Intervention: 54.9±8.7, 
Control: 55.8±10.3 years 
Sex: intervention 9.4%, 
control 10.9% female 
Ethnicity: not reported 
Comprehensive rehabilitation – 
exercise plan and education 
booklet focussed on 
psychologically related content 
(relaxation, stress management, 
CHD symptom monitoring) 
Home-based 
Duration: not described 
Intensity: not described 
Modality: not described 
 
Usual care 




CHD – AMI 
N= 1813 (intervention 903, 
control 913) 
Comprehensive rehabilitation – 
exercise, health education and 
counselling 
All patients in the 
trial had similar care 
in all respects other 
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Age: Intervention: 64.2±11.2, 
Control: 64.7±10.9 years 
Sex: intervention 27.4%, 
control 25.6% female 
Ethnicity: not reported 
Centre-based 
Duration: 6-8 weeks, 1-2 
sessions/week, averaged 20 hours 
over 6-8 weeks 
Intensity: not described 
Modality: Warm up, cool down and 
used exercise equipment in 
physiotherapy gyms, no further 
information. Use of resistance 
training not described. In most 
centres led by nurses with 
previous acute cardiac care 
experience, and in a few by 
occupational therapists or 
physiotherapists. 




being advised to see 
their GP and attend 
routine outpatient 
follow up, with 













NYHA class 2.1±0.7. Control: 
LVEF 0.38±0.10, NYHA class 
2.4±0.7 




Duration: 16 weeks, 2 
sessions/week increasing to 3 
after week 7. 15 mins/session 
increasing to 45. 
Asked not to change 
their degree of 
physical activity 




Age: Intervention: 64±5, 
Control:64±8 years 
Sex: intervention 29%, 
control 30% female 
Ethnicity: not reported 
Intensity: 80% peak VO2 ±5bpm. 
Or RPE 15 (Borg scale, for those 
with AF) 
Modality: cycle ergometer, interval 
training. No resistance training 








NYHA class II/III – 56%/44% 
LV systolic dysfunction: 
Mild 35%, Moderate 30%, 
Severe 34% 
N= 82 (intervention 41, 
control 41) 
Age: Intervention: 80±6, 
Control:81±4 years 
Sex: intervention 37%, 
control 54% female 
Ethnicity: not reported 
Exercise only 
Centre-based, then home-based 
Duration: 6 months, 2-3 
sessions/week, 20 
minutes/session 
Intensity: Borg scale RPE 11-13 
Modality: Chair based aerobic 
exercise. No resistance training 
included. Supervised by 
physiotherapist during centre-
based phase. 









LVEF not reported 
Intervention group: NYHA 
class II/III – 70/30%. Control 
Comprehensive rehabilitation - 
Exercise, education and 
psychosocial support 
Usual care – given a 
booklet with general 




group: NYHA class II/III – 
89/11% 
N=107 (intervention 53, 
control 54) 
Age: Intervention: 80.4±5.8, 
Control: 79.5±4.9 years 
Sex: intervention 34%, 
control 31% female 
Ethnicity: not reported 
Centre-based progressing to 
home-based 
Duration: 24 weeks, 2 
sessions/week, up to 60 
mins/session. 
Intensity: Not reported other than 
intensity increased incrementally 
by raising the number of 
repetitions and resistance level of 
elasticated bands. 
Modality: Shuttle walking and 
resistance exercises. Centre-
based supervised by 
physiotherapist. 
lifestyle. Participants 
not discouraged from 
exercise if already in 
the habit of doing so. 





CHF (12%), IHD (58%), HR 
(30%) 
N= 770 (intervention 380, 
control 390) 
Age: Intervention: median 66 
(range 33-91), Control: 
median 66 (range 29-94) 
years 
Comprehensive rehabilitation – 
exercise, education, dietary 
counselling, smoking cessation, 
psychosocial support, risk factor 






Sex: Intervention 36%, 
control 37% female 
Ethnicity: not reported 
Duration: 6 weeks (12 weeks for 
HF patients), 2 sessions/week, 90 
mins/session. 
Intensity: 60-85% HRR based on 
initial bike test and perceived 
exertion. HF patients exercised at 
about 50% of the theoretical 
maximum heart rate. 
Modality: Mixture of endurance 
and strengthening training using 
various upper and lower body 
modalities. Supervised exercise. 
*Unless otherwise stated, numbers refer to mean ± standard deviation. RCT=Randomised controlled trial, CHD=coronary 
heart disease, MI=myocardial infarction, HR=heart rate, AMI=acute myocardial infarction, HF=heart failure, NYHA=New York 
Heart Association, LVEF=left ventricular ejection fraction, PA=physical activity, RPE=rating of perceived exertion, LV=left 
ventricular, CABG=coronary artery bypass graft, PCI=percutaneous coronary intervention, ACS=acute coronary syndrome, 




Appendix 2.5: Description of methods of physical activity assessment and summary 
Author Physical Activity Measure 
Objective Subjective 
Astengo et al. 
2010 
N/A Name: Not stated 
Type: Not stated 
Validated? Not reported 
Evidence of outcome validated for use in 
population? Uncertain 
Derived measure: Training days/week, 
minutes/session 
Time frame: Not described 
Units of PA: Days/week 
Bengtsson 
1983 
N/A Name: not stated 
Type: Not described 
Validated? Not reported 
Evidence of outcome validated for use in 
population? Uncertain 
Derived measure: (1) habits to exercise, (2) leisure 
time exertion 
Time frame: not reported 
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Units of PA: (1) N patients habits to exercise (1. 
Never, 2. 1-2 times per month, 3. 1-3 times per 
week, 4. Daily) 
(2) N patients undertaking (1. Much less, 2. Rather 
less, 3. Unchanged, 4. Rather more, 5. Much 
more) leisure time exertion compared to before 
infarction 
Bertie et al. 
1992 
Device name: Not stated 
Type: Pedometer 
Placement site: Not described 
Epoch length*: Not described 
Number of days of observation: 7 days 
Criteria for a valid day defined? Not described 
Minimum data requirement for inclusion in analysis 
defined? Not described 
Data reduction techniques† defined? Not described 
Units of PA: Mean daily mileage walked 
 N/A 
Borland et al. 
2014 
Device name: KeepWalking LS2000 
Type: Pedometer 
Placement site: Waist (or ankles for overweight 
patients) 
Epoch length*: Not reported 
Number of days of observation: 7 days 
Name: IPAQ 
Type: Questionnaire 
Validated? Yes, but reference provided shows use 
of IPAQ as indicator for PA is weak 
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Criteria for a valid day defined? Not fully described 
– Patients instructed to wear pedometer throughout 
the day and register the total number of steps on a 
log sheet at bedtime and reset device to zero each 
morning. 
Minimum data requirement for inclusion in analysis 
defined? Not described 
Data reduction techniques† defined? Not fully 
described – pedometer data was divided into 3 
categories: 0-4396, 4397-5999 and ≥6000 
steps/day. 
Units of PA: steps/day 
Evidence of outcome validated for use in 
population? Validated internationally in healthy 
population, not in CHD 
Derived measure: Category (low/moderate/high) 
and time sitting 
Time frame: 7 days 
Units of PA: IPAQ category, minutes sitting 












Name: Not reported 
Type: Questionnaire 
Validated? Not reported 
Evidence of outcome validated for use in 
population? Uncertain 
Derived measure: Habitual PA level (1. Sedentary, 
2. Walking or bicycling daily with minimum 30 
minutes, 3. Sport activities in average once weekly, 
4. Sport activities in average twice or more weekly, 
5. Vigorous physical training) 
Time frame: Not reported 
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Units of PA: Number of patients considered 
physically active 
Cowie et al. 
2011 
Device name: ActivPAL™ 
Type: Accelerometer 
Placement site: Front of thigh 
Epoch length*: Not reported 
Number of days of observation: 7 days 
Criteria for a valid day defined? Not described 
Minimum data requirement for inclusion in analysis 
defined? Not described 
Data reduction techniques† defined? Not fully 
described – monitor produces signal related to 
inclination and movement of the thigh which is 
interpreted by algorithms using the proprietary 
software. 
Units of PA: Mean time spent sitting and standing, 
mean number of steps, over an average 24-hr 
period. Walking pattern also recorded – mean 
steps/day and mean cadence during ‘extra long’, 
‘long’, ‘moderate’, and ‘short’ walks over an 
average 24-hr period 
N/A 
DeBusk et al. 
1979 




Validated? Not reported 
Evidence of outcome validated for use in 
population? Uncertain 
Derived measure: walking distance 
Time frame: not reported 
Units of PA: miles/day 
Devi et al. 2014 Device name: Sensewear Pro 3 
Type: Accelerometer 
Placement site: Right upper arm 
Epoch length*: Not reported. 
Number of days of observation: 2 weekdays (12 
hours per day) 
Criteria for a valid day defined? Not described 
Minimum data requirement for inclusion in analysis 
defined? Not described 
Data reduction techniques† defined? Not fully 
described – monitor uses physiological signals, 
bodily movement and in-built algorithms to estimate 
physical activity.  
Units of PA: Daily average step count. Secondary – 
energy expenditure, duration of sedentary activity, 




Engblom et al. 
1992 
N/A Name: not reported 
Type: questionnaire 
Validated? Not reported 
Evidence of outcome validated for use in 
population? Uncertain 
Derived measure: exercise habits 
Time frame: not reported 
Units of PA: 3 categories: no exercise, exercise in 
conjunction with other hobbies, and regular 
exercise. 
Erdman et al. 
1986 
N/A Name: N/A 
Type: structured interview 
Validated? Not reported 
Evidence of outcome validated for use in 
population? Uncertain 
Derived measure: habitual exercise (measured in a 
binary fashion, yes or no) 
Time frame: not reported 
Units of PA: % patients with specific answer 
pattern at the three time points. 
Gottlieb et al. 
1999 
(1) Name: N/A 
Type: Doubly labelled water 




Epoch length*: N/A 
Number of days of observation: 10 days 
Criteria for a valid day defined? Not described 
Minimum data requirement for inclusion in analysis 
defined? Not described 
Data reduction techniques† defined? Equations for 
calculating energy expenditure reported. 
Units of PA: total energy expenditure, kcal/day 
(2) Name: Caltrac 
Type: Accelerometer 
Placement site: Hip 
Epoch length*: not reported 
Number of days of observation described? Not 
described 
Criteria for a valid day defined? Not described 
Minimum data requirement for inclusion in analysis 
defined? Not described 
Data reduction techniques† defined? Not described 
Units of PA: total energy expenditure, kcal/day 
Gulanick 1991 N/A Name: not reported 
Type: questionnaire 
Validated? Yes, by author 
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Evidence of outcome validated for use in 
population? Yes, validated by author in pilot study 
with recovering cardiac patients.  
Derived measure: Performance of physical activity 
score, broken down into each activity and total. 
Time frame: not described 
Units of PA: performance of physical activity score 
Hämäläinen et 
al. 1989 
N/A Method of obtaining PA data not described 




N/A Name: modified Minnesota leisure time physical 
activity questionnaire 
Type: questionnaire 
Validated? Not reported, reference to validation 
provided, but validated against physical capacity 
not energy expenditure. 
Evidence of outcome validated for use in 
population? No evidence of validation in CHD 
population 
Derived measure: energy expenditure in leisure 
time PA 
Time frame: previous weekend and on the 
previous 2 days 
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Units of PA measure: Kcal/week 
Heath et al. 
1987 
N/A Name: Harvard Alumni Activity Survey 
Type: questionnaire 
Validated? Not reported but reference provided 
Evidence of outcome validated for use in 
population? 
Validated in healthy population, not CHD 
Derived measure: leisure time physical activity 
Time frame: not described 
Units of PA: kcal/week 
Higgins et al. 
2001 
N/A Name: N/A 
Type: interview 
Validated? Not reported 
Evidence of outcome validated for use in 
population? 
Uncertain 
Derived measure: exercise habits 
Time frame: previous 3 months 
Units of PA: exercise participation classification: 
very active (exercising more than 3 times per week 
for at least 20 mins per time), moderately active 
(exercising less than 3 times per week for at least 
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20 mins per time), or sedentary (exercising less 
than 20 min, once per week) 
Houle et al. 
2011 
Name: Yamax Digiwalker NL-2000 
Type: pedometer 
Placement site: waist 
Epoch length*: not described 
Number of days of observation: 7 consecutive days 
Criteria for a valid day defined? Not fully described 
– morning to bedtime. 
Minimum data requirement for inclusion in analysis 
defined? Not described 
Data reduction techniques† defined? Not described 




N/A Name: WHO questionnaire 
Type: questionnaire 
Validated? Uncertain, reference provided but 
unable to locate full publication 
Evidence of outcome validated for use in 
population? uncertain 
Derived measure: PA habits (dichotomised – 
started to exercise after MI, did not start to 
exercise after MI) 
Time frame: not described 
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Units of PA: % patients physically exercising 
Maddison et al. 
2015 
N/A Name: IPAQ 
Type: questionnaire 
Validated? Yes, reference provided for validation 
study 
Evidence of outcome validated for use in 
population? Validated internationally in healthy 
population, not in CHD 
Derived measure: Total physical activity, leisure 
time physical activity and walking time 
Time frame: 7 days 
Units of PA: minutes per week 
Mueller et al. 
2007 
N/A Name: not described (interview using 
questionnaire modelled after Harvard Alumni 
studies of Paffenberger and colleagues (1986)) 
Type: questionnaire  
Validated? Not reported (3 different references 
provided in description of PA measure) 
Evidence of outcome validated for use in 
population? Uncertain 
Derived measure: energy expenditure 
Time frame: the previous year 
Units of PA: kcal/week 
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Naser et al. 
2008 
N/A Name: not reported 
Type: questionnaire 
Validated? Not reported 
Evidence of outcome validated for use in 
population? uncertain 
Derived measure: physical activity level – 
exercising vigorously 20min 3 times per week 
Time frame: 3 days 
Units of PA: % patients exercising 
Oldenberg et al. 
1995 
N/A Name: Self-report inventory (adapted from National 
Heart Foundation’s 1986 Risk Factor Prevalence 
Survey. 
Type: questionnaire 
Validated? Not reported 
Evidence of outcome validated for use in 
population? Uncertain 
Derived measure: exercise classification 
Time frame: not described 
Units of PA: Classification (“regular exerciser” – 3+ 
times per week, “moderately regular exerciser” – 2 




Oliveira et al. 
2014 
Name: Actigraph GT1M 
Type: accelerometer 
Placement site: right hip 
Epoch length*: not reported 
Number of days of observation: 7 consecutive days 
Criteria for a valid day defined? Not fully described 
– during the day except while sleeping, bathing and 
during aquatic activities 
Minimum data requirement for inclusion in analysis 
defined? Not described 
Data reduction techniques† defined? Not described 
Units of PA: Average minutes per day spent at 
sedentary, light, moderate-vigorous intensity PA 
N/A 
Ornish et al. 
1998 
N/A Name: not reported 
Type: questionnaire 
Validated? Not reported 
Evidence of outcome validated for use in 
population? Uncertain 
Derived measure: frequency and duration of 
exercise. 
Time frame: not reported 
Units of PA: Exercise times per week, exercise 
hours per week 
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Otterstad et al. 
2003 
N/A Name: food frequency questionnaire 
Type: questionnaire (patients in intervention group 
also kept diaries) 
Validated? Not reported 
Evidence of outcome validated for use in 
population? Uncertain 
Derived measure: exercise habits 
Time frame: not reported 
Units of PA: amount of exercise per week 
Reid et al. 2011 Name: Yamax DIGI-WALKER 
Type: pedometer 
Placement site: hip 
Epoch length*: not described 
Number of days of observation: 9 days, first and 
last day discarded 
Criteria for a valid day defined? Not described 
Minimum data requirement for inclusion in analysis 
defined? Not described 
Data reduction techniques† defined? Not described 
Units of PA: steps per day 




Evidence of outcome validated for use in 
population? Previously validated in population by 
authors. 
Derived measure: Frequency and duration of 
moderate and vigorous exercise 
Time frame: ‘a typical week’ 
Units of PA: Total minutes of moderate and 
vigorous exercise per week. 







Placement site: waist 
Epoch length*: not described 
Number of days of observation: 7 consecutive days 
Criteria for a valid day defined? Not described – 
asked to wear during all waking hours 
Minimum data requirement for inclusion in analysis 
defined? Not described 
Data reduction techniques† defined? Analysed with 
a computer programme (ActiLife Software, 
ActiGraph), computing the average min/day spent 
at different PA intensities according to cut points 
relating to cound/min to PA intensity (Freedson, 
Melanson, Sirard 1998). 
Units of PA: Minutes per day performing light, 
moderate, vigorous and very vigorous PA 
Senden et al. 
2005 
N/A Name: Modified Baecke questionnaire for physical 
activity in elderly people.  
Type: questionnaire 
Validated? Yes 
Evidence of outcome validated for use in 
population? Validated for Dutch elderly population, 
not in HF. 
Derived measure: DPA score 
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Time frame: over the past year 
Units of PA measure: DPA score 
Sivarajan et al. 
1982 
N/A Name: Activity summary questionnaire 
Type: questionnaire 
Validated? Reference for validation study reported. 
Evidence of outcome validated for use in 
population? Validated for use in cardiac 
rehabilitation. 
Derived measure: activity level 
Time frame: not described 
Units of PA: METS, and maximum distance walked 
(miles) in a day at least 3 times per week 
Ståhle et al. 
1999 
N/A Name: N/A 
Type: Self-reported estimation of physical activity 
level 
Validated? Not reported, reference of previous use 
provided. 
Evidence of outcome validated for use in 
population? Literature search shows use of tool in 
elderly, but not CHD 
Derived measure: Score 1-6 where 1 corresponds 
to sedentary and 6 to strenuous exercise 
comprising at least 3h a week on activities such as 
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jogging, skiing, tennis, swimming and aerobic 
training. 
Time frame: A typical week 
Units of PA: classification scale, 1-6 
Todd & 
Ballantyne 1992 
N/A Name: N/A 
Type: activity diary 
Validated? Not reported 
Evidence of outcome validated for use in 
population? Uncertain 
Derived measure: level of PA 
Time frame: not reported 
Units of PA: not described 
Toobert et al. 
1998 
N/A Name: (1) Stanford 7 day recall 
(2) Summary of Self-Care Activities Questionnaire 
Type: questionnaire 
Validated? Not described in paper, but literature 
search showed both measures validated. 
Evidence of outcome validated for use in 
population? Neither measure validated in CHD 
population. 
Derived measure: (1) Average kcal per day 
(2) number of days and amount of time engaged in 
physical activity in last 7 days 
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Time frame: 7 days 
Units of PA: (1) Average daily kcal, (2) Number of 
days and amount of time 
Van den Berg-
Emons et al. 
2004 
Name: Activity monitor AM 
Type: accelerometer 
Placement site: Four uniaxial accelerometers 
attached to trunk and thighs, connected to the AM 
worn around the waist. 
Epoch length*: not described 
Number of days of observation: 2 randomly 
selected consecutive weekdays (48 hours) 
Criteria for a valid day defined? Not described 
Minimum data requirement for inclusion in analysis 
defined? Not described 
Data reduction techniques† defined? Not fully 
described – data calculated per day and averaged 
over 2 days.  
Units of PA: (1) % of 24 hours engaged in dynamic 
activity, (2) G, (3) Number of transitions, (4) 
Number of walking periods >10s, (5) Number of 
walking periods >5s 
N/A 





Evidence of outcome validated for use in 
population? Validated in healthy older populations, 
not HF patients 
Derived measure: Vigorous activity, leisurely 
walking, moving, standing, sitting and total index 
scores. 
Time frame: typical week 
Units of PA: index score. 
 Wang et al. 
2016 
N/A Name: Myocardial infarction dimensional 
assessment scale (MIDAS) – physical activity one 
of the subscales 
Type: questionnaire 
Validated? Yes 
Evidence of outcome validated for use in 
population? Validated in MI patients 
Derived measure: Physical activity score 
Time frame: not described 
Units of PA: Likert scale 1-5 
West et al. 2012 N/A Name: N/A 
Type: structured interview 
Validated? Not reported 
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Evidence of outcome validated for use in 
population? Uncertain 
Derived measure: Undertaking physical exercise 
(>100kcal/day) 
Time frame: not reported 




N/A Name: N/A 
Type: interview 
Validated? Not reported 
Evidence of outcome validated for use in 
population? Uncertain 
Derived measure: degree of habitual physical 
activity (score calculated by average time 
(min/week) x intensity (1 to 3)2 / 100) 
Time frame: 1 week 
Units of PA: Total activity score 
Witham et al. 
2007 
Name: Stayhealthy RT3 
Type: accelerometer 
Placement site: waist 
Epoch length*: 1 minute 




Criteria for a valid day defined? Not fully described, 
first and last days discarded to reduce influence of 
incomplete days and transport artefact. Participants 
asked to wear device from when they first dressed 
in the morning to when they retired at night. 
Minimum data requirement for inclusion in analysis 
defined? Not described 
Data reduction techniques† defined? Not described. 
Units of PA: Counts/24 hours 
Witham et al. 
2012 
Name: Stayhealthy RT3 
Type: accelerometer 
Placement site: waist 
Epoch length*: not reported 
Number of days of observation: 7 days 
Criteria for a valid day defined? Not described 
Minimum data requirement for inclusion in analysis 
defined? Not described 
Data reduction techniques† defined? Not described 
Units of PA: Counts/24 hours 
N/A 
Zwisler et al. 
2008 
N/A Name: N/A 
Type: adapted interview questionnaire 
Validated? Not reported 
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Evidence of outcome validated for use in 
population? Uncertain 
Derived measure: physical activity level 
Time frame: not reported 
Units of PA: % patients undertaking <4hours per 
week 
PA=physical activity, IPAQ=international physical activity questionnaire, kcal=kilocalories, CHD=coronary heart disease, 
WHO=world health organisation, MI=myocardial infarction, METS=metabolic equivalents. *Epoch length: the defined time 
interval over which data is recorded. †Data reduction techniques: the criteria used to define valid data for use in analysis. 
 
Summary: 
Subjective methods: The most commonly used subjective approach was questionnaires (20 studies). 
[17,18,20,22,25,27,28,31-36,38,39,41,42,45,47,48] Fourteen different questionnaires were used across the studies, and six 
did not provide a name for the questionnaire that was used. Eleven of the questionnaires were validated, [XII-XVIII] however 
only four were clearly validated in the appropriate cardiac populations. [XIX-XXII] Other subjective methods included structured 
interview in five studies, [23,29,49,50,53] an activity diary, [44] self-reported estimation, [43] and no description provided in 
three studies. [14,15,26]  
Objective methods: Eight studies used accelerometers, [19,21,24,36,40,46,51,52] four used pedometers [16,17,30,39] and 
one used doubly labelled water. [24] The number of days observation was most commonly seven days 
[16,17,19,30,36,39,40,51,52], two studies used two day observation, [21,46] and one study did not describe the observation 
days.[24] Placement of the pedometers and accelerometers also varied across studies; most frequently used was waist 
placement [17,30,40,51,52] followed by hip placement, [24,36,39] and thigh, [19] upper arm, [21] and trunk [46] in one study 
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each. Epoch length was described in one study only. [51] Similarly, data reduction techniques were described adequately in 
one study only. [40] The criteria for a valid day was not defined sufficiently in any study, nor the minimum data requirement for 











PA outcome Intervention vs control result 
% or mean (SD), P-value, unless otherwise stated 
a p-value between groups 
b p-value between group change 






Bertie et al. 
1992 
Objective Mean daily 
mileage (km) 
8.2 (0.6) vs 6.6 (0.5), <0.05a I>C  





























4849 (2866)* vs 5458 (2678)* vs 4052 (1910), 0.1a 
4.32 (1.45)* vs 4.9 (1.78)* vs 3.85 (1.85), 0.29a 
 
672 (751)* vs 1264 (1640)* vs 417 (713), 0.05a 
 
1312 (1224)* vs 1557 (1039)* vs 825 (641), 0.11a 
 
2294 (1078)* vs 2291 (867)* vs 1658 (1052), 0.14a 
 
956 (311)* vs 1129 (474)* vs 955 (474), 0.39a 
 
95 (65)* vs 98 (57)* vs 70 (57), 0.36a 
 















































62 (6)* vs 61 (5)* vs 59 (5), 0.39a 
 






















Difference at 6 weeks: 497 (2171) vs -861 (2534), 0.02b 
6 months: NR vs NR, 0.15b 
Difference at 6 weeks: 43.94 (271.9) vs -133.01 
(302.01), 0.01b 
6 months: NR vs NR, 0.14b 
Difference at 6 weeks: -7.79 (40.14) vs 23.23 (62.78), 
0.01b 
















Difference at 6 weeks: 6.31 (34.37) vs -22.29 (61.34), 
0.01b 








Daily EE (kcal) 
doubly labelled 
water 
Daily EE (kcal) 
accelerometer 
273 (133) vs NR, NR 
 
 






















3 months: 9234 (3502) vs 7972 (3828), <0.001c 
12 months: 9850 (3282) vs 7970 (3433), 0.003c 
 
3 months: NR vs NR, 0.098c 
6 months: 75% vs 41%, 0.01c 
9  months: 68% vs 36%, 0.03c 






















479.3 (262.9) vs 402.9 (162.8), 0.056c 
 
372 (66.2) vs 382.5 (85.6), 0.04c 
 
278.2 (93.2) vs 297.2 (104.9), 0.106c 























53.3 (94.3) vs -11.1 (120.3), >0.05b 
 
































periods >5s (n) 
9.9 (4.2) vs 7.4 (2.9), >0.05b 
 
0.026 (0.009) vs 0.02 (0.007), >0.05b 
0.18 (0.06) vs 0.18 (0.07), >0.05b 
 
132 (55) vs 129 (57), >0.05b 
318 (109) vs 165 (62), >0.05b 
 
 




















3 months (median % (IQR): 18.7 (-27.5 to 51.8) vs 7 (-
29.1 to 36.8), 0.51b 
6 months (median % (IQR): 2.3 (-11.1 to 46.6) vs -14 (-
37.7 to 25.4), 0.036b 
19 months (mean (95% CI)): -5139 (-26859 to 16580) 













8 weeks: 270, 0.97b 













4963 (2950) vs 3063 (2226), 0.351b 
2 (1-3) vs 1 (1-3), 0.008b 












7392 (3365) vs 6750 (3366), 0.656c 













4.5 (1.8) vs 0.1 (0.8), <0.001b 
 































10% vs 15%, >0.05a 
7% vs 5%, >0.05a 
37% vs 38%, >0.05a 
48% vs 43%, >0.05a 
 
 
44% vs 34%, >0.05a 
24% vs 34%, >0.05a 
29% vs 31%, >0.05a 
2% vs 0%, >0.05a 





















13% vs 17%, >0.05a 
















per week (%) 
6 month: 13% vs 9%, >0.05a 

























6 month: 29% vs 29%, >0.05a 
12 month: 31% vs 25%, >0.05a 
6 month: 10% vs 6%, >0.05a 
12 month: 8% vs 6%, >0.05a 
6 month: 22% vs 22%, >0.05a 
12 month: 19% vs 14%, >0.05a 
6 month: 10% vs 10%, >0.05a 
12 month: 15% vs 15%, >0.05a 
6 month: 58% vs 62%, >0.05a 

















6 months: 86% vs 33%, 0.01 <P< 0.001a 
























4 week: 13.5 (4.9)* vs 11 (3.5)* vs 10.3 (3.4), >0.05a 
9 week: 17.2 (4.4)* vs 14.6 (3.9)* vs 15.8 (5.3), >0.05a 
4 week: 11.4 (5.3)* vs 10.4 (2.4)* vs 9.2 (3.7), >0.05a 
9 week: 14.3 (5)* vs 13.2 (2.5)* vs 12.3 (4.9), >0.05a 
4 week: 9.9 (5.4)* vs 9.1 (5.2)* vs 7.5 (3.3), >0.05a 
9 week: 15.5 (4.3)* vs 15.5 (6.8)* vs 12.7 (5.6), >0.05a 
4 week: 13.6 (3.8)* vs 14.1 (2.9)* vs 13.2 (3), >0.05a 
9 week: 16.9 (3.1)* vs 17.7 (2.7)* vs 15.9 (2,9), >0.05a 

































9 week: 18.8 (3.8)* vs 17.2 (2.8)* vs 17.3 (4.2), >0.05a 
4 week: 12.8 (5.1)* vs 11.5 (2.7)* vs 10.4 (2.8), >0.05a 
9 week: 19.4 (3.9)* vs 16.3 (3.8)* vs 15.7 (4.3), >0.05a 
4 week: 9.6 (5.2)* vs 7.8 (4.4)* vs 7.3 (2.8), >0.05a 
9 week: 14.6 (6.8)* vs 12.5 (6.2)* vs 10 (4.8), >0.05a 
4 week: 83.8 (28)* vs 77.5 (13.9)* vs 68.4 (13), >0.05a 











All groups sig. 
increased 
(p<0.001) from 
4 weeks to 9 
weeks 
recovery. 





to 9 weeks 
recovery. 
Hämäläinen 
et al. 1989 





NR vs NR, >0.05a I=C  
Hambrecht 
et al. 1993 
Subjective EE in leisure 
time PA 
(kcal/week) 
1876 (163) vs 1187 (97), <0.001a I>C  
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Heath et al. 
1987 






Subjective % patients 
currently 
exercising 
10 weeks: 88% vs 59%, <0.01a 







Subjective % patients 
physically 
exercising 
1 year: 66.7% vs 27.6%, <0.001a 






















1555 (NR) vs 1321.1 (NR), 0.22a 
 
383.2 (NR) vs 273 (NR), 0.04a 
 
512.3 (NR) vs 360.9 (NR), 0.02a  
 















2704 (1970) vs 2085 (1522), 0.4a I=C  
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Naser et al. 
2008 
Subjective % exercising 
vigorously 
20min 3x per 
week 
88% vs 20%, <0.05a I>C  
Oldenberg 
et al. 1995 
Subjective Exercise 
classification 
Both groups' level of activity generally changed over 
time (Z=3.52, p<0.001) 











1 year: 4.97 (0.35) vs 2.87 (0.7), 0.06b 
5 years: 4.34 (0.49) vs 3.57 (0.56), 0.64b 
1 year: 5.02 (0.61) vs 2.52 (0.7), 0.12b 













% no exercise 
6 months: 93% vs 72%, <0.001a 
2 years: 67% vs 46%, <0.01a 


















3 months: 5 (NR)* vs 4.6 (NR)* vs 4.3 (NR), NR 
6 months: 5.2 (NR)* vs 5 (NR)* vs 4.7 (NR), NR 
3 months: 2.4 (NR)* vs 2.2 (NR)* vs 1.5 (NR), 
<0.001**a, <0.01***a 















ng vs control 
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3 months (difference): 1.4 (1.2) vs 0.7 (1.0), <0.01b 
12 months (difference): 0.7 (1.0) vs 0.4 (1.1), >0.05b 























4 months: 164 (101) vs 128 (87), 0.497a 
12 months: 198 (99) vs 138 (76), 0.307a 
4 months: 4.8 (1) vs 2.4 (1.1), 0.00a 
12 months: 4.5 (1.6) vs 2.5 (1.8), 0.03a 





























6 months: 1.88 (7.25) vs 2.14 (3.06), >0.05a 
12 months: 6.88 (8.34) vs 2.86 (2.86), >0.05a 
 
 
6 months: 1,78 (2.32) vs 1.71 (2.45), >0.05a 
12 months: 4.89 (3.25) vs 1.71 (2.74), >0.05a 
 
6 months: 0.33 (1.17) vs 0.3 (1.22), >0.05a 


























6 months: -0.02 (0.4) vs 0.25 (0.25), >0.05a 
12 months: -0.89 (0.35) vs 0 (0), <0.05a 
6 months: 0.33 (0.44) vs -0.1 (0.28), >0.05a 
12 months: 0.11 (0.39) vs 0.1 (0.41), >0.05a 
6 months: 3.89 (7.52) vs 2.8 (5.13), >0.05a 







Wang et al. 
2016 
Subjective MIDAS PA 
score 
9.27 (9.71) vs 14.63 (11.09), 0.02c I>C Low score 
favourable 
West et al. 
2012 
Subjective % exercising 
>100kcal/day 
9% vs 12%, <0.05a I<C  
Willenheim
er et al. 
2001 
Subjective PA score 4 months: 60 (85) vs 42 (55), 0.507b 






Subjective % PA <4 hours 
per week 
34% vs 43%, 0.01a I>C  
PA=physical activity, EE=energy expenditure, NR=not reported, MVPA=moderate-vigorous physical activity, 
IPAQ=international physical activity questionnaire, IQR=interquartile range, CI=confidence interval, SE=standard error, 
MET=metabolic equivalent. 
Effect categorisations: 
I=C: no statistical difference in PA between intervention and control 
I>C: PA statistically superior in intervention compared to control  
I<C: PA statistically superior in intervention compared to control 
?: between group not reported, difference between intervention and control uncertain  
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Appendix 2.7: Vote counting – subjective vs objective PA measures 
 Number of results 
Direction of result  
 




PA in CR same as control 
(P>0.05) 
100 (69%) 30 (65%) 70 (71%) 
PA in CR higher than 
control (P≤0.05) 
38 (26%) 14 (31%) 24 (24%) 
PA in control higher than 
CR (P≤0.05) 
2 (1%) 0 2 (2%) 
PA difference between CR 
and control not clear (no 
P-value reported) 
5 (3%) 2 (4%) 3 (3%) 





Appendix 2.8: Vote counting – comparing statistical methods 
 Number of results 



















70 (75%) 24 (71%) 6 (46%) 
PA in CR higher than 
control (P≤0.05) 
38 (26%) 21 (23%) 10 (29%) 7 (54%) 
PA in control higher 
than CR (P≤0.05) 
2 (1%) 2 (2%) 0 0 
PA difference 
between CR and 
control not clear (no 
P-value reported) 
5 (3%) NA NA NA 





Appendix 2.9: Vote counting – comparing diagnoses 
 
  
 Number of results 
Direction of result  All studies CHD Heart failure Both 
PA in CR same as 
control (P>0.05) 
100 (69%)  62 (63%) 36 (86%) 2 (40%) 
PA in CR higher than 
control (P≤0.05) 
38 (26%) 31 (32%) 4 (10%) 3 (60%) 
PA in control higher 
than CR (P≤0.05) 
2 (1%) 2 (2%) 0 0 
PA difference 
between CR and 
control not clear (no 
P-value reported) 
5 (3%) 3 (3%) 2 (4%) 0 
Total 145 98 42 5 
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Appendix 2.10: Vote counting – comparing dose of exercise (dose units = 
weeks of exercise training x average sessions/week x average duration of 
session (minutes) 
 Number of results 
Direction of result  Dose ≥2000 units Dose <2000 units 
PA in CR same as control 
(P>0.05) 
24 (56%) 55 (85%) 
PA in CR higher than control 
(P≤0.05) 
16 (37%) 8 (12%) 
PA in control higher than CR 
(P≤0.05) 
1 (2%) 1 (1.5%) 
PA difference between CR and 
control not clear  
(no P-value reported) 
2 (5%) 1 (1.5%) 





Appendix 2.11: Vote counting – sensitivity analysis, removing frequency 
of exercise outcomes, and removing studies pre-1990 
 Number of results 
Direction of result  All studies PA outcome 
results based 
on frequency 





PA in CR same as control 
(P>0.05) 
100 (69%) 70 (67%) 90 (71%) 
PA in CR higher than 
control (P≤0.05) 
38 (26%) 29 (28%) 33 (26%) 
PA in control higher than 
CR (P≤0.05) 
2 (1%) 1 (1%) 1 (1%) 
PA difference between CR 
and control not clear (no P-
value reported) 
5 (3%) 4 (4%) 3 (2%) 





Appendix 2.12: Vote counting – comparing CR intervention type 
 Number of results 




PA in CR same as control 
(P>0.05) 
100 (69%) 25 (61%) 75 (72%) 
PA in CR higher than 
control (P≤0.05) 
38 (26%) 13 (32%) 25 (24%) 
PA in control higher than 
CR (P≤0.05) 
2 (1%) 1 (2%) 1 (1%) 
PA difference between CR 
and control not clear (no 
P-value reported) 
5 (3%) 2 (5%) 3 (3%) 
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1. Summary 
Study Title Identifying physical activity through accelerometry in 
heart failure 
Study Design Cohort study 
Study Participants Heart failure patients 
Planned Size of Sample (if applicable) 18-30 
Follow up duration (if applicable) NA 
Planned Study Period February 2018 - December 2018 
Research Question/Aim(s) 
 
The primary objective of this study is to identify and 
evaluate the range of values provided by 
accelerometers during a variety of typical daily lifestyle 
activities, and to relate these to the intensity of 
performing each activity in the heart failure population. 
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3.1 Background information 
Physical activity is defined as bodily movement produced by skeletal muscles that 
results in energy expenditure beyond resting expenditure (Caspersen, Powell & 
Christenson, 1985). The current national recommendation for physical activity in 
adults and older adults is at least 150 minutes of moderate intensity activity in bouts 
of 10 minutes or more (Department of Health, Physical Activity, Health Improvement 
and Protection, 2011). Physical inactivity is common in patients with chronic diseases 
such as heart failure, where dyspnoea and fatigue cause restrictions to the 
performance of daily physical activity such as walking and household chores (Dontje et 
al., 2014). The ability to accurately measure physical activity is important in order to 
properly evaluate interventions aimed at improving levels of physical activity (Van 
Remoortel et al., 2012). 
 
Daily physical activity levels are closely linked to exercise capacity and to clinical 
prognosis in patients with heart failure (Walsh, Charlesworth, Andrews, Hawkins & 
Cowley, 1997; Jehn et al., 2009). One of the key aims of cardiac rehabilitation is to 
improve total daily energy expenditure alongside physical fitness (BACPR, 2017). 
However, previous research has demonstrated that a large proportion of patients with 
heart disease are failing to meet recommended daily levels of physical activity (Dontje 
et al., 2014; Yates, Pozehl, Kupzyk, Epstein, & Deka, 2015).  
 
Daily physical activity can be estimated via numerous methods; questionnaires are 
commonly utilised, however these rely on the subject’s recollection and may lack the 
accuracy to detect changes in daily physical activity. There are a range of devices 
available to objectively measure physical activity, such as accelerometers, which 
provide information on the amount, frequency, duration and intensity of activity and 
are able to overcome the limitations of self-report measures. In a review of the validity 
of activity monitors in health and chronic disease by Van Remoortel at al., (2012), the 
majority of validation studies had been performed in healthy adults and not in older or 
chronically ill, where movements tend to be slower and exercise capacity is reduced. 
They also found that activity monitors are less accurate at slower walking speeds and 
therefore concluded that proper validation studies in chronic disease populations are 
required prior to their inclusion in clinical trials. Hall, Howe, Rana, Martin and Morey 
(2013) also confirmed that those with chronic conditions demonstrated significantly 
greater work rates in terms of metabolic equivalents (METS) compared to healthy 
counterparts, and identified the need for regression equations and cut points specific 




Advances in physical activity monitoring technology allow for raw signal data to be 
equated to energy expenditure. This can then be classified into light, moderate or 
vigorous intensity activity. Activity monitors such as accelerometers have been mostly 
calibrated in the young and healthy, and not in those with chronic diseases such as 
292 
 
heart failure, where daily activity habits are different and movements tend to be 
slower. In order to accurately estimate physical activity levels in heart failure patients, 
a calibration study is necessary to identify the range of acceleration values provided by 
accelerometry for behaviours of varying intensities.  
 
4. Aims/objectives 
The primary objective of this study is to identify and evaluate the range of values 
provided by accelerometers during a variety of typical daily lifestyle activities for heart 
failure patients, and to relate these to the measured intensity of performing each activity 
in the heart failure population.  
5. Participants, interventions, and outcomes 
 
5.1 Study design 
This study will be a single centre, observational study of a cohort of heart failure 
patients. This design is based on the experiences of three studies previously completed 
by Phillips, Parfitt and Rowlands (2013), Hildebrand et al., (2014) and Hildebrand et al., 
(2017).  
 
5.2 Study setting 
This is a single centre study, that will be run from the Sport and Health Sciences 
department at St Luke’s campus, University of Exeter. The Royal Devon & Exeter NHS 
Foundation Trust will be a Patient Identification Centre (PIC), only.  
At St Luke’s Campus, recruitment and consent of patients will take place, along with 
data collection. The Sport and Health sciences department is set up with all the 
necessary equipment and appropriately trained staff in order to run the study. 
 
5.3 Study participants 
Participating patients will be adults aged 18 years or older, with confirmed diagnosis of 
heart failure within the past 5 years. Patients with contraindications to exercise testing 
or physical activity will be excluded from the study. Complete inclusion and exclusion 
criteria are detailed below. 
 
Participants are free to withdraw from the study at any time, and do not have to give a 
reason for their withdrawal. Data collected on participants prior to withdrawal will be 
retained for analysis. 
 
5.3.1 Inclusion Criteria 
 Patient willing and able to give written informed consent to participate in study 
 Adult (aged ≥18 years) 
 Patients with confirmed diagnosis of heart failure (HFrEF or HFpEF) within the past 
5 years. 
 NYHA class ≤III 
 Stable symptoms of heart failure 
 
5.3.2 Exclusion criteria 
 Patients with contraindications to exercise testing or physical activity 
 Patients who are in a long term care establishment or who are unwilling or unable 
to travel to research site 
 Patients who are unable to understand the study information. 
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 Patients judged to be unable to participate in the study for any other reason (e.g. 
diagnosis of dementia, psychiatric disorder, life-threatening comorbidity). 
 
5.4 Device specifications 
GENEActiv accelerometer:  
The GENEActiv accelerometer is manufactured and distributed by Activinsights Ltd., 
UK. It is a small, body worn, tri-axial accelerometer which continuously records raw 
data up to 100Hz. 
 
5.5 Outcomes 
The primary outcome of the study is the acceleration (mg) values obtained via 
GENEActiv accelerometer (Activinsights, Kimbolton, UK) at multiple wear locations 
(both wrists, left hip), during typical daily physical activities of different intensity. 
 
Secondary outcomes will include the oxygen consumption (VO2), carbon dioxide 
production (VCO2), and RER obtained via breath-by-breath analysis using indirect 
calorimetry (OxyCon Pro, CareFusion, Basingstoke, UK). Rating of perceived exertion 
(RPE) will be recorded during the last 30 seconds of each activity using the Borg 6-20 
scale.  
 
5.6 Participant timeline 
 
Study visit appointments will all take place in the morning. Participants will be asked to 
take all their medication with water as normal prior to the study visit. Participants will 
be required to attend the visit having fasted overnight, however, they will be provided 
breakfast and refreshments throughout the visit. 
If patients attend the visit and have not fasted overnight, and would still like to 
participate in the study, they will be invited to attend a second visit where the resting 
metabolic rate will be measured. 
 
Upon arrival, participants will be given the opportunity to ask investigators any final 
questions they may have, before the informed consent form is countersigned by the 
investigator. Participants will be given a copy of this along with the PIS for their 
records. 
 
Anthropometric measures:  
Prior to starting the protocol, the following anthropometric measures will be taken 
and recorded: 
 Height (cm, using freestanding stadiometer) 
 Weight (kg, electronic scales) 
 Body mass index (BMI) calculated using the standard formula 
 Blood pressure (mmHg, using automated sphygmomanometer). 
Following these measurements, participants will be fitted with three GENEActiv 
accelerometers (Activinsights, Kimbolton, UK); at the right and left wrists, and over the 
left hip (via an elasticated waist band). Participants will also be fitted with the Oxycon 
Pro (OxyCon Pro, CareFusion, Basingstoke, UK) to measure energy expenditure. 
Participants will then be asked to lie down on a bed for 30 minutes in order to estimate 
their resting metabolic rate. After 30 minutes, participants will be asked to sit 
comfortably for 5 minutes. The metabolic rate measured here will be used as a 




At this point, participants will be provided with breakfast, followed by a short period of 
rest. 
Incremental shuttle walk test:  
Participants will complete the incremental shuttle walk test established by Singh, 
Morgan, Scott, Walters and Hardman (1992) in order to estimate their maximum 
exercise capacity. Participants are required to walk between two cones placed 10m 
apart at a speed dictated by signals from a CD player. The walking speed starts at 0.5 
ms-1 and increases in small increments (0.17 ms-1), at 1 minute intervals. The test may 
be terminated by investigators when the participant is unable to complete a shuttle in 
the time allowed, or by the participant if they feel too breathless or fatigued to continue 
the test. During the test, Heart rate (bpm) and rating of perceived exertion (RPE) using 
Borg 6-20 scale will be recorded at the end of each minute stage. Upon completion the 
number of shuttles completed, peak heart rate, peak RPE, and reason for termination 
will be recorded on the data collection form.  
Lifestyle activities:  
After a period of rest, participants will be asked to perform a variety of lifestyle based 
activities of varying intensity whilst wearing the accelerometers and Oxycon Pro 
(further detail of these activities is provided in table 1). RPE will be measured in the 
last 30 seconds of each activity using the Borg 6-20 scale. There will be a one minute 
transition period between each activity to allow for set up, and a five minute rest 
period between all ambulatory activities to allow metabolism to return to a value close 
to rest.  
 
 
Table 1: Activities 
Duration Activity Notes 
30 minutes Laying down on a bed Resting metabolic rate measured 
5 minutes Sitting Metabolic rate measured here used as 




Incremental Shuttle Walk Test  
Rest period* 
5 minutes Sitting watching television  
5 minutes Standing washing dishes  
5 minutes Sitting  
Rest period* 
5 minutes Light intensity walk Pace derived from ISWT (RPE 11) 
5 minutes Rest, sitting  
5 minutes Moderate intensity walk Pace derived from ISWT (RPE 13) 
10 minutes Rest, sitting  
5 minutes Light intensity walk carrying 
shopping bag 
Pace derived from ISWT (RPE 11) 
Equipment returned and patients provided with refreshments 
* Where there are resting periods, patients will be asked to sit until their metabolic rate 
reaches that measured during the first sitting session, and has remained there for 15 
minutes. 
Once all activities have been completed, the equipment will be removed, and 
participants provided with refreshments and allowed to rest under supervision for as 
long as desired before leaving. 
 
5.7 Sample size 
Assuming a conservative expectation of a ROC AUC of 0.85 (based on lowest AUC 
reported in the papers by Hildebrand et al., 2017; Hildebrand et al., 2014; and Phillips 
et al., 2013), and assumed null AUC of 0.5 (no association) at 90% power and 5% alpha, 
a minimum sample size of 18 patients is required. Therefore a sample size of at least 
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18, and no more than 30 patients will be recruited.   
 
5.8 Recruitment 
Potential participants will be identified by the local cardiologist, Dr Manish Gandhi in 
the Royal Devon & Exeter NHS Foundation Trust heart failure clinic. At their routine 
clinic appointments, patients will be given a one page information leaflet with brief 
details about the study and an invitation to contact the investigator via telephone, 
email or post if they are interested in participating in the study or wish to find out 
more information. The leaflet contains a page for patients to write down their contact 
number and sign to say they are happy to be contacted by the chief investigator, which 
will be collected by the clinic staff and posted to the chief investigator.  
 
Once the patient has made contact with the chief investigator, and they have indicated 
an interest in participating, more detailed information sheets will be sent via email or 
post, along with a copy of the consent form to ensure they are fully informed of the 
requirements. Patients will be given at least 24 hours to consider whether they would 
like to participate and for appointments made for the study visit. Upon making the 
appointment, patients will be asked to sign the consent form and bring it with them to 
their appointment to be countersigned by the investigator, and reminded that they 
will need to fast overnight prior to attending their appointment.  
 
On occasion, the chief investigator will attend the heart failure clinics, where patients 
who are identified as potential participants will be directed by the HF nurses to meet 
with the chief investigator in a nearby room to discuss the study and be provided the 
information leaflet and full patient information sheets. These patients will not be 
consented at this initial meeting, and will follow the same recruitment process as the 
patients that are first approached by the HF nurses. 
 
If participants attend the visit and have not fasted, but would still like to participate in 
the study; they will be invited to attend a second visit, ensuring they are fasted in 
order to measure resting metabolic rate. 
 
Participating patients will be reimbursed for transport to and from the university 
campus. 
 
6. Data collection, management and analysis 
 
6.1 Data collection methods 
GENEActiv accelerometers will be placed on both wrists and the left hip and worn 
continuously throughout the testing period. Manufacturer’s software will be used to 
initialise and extract data from both devices. Further data processing will be 
undertaken using custom programmes written in the statistics package R.  
 
Oxygen consumption (VO2), carbon dioxide production (VCO2), and RER obtained via 
breath-by-breath analysis using indirect calorimetry (OxyCon Pro, CareFusion, 
Basingstoke, UK). Expired air passes through a facemask connected via a bidirectional 
flowmeter to oxygen and carbon dioxide analysers allowing the determination of FEO2 
and FECO2. Oxygen consumption and CO2 production will be averaged over a 30-




RPE will be collected using the Borg 6-20 RPE scale during the last minute of each 
activity by the chief investigator asking patients to describe which number on the scale 
represents their perceived level of exertion and the number recorded on a paper data 
collection form.  
 
If data is missed due to technical issues with the equipment, participants may be asked 
to return for a second visit in order to complete data collection. 
 
6.2 Data management 
Electronic data will be stored on a password protected computer, and only immediate 
members of the research team will have access to the data. Signed informed consent 
forms and paper data collection forms will be stored in a locked cabinet in the lead 
researcher’s secure office.  
 
Participants will be assigned a unique ID number on a password protected database 
and only these labels will be used for data analysis.   
 
6.3 Statistical methods 
Descriptive statistics will be used to determine the range of mg values for each 
behaviour. 
Receiver operator characteristic (ROC) curve analysis will be used to determine the mg 
value with the highest sensitivity, specificity and area under the curve for classifying 
accelerometer intensity thresholds (Hildebrand et al., 2017; Hildebrand et al., 2014; 
Phillips et al., 2013). Manufacturer’s software will be used to initialise and extract data 
from both devices. Further data processing will be undertaken using custom 




7.1 Data Monitoring 
A data monitoring committee (DMC) is not required for this study as the study will be 
running for a short period only, and the protocol is unlikely to be modified regardless 
of the interim data. In addition the likely risks are minimal in this study due to the 
nature of the activities.  
 
7.2 Adverse Events 
A full risk assessment can be found in the appendices.  
 
The incremental shuttle walk test is a predictive fitness test that has been tested and 
validated for use in the heart failure population. Participants will be monitored closely 
at all times by investigators during their test and participants will be advised to report 
any discomfort or desire to stop the exercise test immediately.  
 
As the proposed protocol requires the completion of typical daily activities in the heart 
failure population the risks associated with all other aspects of the study are minimal. 
Any adverse events that occur during the participant’s visit will be documented on the 
data collection form.  
 
Serious adverse events (SAEs) are defined as any untoward occurrence that (a) results 
in death, (b) is life-threatening, (c) requires inpatient hospitalisation or prolongation of 
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existing hospitalisation, (d) results in persistent or significant disability or incapacity or 
(e) consists of a congenital anomaly or birth defect. SAEs will be reported by 
investigators to the Research Ethics Committee within 15 days of becoming aware of 
the event. 
Patients will be asked on the ICF whether they give permission for their GP to be 
informed of their participation in the study. A space is provided for them to enter their 
GP’s name and the name of the surgery in order for the chief investigator to post the 
GP letter.  
7.3 Auditing 
Internal audit of data collection, data entry, and documentation will be completed 
after the first participant has completed the study, and then after every 5th participant 
until recruitment has ended. This will be conducted by the chief investigator in order 
to ensure the quality of research is maintained. 
 
8. Ethics and dissemination 
 
8.1 Research ethics approval 
Before the start of the study a favourable ethical opinion will be sought for the study 
protocol, informed consent form, patient information sheet, patient leaflet and GP 
letter from an NHS Research Ethics Committee (REC). 
 
All correspondence with the REC will be retained in the ISF. The REC will be notified of 
the end of the study by the chief investigator. An annual progress report will be 
submitted to the REC within 30 days of the anniversary date on which favourable 
opinion was given, and annually until the study is declared ended. If the study is ended 
prematurely, the chief investigator will notify the REC, and include the reasons for 
premature termination. Within one year after the end of the study, the chief 
investigator will submit a final report with the results, including any 
publications/abstracts to the REC. 
 
8.2 Protocol amendments 
Substantial amendments that require review by REC will not be implemented until 
favourable opinion is granted. 
 
8.3 Patient and public involvement 
During the study design phase, the proposed data collection protocol was presented to 
a local heart failure PPI group for feedback. The group was made up of heart failure 
patients and their caregivers. The patients provided feedback on the protocol, and as a 
result of this, the protocol was shortened and some activities amended to suit the 
daily lives of the patient group. 
 
8.4 Consent or assent 
Informed consent will be obtained from participants by the lead researcher prior to 
any study related activity being undertaken on the morning of the visit. Participants 
will be asked to sign and date the informed consent form and will be given a copy of 
this to keep for their own records.  
 
8.5 Confidentiality 
All investigators and study site staff will comply with the requirements of the Data 
Protection Act 1998 with regards to the collection, storage, processing and disclosure 




Participants will be assigned a unique ID number in order to ensure anonymity. 
Electronic data will be stored on an encrypted password protected computer, and only 
immediate members of the research team will have access to the data. Paper based 
information such as signed informed consent forms and data collection forms will be 
stored in a locked cabinet in the lead researcher’s secure office. 
 
Personal data will be stored for 6-12 months after the study has ended in order for the 
research team to post study newsletters with results of the study to participants if 
they requested this at study entry. Anonymised data will be securely stored 
electronically for at least 5 years in the University of Exeter open research repository, 
according to the University of Exeter data management policy. 
 
8.6 Declaration of interests 
There are no financial or other competing interests for investigators for the overall 
trial.  
 
8.7 Access to data 
All members of the research team involved in the study will have a duty of 
confidentiality, and nothing that could reveal the patient's identity will be disclosed 
outside the research team. Information will be collected and stored in accordance with 
the Data Protection Act 1998. 
 
The participants' names and other identifying information will be removed from any 
study data, and will be linked to an anonymous ID number on a password protected 
database so that they cannot be identified from the data. 
 
8.8 Ancillary and post-trial care 
Arrangements have been made through University of Exeter for insurance and/or 
indemnity to meet the potential legal liability of the sponsor for harm to participants 
arising from the management/conduct/design of the research. 
 
8.9 Dissemination policy 
Results will be written up and submitted to a peer review journal and presented at 
conferences. The study will also form part of a PhD thesis. 
 
Participants will be given a newsletter at the end of the study to inform them of the 
results.  
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Participant Information Sheet 
 
Study title  
 
Identifying physical activity through accelerometry in heart failure 
Invitation and brief summary  
 
We would like to invite you to take part in a research study to help better 
understand physical activity in patients with your heart condition. Participation is 
entirely voluntary, and before you decide whether or not you would like to take 
part, we would like you to understand why the research is being done, and what 
would be involved. After reading this information sheet, please do not hesitate to 
ask the research team any questions you may have, to help you decide whether 
or not you would like to take part. 
 
Thank you for taking the time to read this information.  
 
What is the purpose of the study?   
The proposed research study is being undertaken as part of a PhD. 
Advances in physical activity monitoring means that we are now able to estimate 
the intensity of specific behaviours with wearable devices. These devices (similar 
to a watch) need to be tested within a laboratory before they can be applied to 
research. Previous laboratory tests have been performed with young and healthy 
people but not in people with heart conditions. We know that in patients with heart 
conditions, their fitness levels may not be as high as a healthy adult, therefore we 
need to perform the laboratory test in patients with your heart condition to make 
sure we are accurately measuring physical activity. 
 
The aim of this study is to identify the range of values provided by activity monitors 
during a variety of typical daily activities (e.g. lying, sitting, standing, walking), and 
to relate these to the energy cost (or intensity) of performing each activity. 










Sport and Health Sciences 
College of Life and 
Environmental Sciences 
 




Telephone: +44 (0)1392 722807 
Email: sshs-school-office@ex.ac.uk  
Web:  www. e x.ac .uk / s s hs  
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Participants will be required to have their fitness measured via an incremental 
shuttle walk test, and will also be asked to complete numerous activities that 
represent everyday life, such as lying, sitting, walking and household tasks. 
These will be completed whilst wearing activity monitors (on the wrists and hip) 
and a facemask to measure expired air.  
 
What would taking part involve?  
 
We have invited you to take part in the study because we are looking for patients 
with your heart condition aged 18 years and above, who meet a range of eligibility 
criteria for the study. We will be recruiting 18-30 heart failure patients in total. 
 
If you agree to take part you will be asked to attend the Sports Science laboratory, 
in the Richard’s Building, at the University of Exeter’s St. Luke’s campus on 
Heavitree Road for a single visit that should last approximately 3 hours. You will 
be reimbursed for your travel to and from the campus. 
 




You will need to attend fasted for us to measure your resting metabolism, 
however breakfast will be provided once these measures are complete 
(within the first hour of the visit), and refreshments at the end of the visit. 
 
Please ensure that you have nothing to eat or drink (other than water) for 8-
12 hours (overnight) prior to attending your appointment.  All appointments 
will be in the morning. Ensure that you drink plenty of water to stay well 
hydrated and take your medications as normal in the morning.  
 
If you attend the appointment but have not fasted overnight, and still wish to 
participate, we will complete the physical activities and then we will ask you to 
come back and complete the resting metabolism at another time.  
 
Overview of the day:  
 
Before starting you will have the opportunity to discuss any final questions you 
may have about the study with the research team. You will then be asked to sign 
a written informed consent form stating that you are happy to take part.  
 
We will collect some preliminary measurements including height, weight, and 
blood pressure. You will then be fitted with a portable gas analyser which consists 
of a rubber face mask, attached to two small boxes which you will wear in a 
harness on your chest (see picture 1); and accelerometers (one on each wrist, 





Picture 1      Picture 2 
 
The activities that you will be asked to complete are detailed in Table 1 below. 
There will be a one minute transition between each activity. The metabolic rate 
that is measured during the first sitting period will be used to determine your 
resting time. During your rest periods you will be seated until you return to this 
resting rate, and remain at this for 15 minutes. Then you will move on to the next 
block of activities.  
 






















The incremental shuttle walk test is an exercise test used to estimate your fitness. 
During the test you will be asked to walk between two cones spaced 10 metres 
apart in time with beeps on a pre-recorded CD. The pace will start off very slow, 
and increase gradually every minute, getting faster until you are unable to keep 
up with the set pace, or feel too breathless or tired to continue. During the last 30 
seconds of each stage we will ask you to rate how difficult you are finding the 
activity using the rating of perceived exertion scale. 
 
During the final minute of each activity we will be asking you to rate how difficult 
you are finding the activity using the rating of perceived exertion scale. 
 
Duration Activity 
30 minutes Laying down on a bed 




Incremental Shuttle Walk 
Test 
Rest period 
5 minutes Sitting watching television 
5 minutes Standing washing dishes 
5 minutes Sitting 
Rest period 
5 minutes Light intensity walk 
5 minutes Rest, sitting 
5 minutes Moderate intensity walk 
10 minutes Rest, sitting 
5 minutes Light intensity walk carrying 
shopping bag 




Once all the activities are complete we will provide you with some refreshments 
and allow you to rest under supervision for as long as desired before returning to 
your day. 
What are the possible benefits of taking part?  
The main benefits of the study will be informative and there will be limited 
personal benefit to you. The results will help to increase our understanding of 
physical activity in the heart failure population. 
What are the possible disadvantages and risks of taking part?  
 
We don’t expect you to be harmed in any way by taking part in this study. The 
incremental shuttle walk test is a predictive fitness test that has been tested and 
validated in the heart failure population, it is commonly used in cardiac 
rehabilitation. The physical activities that you will be asked to undertake should 
replicate activities you usually undertake on a day to day basis, therefore have 
little risk involved. You may experience some side effects from fasting, such as 
light-headedness. However, while fasted you will only be laying down and sitting 
to have your metabolic rate measured before you can eat. 
 
You will be monitored closely at all times during the visit and you will be advised 
to report any discomfort or desire to stop the activities immediately.  
 
Your attendance at the university campus may incur an expense to you in the first 
instance. However, please be assured that any travel expenses for taking part in 
the study, including those incurred through use of your own vehicle will be 
reimbursed at public transport rates. The research team member will let you know 
how to claim travel expenses at the research visit.  
 
Do I have to take part? 
 
Participation in this study is entirely voluntary. It is your choice whether you would 
like to take part or not and if you decide to take part, you are free to withdraw 
from the study at any time without giving a reason as to why you wish to do so. If 
you do decide to participate in this study you will be asked to sign a consent form 
before you start. You will be given a copy of the consent form and this information 
sheet for your own records. 
 
Your participation will not affect your routine patient care now, or in the future. 
 
 
Are my results confidential? 
 
If you consent to take part in this study, all information that is collected about you 
will be kept strictly confidential. Your medical records will be reviewed by your 
clinical care team at the RD&E clinic to confirm eligibility to take part. The chief 
investigator may review your medical records to collect clinical data about the 
type and degree of heart failure, or this information will be passed onto the 
research team via secure NHS email. The research team at University of Exeter 
will prepare the trial data collected about you for analysis. Your name and other 
identifying information will be removed from any study data, and will be linked to 
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an anonymous ID number on an encrypted  password protected database so that 
you cannot be identified from the data.  
 
Paper based information will be stored in locked cupboards in locked offices and 
information stored on computers will be stored securely on a system maintained 
by the University of Exeter. Your name, address and GP details will be stored 
securely on computers, accessible only by members of the study team for the 
purposes of contacting you, mailing information and results about the study if 
requested, and in order to contact your GP about participation in the study. Your 
personal information will be stored separately from the research information 
collected in the study. Any communication between your clinical care team and 
the investigator will be done via secure NHS email. 
 
All members of the research team involved in the study will have a duty of 
confidentiality to you as a research participant, and nothing that could reveal your 
identity will be disclosed outside the research team. Information will be collected 
and stored in accordance with the Data Protection Act 2018. 
 
What will happen to the results of this study? 
 
The results will increase our understanding of the lifestyle physical activities of 
heart failure patients. We will aim to publish the findings in research journals and 
to present them at conferences in the UK or abroad. If you are interested we will 
send you a newsletter at the end of the study to inform you of the results. Your 
data will always remain anonymous and your name will not appear on any results. 
 
How have patients and the public been involved in this study? 
 
A heart failure patient and public involvement group, consisting of heart failure 
patients and their caregivers were involved in designing this study; we have taken 
into account patient opinions of the frequency and length of participant visits and 
the physical activities included in the protocol.  
 
Involvement of your General Practitioner/Family Doctor (GP) 
 
With your permission, we will write to your GP to inform them of your 
participation in this study. They may also be contacted should the research 
team have any concerns about your health during your involvement with the 
study. 
 
Who has reviewed this study? 
 
All research activity in the NHS is reviewed by an independent group of people,  
called a Research Ethics Committee, to protect your interests. This study has 
been reviewed and given favourable opinion by East of England - Cambridge 
South Research ethics committee Research Ethics Committee.  
 
Contacts for further information 
 
If you would like more information or if you have any further questions about the 




Grace Dibben Associate Professor Melvyn Hillsdon 
European Centre for Environment 
and Human Health 
School of Sport and Health Sciences 
University of Exeter Medical School Richards Building 
Knowledge Spa St. Lukes Campus 
Royal Cornwall Hospital Exeter University 
Truro, TR1 3HD EX12LU 
Tel: 01872 255179 Tel: 01392 722868 
Email: gd318@exeter.ac.uk Email: m.hillsdon@exeter.ac.uk 
 
If you would like to make a complaint please contact: 
















Sport and Health 
Sciences 
College of Life and 
Environmental 
Sciences 
St Luke’s Campus, 
Heavitree Road, Exeter, 
EX1 2LU 
Telephone: +44 (0)1392 26 
Email: sshs-school-
office@ex.ac.uk  
Web:  www. e x.a .uk  
Study: Identifying physical activity through accelerometry in heart failure 
Researcher: Grace Dibben 
Organisation: The University of Exeter 
Version: #1.2 04/05/2018: reviewed by East of England - Cambridge South Research ethics 
committee 
IRAS project ID: 225596 
 
Participant Identification Number:             
Informed Consent form for participants  Please 
initial box 
I confirm that I have read and understand the information sheet version 
#1.2 dated 04.05.18 for the above study. I have had the opportunity to 




I understand that my personal details will be kept securely and 
confidentially, and any information that is entered onto a computer will 
be password protected. My personal details will be stored separately 
from the data I provide (which will be stored anonymously) and none of 
my identifiable details will appear in any reports, articles or 
presentations by the research team. 
  
I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason or affect on my care 
now or in the future. 
 
 
I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from 
University of Exeter, from regulatory authorities or from the NHS Trust, 
where it is relevant to my taking part in this research.  I give permission 






I give permission for my GP to be informed of my participation in the 
study.   
 
GP name and surgery: 
 
 
   
I understand that if the researcher becomes aware of any factors 
relating to my health that they consider pose a serious threat to my well-
being they will act in my best interest and inform my GP as a matter of 
urgency, without my express permission if considered necessary.  In the 
very unlikely event that this will occur I understand that the researcher 
will always inform me that they have contacted my GP and tell me what 






I understand that in order for resting metabolism to be measured I will 
be required to fast overnight, prior to attending my appointment the 
following morning. I understand that I will be provided breakfast once 
these measures are complete. 
 
 
   





Name of Participant  Date  Signature 
     
     
Name of Researcher  Date  Signature 





































Appendix 3.5: Health research authority favourable ethical opinion letter 












Appendix 3.6: Sensitivity, specificity, area under the curve and resulting intensity thresholds for each accelerometer, 
and each data reduction method 

















SVM Right Wrist         
All patients  
(n=21, obs =168) 
94.5 96.1 0.96  
(0.93-
0.99) 





walking activity data* 
(n=21, obs=159) 
91.5 98.7 0.96  
(0.92 to 
0.99) 





walking and washing 
up activity data† data 
(n=21, obs=138) 
91.9 97.4 0.96  
(0.92-
1.00) 




SVM Left wrist         
All patients  
(n=20, obs =160) 
92.0 91.8 0.96  
(0.92-
0.99) 







walking activity data* 
(n=21, obs=151) 
92.3 94.5 0.96  
(0.92-
0.99) 





walking and washing 
up activity data† 
(n=21, obs=131) 
88.1 98.6 0.95  
(0.91-
1.00) 




SVM Waist         
All patients  
(n=21, obs =168) 
90.1 90.9 0.95  
(0.92-
0.98) 





walking activity data* 
(n=21, obs=159) 
86.6 97.4 0.94  
(0.91-
0.98) 





walking and washing 
up activity data† 
(n=21, obs=138) 
87.1 100.0 0.93  
(0.89-
0.98) 




MAD Right wrist         
All patients  
(n=21, obs =168) 
75.8 63.6 0.76  
(0.69-
0.84) 







walking activity data* 
(n=21, obs=159) 
82.9 63.6 0.79  
(0.72-
0.86) 





walking and washing 
up activity data† 
(n=21, obs=138) 
77.4 64.5 0.76  
(0.68-
0.84) 




MAD Left wrist         
All patients  
(n=21, obs =168) 
77.0 63.0 0.73  
(0.65-
0.81) 





walking activity data* 
(n=21, obs=159) 
80.8 63.0 0.75  
(0.67-
0.83) 





walking and washing 
up activity data† 
(n=21, obs=138) 
74.6 63.9 0.72  
(0.63-
0.80) 




MAD Waist         
All patients  
(n=21, obs =168) 
83.5 87.0 0.90  
(0.85-
0.95) 







walking activity data* 
(n=21, obs=159) 
84.2 87.0 0.90  
(0.85-
0.95) 





walking and washing 
up activity data†  
(n=21, obs=138) 
87.1 90.8 0.91  
(0.85-
0.97) 




METS, metabolic equivalents; MVPA, moderate-vigorous physical activity; AUC, area under the curve; SVM, sum of vector 
magnitude; MAD, mean amplitude deviation.* Excluded walking activity data for n=3 patients using walking aids. † Excluded 




Appendix 3.7: Leave-one-out cross validation 
 
Figure B1 – Scatter plot where each point represents the prediction from a 
multilevel mixed effects regression linear regression model leaving out one 









Figure B2 - Scatter plot where each point represents the prediction from a 
multilevel mixed effects regression linear regression model leaving out one 










Figure B3 - Scatter plot where each point represents the prediction from a 
multilevel mixed effects regression linear regression model leaving out one 










Figure B4 - Scatter plot where each point represents the prediction from a 
multilevel mixed effects regression linear regression model leaving out one 










Figure B5 - Scatter plot where each point represents the prediction from a 
multilevel mixed effects regression linear regression model leaving out one 










Figure B6 - Scatter plot where each point represents the prediction from a 
multilevel mixed effects regression linear regression model leaving out one 





Appendix 3.8: Letter to the editor associated with Chapter 3 of this thesis 
One size does not fit all – application of accelerometer thresholds in chronic 
disease 
Grace Olivia Dibben1*, Rod S Taylor2,3, Hasnain Dalal1,2, Melvyn Hillsdon4.  
1University of Exeter Medical School, Knowledge Spa, Royal Cornwall Hospitals 
NHS Trust, Truro, TR1 3HD, UK.  
2Institute of Health Research (Primary Care), University of Exeter Medical 
School, St. Luke’s Campus, Heavitree Road, Exeter, EX1 2LJ, UK. 
3Institute of Health and Wellbeing, University of Glasgow, Glasgow G12 8QQ 
4Department of Sport and Health Sciences, University of Exeter, Richard’s 
Building, St Luke’s Campus, Exeter EX1 2LU, UK. 
 
Comment on: Physical activity of UK adults with chronic disease: cross-
sectional analysis of accelerometer-measured physical activity in 96706 UK 
Biobank participants. 
 
We would like to congratulate the recent publication from Barker et al., 
comparing physical activity (PA) of those with and without chronic disease from 
the UK Biobank participants.(1) The authors conclude that those with chronic 
disease have lower PA levels than their healthy peers. However, we would like 
to draw attention to what believe a key limitation of this study. 
The accelerometer thresholds used by the authors to classify PA into moderate 
(100mg) or vigorous (400mg) intensity have been applied to all study 
participants, both with and without chronic disease. These thresholds are 
derived from a study of 30 healthy adults (2), and have been used in a number 
of studies including those of older adults and patients with heart failure.(3-4) 
Applying the same intensity thresholds to all individuals, make the strong (and 
we believe inappropriate) assumption that energy expenditure is the same for 
all i.e. an activity that generates a vector magnitude between 100-400mg 
requires 3-6 METS for everyone, and does not take into account an individual’s 
exercise capacity.  
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We have recently conducted an accelerometer calibration study in 21 heart 
failure patients (paper currently in preparation), and have derived acceleration 
values that relate to moderate intensity activity in this population. The value of 
100mg used in the paper by Barker et al.(1) is more than double the values that 
we observed (i.e. 43.2 to 45.5mg).  
We do not dispute that PA levels of those with chronic disease are lower than 
those of their healthy counterparts. However, the magnitude of the difference 
between these two groups may be exaggerated with the application of the same 
intensity threshold of 100mg. As a result, the amount of MVPA in those with 
chronic disease, such as heart failure, has been underestimated in the study of 
Barker et al.  
It is vital that accelerometer data is interpreted correctly. If a PA threshold is 
applied that is too high it will result in activity recommendations that are 
inappropriate and likely to be too difficult for patients perform. As a result, 
patients may become demoralised, demotivated and less likely to make the 
behaviour change that is so important for their health.(5) 
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chronic disease: cross-sectional analysis of accelerometer-measured physical 
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2019; 1-8. 
2. Hildebrand M, van Hees VT, Hansen BH, Ekelund U. Age group 
comparability of raw accelerometer output from wrist- and hip-worn monitors. 
Med Sci Sports Exerc 2014;46(9):1816-1824. 
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Appendix 4.1: REACH-HF trials full inclusion and exclusion criteria 
HFrEF trial 
Inclusion criteria 
 Provision of informed consent to participate 
 Adults (aged ≥18 years) 
 Confirmed diagnosis of systolic heart failure on echocardiography (i.e. 
left ventricular ejection fraction <45% within the past 5 years) 
 Patients who have experienced no deterioration of heart failure 
symptoms in the past 2 weeks resulting in hospitalisation or alteration of 
heart failure medication. 
 
Exclusion criteria 
 Patients who have undertaken cardiac rehabilitation in the last 12 months 
 Patients who have received an intracardiac defibrillator (ICD), cardiac 
resynchronisation therapy (CRT) or combined CRT/ICD device implanted 
in the last 6 months 
 Patients who have any of the following contraindications to exercise 
testing or exercise training: 
o Early phase after acute coronary syndrome (up to 2 days) 
o Untreated life-threatening cardiac arrhythmias 
o Acute heart failure (during the initial period of haemodynamic 
instability) 
o Uncontrolled hypertension (systolic blood pressure >200 and/or 
diastolic blood pressure >100) 
o Advanced atrioventricular block 
o Acute myocarditis and pericarditis 
o Symptomatic aortic stenosis 
o Severe hypertrophic obstructive cardiomyopathy 
o Acute systemic illness 
o Intracardiac thrombus 
o Progressive worsening of exercise tolerance or dyspnoea at rest 
over previous 3–5 days 
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o Significant ischaemia during low-intensity exercise (<2 Metabolic 
equivalents, <50 Watts) 
o Uncontrolled diabetes (blood glucose >16 mmol/L or glycated 
hemoglobin >9% or equivalent unit) 
o Recent embolism 
o Thrombophlebitis 
o New-onset atrial fibrillation/atrial flutter 
 Patients who are in a long term care establishment or are unwilling or 
unable to travel to research assessments or accommodate home visits 
 Patients who are unable to understand the study information or unable to 
complete the outcome questionnaires 
 Patients judged to be unable to participate in the study for any other 
reason (eg, psychiatric disorder, diagnosis of dementia, life threatening 
co-morbidity) 
 Patients participating in concurrent interventional research which may 




 Adult aged ≥18 years 
 Patients with heart failure defined by the presence of at least one of the 
following symptoms at the time of screening: 
o Paroxysmal nocturnal dyspnoea 
o Orthopnoea 
o Dyspnoea on mild or moderate exertion 
AND at least one of the following signs prior to study entry: 
o Basal crepitations 
o Elevated jugular venous pressure 
o Lower extremity oedema 
o Chest radiograph demonstrating pleural effusion, pulmonary 
congestion or cardiomegaly.  
 Patients with left ventricular ejection fraction ≥45% obtained within 6 
months prior to randomisation and after any myocardial infarction or 
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other event that would affect ejection fraction (ideally obtained by 
echocardiography, although radionuclide ventriculography and 
angiography are acceptable) 
 Provision of informed consent to participate 
 
Exclusion criteria 
 Patients who have undertaken cardiac rehabilitation in the last 6 months 
 Patients with severe chronic pulmonary disease defined as requiring 
home oxygen or hospitalisation for exacerbation within 12 months or 
significant chronic pulmonary disease in the opinion of the investigator 
 Patients who have any of the following contraindications to exercise 
testing or exercise training: 
o Early phase after acute coronary syndrome (up to 2 days) 
o Untreated life-threatening cardiac arrhythmias 
o Acute heart failure (during the initial period of haemodynamic 
instability) 
o Uncontrolled hypertension (systolic blood pressure  >200 and/or 
diastolic blood pressure >100) 
o Advanced atrioventricular block 
o Acute myocarditis and pericarditis 
o Symptomatic aortic stenosis 
o Severe hypertrophic obstructive cardiomyopathy 
o Acute systemic illness 
o Intracardiac thrombus 
o Progressive worsening of exercise tolerance or dyspnoea at rest 
over previous 3–5 days 
o Significant ischaemia during low-intensity exercise (<2 metabolic 
equivalents, <50 W) 
o Uncontrolled diabetes (blood glucose >16 mmol/L or HbA1C >9% 
or equivalent unit) 
o Recent embolism 
o Thrombophlebitis 
o Recent-onset atrial fibrillation/atrial flutter (in the last 4 weeks) 
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 Patients who are unable to understand the study information or unable to 
complete study procedures 
 Patients who are in a long-term care establishment or who are unwilling 
or unable to travel to research assessments or accommodate home visits 
 Patients judged to be unable to participate in the study for any other 
reason, for example, psychiatric disorder, diagnosis of dementia, life-
threatening comorbidity 
 Patients participating in concurrent interventional research which may 




Appendix 4.2: Univariate linear regressions between MVPA and 
sociodemographics, exercise capacity and health status variables 
Sociodemographic, exercise 
capacity and health status 
variables 
N=247 unless otherwise 
stated 
Unstandardized beta 




Age -11.44 (-16.13 to -6.75) <0.001 0.09 
Gender 3.92 (-108.68 to 116.52) 0.95 <0.001 










-435.64 (-579.59 to -
291.69) 
-621.03 (-1378.5 to 
136.41) 
-285.04 (-556.16 to -13.92) 
-160.2 (-492.73 to 172.28) 
<0.001 0.14 







-303.94 (-436.43 to -
171.45) 
-475.74 (-627.39 to -
324.08) 
<0.001 0.14 






14.61 (-113.73 to 162.94) 
-73.21 (-189.68 to 43.26) 
0.30 0.01 






131.87 (28.28 to 235.45) 
179.40 (-30.63 to 389.44) 
0.03 0.03 
LVEF (%) (N=188) 1.37 (-2.25 to 4.99) 0.46 0.003 
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NT-proBNP (pg/ml) -0.03 (-0.06 to -0.001) 0.04 0.02 
Living alone -148.13 (-261.28 to -34.98) 0.01 0.03 
Living with partner 52.28 (-53.21 to 157.77) 0.33 0.004 
Living with child >18 213.72 (15.08 to 412.35) 0.04 0.02 
Living with child <18 258.26 (-100.59 to 617.11) 0.16 0.008 







76.28 (-143.42 to 295.97) 
228.90 (4.44 to 453.35) 
0.008 0.04 
Trial site 
  Truro 
  Gwent 
  Birmingham 
  York 
  Dundee 
 
Comparison group 
-8.29 (-31.21 to 14.62) 
-13.64 (-36.02 to 8.73) 
7.07 (-15.06 to 29.20) 













Chronic back pain 





Total number of comorbidities  
 
-108.32 (-222.75 to 6.11) 
-128.01 (-245.92 to -10.09) 
-69.89 (-182.15 to 42.37) 
-74.64(-176.07 to 26.78) 
-153.66 (-353.17 to 45.85) 
-41.25 (-198.80 to 116.30) 
-105.58 (-265.09 to 53.93) 
-29.67 (-139.55 to 80.21) 
-0.23 (-0.57 to -1.03) 
-4.16 (-106.56 to 98.25) 
-46.77 (-148.18 to 54.65) 
-108.45 (-270.51 to 53.60) 
-47.36 (-164.88 to 70.16) 































Total number of 
cardiorespiratory and 
metabolic comorbidities*  
-63.95 (-99.70 to -28.20) 0.001     0.05 
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     Total number of physical and 
musculoskeletal 
comorbidities†  
-18.03 (-73.89 to 37.84) 0.53 0.002 
Medication 












24.96 (-90.23 to 140.16) 
25.53 (-79.38 to 130.44) 
-8.99 (-110.57 to 92.59) 
-57.26 (-158.80 to 44.27) 
67.02 (-56.30 to 190.34) 
11.47 (-127.69 to 150.62) 
-104.91 (-331.78 to 
121.96) 
-133.41 (-241.67 to -25.16) 
-106.34 (-246.34 to 33.67) 
























Type of HF (HFrEF vs 
HFpEF) 
-29.64 (-156.83 to 97.55) 0.65 0.001 
ISWT (peak distance) 
(N=229) 
1.19 (0.88 to 1.51) <0.001 0.20 
MLHFQ    
   Overall -3.40 (-05.49 to -1.30) 0.002 0.04 
   Physical -7.96 (--12.20 to --3.73) <0.001 0.05 
   Emotional -8.22 (-15.06 to -1.39) 0.02 0.02 
HADS    
   Anxiety -0.09 (-11.57 to 11.39) 0.99 <0.001 
   Depression -26.18 (-40.37 to -11.98) <0.001 0.05 
HeartQoL    
   Global 94.20 (29.66 to 158.74) 0.004 0.03 
   Physical  96.48 (37.30 to 155.65) 0.001 0.04 
   Emotional 35.42 (-22.51 to 93.35) 0.23 0.005 
EQ-5D-3L (N=244) 282.61 (86.81 to 478.41) 0.005 0.03 
SCHFI    
   Maintenance 0.73 (-2.49 to 3.96) 0.66 0.001 
   Management (N=139) 0.21 (-2.38 to 2.80) 0.87 0.0002 
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   Confidence 1.08 (-1.01 to 3.17) 0.31 0.004 
BMI, body mass index; NYHA, New York heart association; HF, heart failure; 
LVEF, left ventricular ejection fraction; NT-proBNP, NT-pro-brain natriuretic 
peptide; COPD, chronic obstructive pulmonary disease; ISWT, incremental 
shuttle walk test; MLHFQ, Minnesota living with heart failure questionnaire; 
HADS, hospital anxiety and depression scale; SCHFI, self-care of heart failure 
index. 
* cardiorespiratory and metabolic comorbidities = angina, asthma, AF, CVD, 
hypertension, stroke, valvular heart disease, COPD, diabetes, PVD 
† physical and musculoskeletal comorbidities = arthritis, chronic back pain, 




Appendix 4.3: Univariate logistic regressions between meeting PA 
guidelines and sociodemographics, exercise capacity and health status 
variables 
Sociodemographic, exercise 
capacity and health status 
variables 
N=247 unless otherwise stated 
OR (95% CI) p-value Pseudo 
R2 
Age 0.95 (0.93 to 0.97) <0.001 0.04 
Gender 1.13 (0.65 to 1.97) 0.66 <0.001 









0.18 (0.08 to 0.45) 
omitted 
0.44 (0.10 to 2.00) 














0.38 (0.18 to 0.80) 











1.37 (0.66 to 2.85) 











1.67 (0.99 to 2.82) 





LVEF (%) (N=188) 1.00 (0.98 to 1.02) 0.99 <0.001 
NT-proBNP (pg/ml) 1.00 (1.00 to 1.00) <0.001 0.05 
Living alone 0.52 (0.29 to 0.93) 0.03 0.01 
Living with partner 1.65 (0.97 to 2.81) 0.06 0.01 
Living with child >18 1.10 (0.41 to 2.94) 0.86 <0.001 
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Living with child <18 1.86 (0.31 to 11.34) 0.5 0.001 







2.01 (0.60 to 6.73) 






  Truro 
  Gwent 
  Birmingham 
  York 
  Dundee 
 
Comparison group 
0.76 (0.34 to 1.68) 
0.5 (0.23 to 1.11) 
1.38 (0.64 to 2.98) 










Chronic back pain 





Total number of comorbidities  
 
0.70 (0.39 to 1.24) 
0.55 (0.30 to 1.01) 
0.76 (0.43 to 1.32) 
0.83 (0.50 to 1.38) 
0.49 (0.17 to 1.43) 
0.85 (0.39 to 1.86) 
0.77 (0.34 to 1.72) 
0.99 (0.57 to 1.70) 
1.01 (0.98 to 1.03) 
1.06 (0.64 to 1.76) 
0.72 (0.43 to 1.19) 
0.58 (0.25 to 1.34) 
1.05 (0.59 to 1.88) 































Total number of cardiorespiratory 
and metabolic comorbidities*  
0.79 (0.65 to 0.95) 0.01 0.02 
     Total number of physical and 
musculoskeletal comorbidities†  
0.95 (0.72 to 1.26) 0.74 <0.001 
Medication 
Angiotensin II receptor antagonist 
ACE inhibitor 
 
0.90 (0.51 to 1.60) 
1.46 (0.86 to 2.46) 



















0.58 (0.35 to 0.96) 
1.19 (0.65 to 2.21) 
0.83 (0.41 to 1.66) 
1.05 (0.34 to 3.23) 
0.45 (0.26 to 0.78) 
0.99 (0.49 to 1.98) 















Type of HF (HFrEF vs HFpEF) 0.73 (0.39 to 1.38) 0.33 0.003 






0.99 (0.98 to 1.00) 
0.98 (0.95 to 1.00) 













1.02 (0.96 to 1.08) 












1.17 (0.84 to 1.62) 
1.23 (0.91 to 1.66) 















1.00 (0.98 to 1.02) 
1.00 (0.98 to 1.02) 









BMI, body mass index; NYHA, New York heart association; HF, heart failure; 
LVEF, left ventricular ejection fraction; NT-proBNP, NT-pro-brain natriuretic 
peptide; COPD, chronic obstructive pulmonary disease; ISWT, incremental 
shuttle walk test; MLHFQ, Minnesota living with heart failure questionnaire; 
HADS, hospital anxiety and depression scale; SCHFI, self-care of heart failure 
index. 
* cardiorespiratory and metabolic comorbidities = angina, asthma, AF, CVD, 
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hypertension, stroke, valvular heart disease, COPD, diabetes, PVD 
† physical and musculoskeletal comorbidities = arthritis, chronic back pain, 




Appendix 5.1: Intervention effects at final follow-up, unbouted PA data 
 Baseline Final follow-up Δ to final follow-up Between group 
difference (mean, 


































































-11.97 (-33.12 to 
9.18) p=0.27 















































10.07 (-15.22 to 
35.35) p=0.43 

















































-21.25 (-43.24 to 
0.75) p=0.06 
REACH-HF: Rehabilitation enablement in chronic heart failure; SD: standard deviation; MVPA: moderate-to-vigorous physical 
activity; PA: physical activity 




Appendix 5.2: Intervention effects on PA outcomes at post-intervention follow-up, bouted PA data 
 Baseline Post-intervention Δ to post-intervention Between group 
difference (mean, 















mean (sd, N) 















































-2.40 (-26.20 to 
21.40) p=0.84 















































15.84 (-13.92 to 
45.59) p=0.30 

















































-13.53 (-39.31 to 
12.25) p=0.30) 
REACH-HF: Rehabilitation enablement in chronic heart failure; SD: standard deviation; MVPA: moderate-to-vigorous physical 




Appendix 5.3: Intervention effects at post-intervention follow-up, unbouted PA data  
 Baseline Post intervention Δ to post-intervention Between group 
difference 






mean (sd, N) 
REACH-HF  
mean (sd, N) 
Control  





mean (sd, N) 















































-0.65 (-18.56 to 
17.26) p=0.94 















































13.10 (-9.90 to 
36.11) p=0.26 

















































-5.43 (-24.22 to 
13.36) p=0.57 
REACH-HF: Rehabilitation enablement in chronic heart failure; SD: standard deviation; MVPA: moderate-to-vigorous physical 




Appendix 5.4: Intervention effects on proportion of patients meeting PA guidelines at post-intervention follow-up 
 Baseline Post-intervention OR (95% CI) p-value 
REACH-HF 
 (n, N, %) 
Control  
(n, N, %) 
REACH-HF 
(n, N, %) 
Control 
(n, N, %) 
Bouted 
Proportion meeting guidelines 
47, 98, 48% 47, 100, 47% 49, 98, 50% 47, 100, 47% 0.79 (0.34 to 1.84) p=0.59 
Unbouted 
Proportion meeting guidelines 
98, 98, 100% 100, 100, 100% 96, 98, 98% 100, 100, 100% - 




Appendix 5.5: Univariate association with change in MVPA at final follow-
up, controlling for trial stratifiers, group and baseline MVPA 
Sociodemographic, exercise 
capacity and health status 
variables 
N=173 unless otherwise stated 
Unstandardized beta 
coefficient (95% CI) 
p-
value 
Age -0.77 (-1.49 to -0.05) 0.04 
Gender 1.19 (-13.50 to 15.89) 0.87 









-17.13 (-38.46 to 4.19) 
-18.44 (-105.09 to 68.21) 
-39.19 (-82.28 to 4.41) 
-38.71 (-84.28 to 6.86) 
 
0.26 







-17.20 (-34.54 to 0.14) 
-21.84 (-43.34 to -0.34) 
 
0.10 






-11.12 (-30.01 to 7.76) 
-11.72 (-26.48 to 3.03) 
 
0.27 






8.53 (-4.84 to 21.90) 
0.91 (-30.46 to 32.29) 
 
0.44 
LVEF (%) (N=137) -0.52 (-1.57 to 0.52) 0.33 
NT-proBNP (pg/ml) -0.003 (-0.009 to 0.004) 0.42 
Living alone -3.06 (-18.40 to 12.28) 0.69 
Living with partner -3.06 (-18.40 to 12.28) 0.69 
Living with child >18 25.98 (1.80 to 50.16) 0.04 
Living with child <18 -1.16 (-50.64 to 48.33) 0.96 
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16.14 (-16.57 to 48.84) 




  Truro 
  Gwent 
  Birmingham 
  York 
  Dundee 
 
Comparison group 
-9.09 (-27.90 to 9.72) 
15.20 (-5.94 to 36.35) 
-2.93 (-21.72 to 15.87) 











Chronic back pain 





Total number of comorbidities  
 
0.16 (-15.50 to 15.82) 
-12.85 (-27.80 to 2.09) 
-5.75 (-20.12 to 8.62) 
-1.92 (-15.17 to 11.33) 
6.64 (-19.25 to 32.52) 
-7.21 (-27.07 to 12.64) 
4.16 (-18.08 to 26.41) 
1.60 (-11.91 to 15.11) 
-3.58 (-21.05 to 13.89) 
9.77 (-3.38 to 22.91) 
-10.54 (-23.55 to 2.47) 
-15.62 (-35.03 to 3.79) 
-2.0 (-17.05 to 13.06) 
















Total number of cardiorespiratory 
and metabolic comorbidities*  
-4.56 (-9.47 to 0.35) 0.07 
     Total number of physical and 
musculoskeletal comorbidities†  
3.85 (-3.25 to 10.95) 0.29 
Medication 
Angiotensin II receptor antagonist 
ACE inhibitor 
 
4.66 (-9.91 to 19.23) 
-0.59 (-14.16 to 12.98) 
4.13 (-9.52 to 17.78) 
















-7.79 (-24.33 to 8.75) 
-0.52 (-18.20 to 17.16) 
5.48 (-25.45 to 36.42) 
-12.65 (-26.68 to 1.39) 
-1.50 (-21.28 to 18.27) 







Type of HF (HFrEF vs HFpEF) collinearity  
ISWT (peak distance) (N=165) 
baseline 
0.06 (0.01 to 0.12) 0.02 
Overall ENMO  1.44 (-0.52 to 3.39) 0.15 
MLHFQ 
   Overall 
0.04 (-0.26 to 0.33) 0.81 
   Physical -0.14 (-0.74 to 0.47) 0.66 
   Emotional 0.47 (-0.43 to 1.36) 0.31 
HADS   
   Anxiety 1.83 (0.40 to 3.25) 0.01 
   Depression -0.13 (-2.27 to 2.01) 0.91 
HeartQoL   
   Global -2.09 (-11.01 to 6.82) 0.64 
   Physical  -0.66 (-9.02 to 7.69) 0.88 
   Emotional -3.82 (-11.27 to 3.64) 0.31 
EQ-5D-5L (N=172) 4.58 (-22.35 to 31.52) 0.74 
SCHFI   
   Maintenance 0.19 (-0.25 to 0.64) 0.39 
   Management (N=94) 
   Confidence 
-0.01 (-0.28 to 0.25) 
0.01 (-0.26 to 0.27) 
0.92 
0.96 
BMI: body mass index; NYHA: New York Heart Association; HF: heart failure; 
LVEF: left ventricular ejection fraction; NT-proBNP: N-terminal proB-type 
natriuretic peptide; MI: myocardial infection; COPD: chronic obstructive 
pulmonary disease; HFrEF: heart failure with reduced ejection fraction; HFpEF: 
heart failure with preserved ejection fraction; ISWT: incremental shuttle walk 
test; ENMO: Euclidean norm minus one; MLHFQ: Minnesota living with heart 
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failure questionnaire; HADS: hospital anxiety and depression scale; SCHFI: 




Appendix 5.6: Univariate association with change in MVPA at post-
intervention follow-up, controlling for trial stratifiers, group and baseline 
MVPA 
Sociodemographic, exercise 
capacity and health status 
variables 
N=198 unless otherwise stated 
Unstandardized beta 
coefficient (95% CI) 
p-
value 
Age -0.39 (-0.85 to 0.08) 0.11 
Gender -5.74  (-15.85 to 4.37) 0.26 









-10.83 (-25.08 to 3.41) 
-10.65 (-72.68 to 51.38) 
-29.16 (-56.92 to -1.40) 
-3.58 (-32.96 to 25.81) 
 
0.30 







-5.67 (-17.94 to 6.59) 
-13.58 (-28.25 to 1.08) 
 
0.17 






-3.15 (-16.06 to 9.76) 
-3.30 (-13.30 to 6.70) 
 
0.80 





Comparison group  
-2.90 (-11.93 to 6.12) 
1.62 (-18.58 to 21.82) 
 
0.78 
LVEF (%) (N=151) -0.08 (-0.67 to 0.51) 0.79 
NT-proBNP (pg/ml) -0.0003 (-0.004 to 0.003) 0.87 
Living alone -5.25 (-15.76 to 5.25) 0.33 
Living with partner 2.94 (-6.55 to 12.42) 0.61 
Living with child >18 2.94 (-14.88 to 20.76) 0.33 
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Living with child <18 5.81 (-29.66 to 41.29) 0.32 







6.47 (-14.09 to 27.04) 




  Truro 
  Gwent 
  Birmingham 
  York 
  Dundee 
 
Comparison group 
4.19 (-8.66 to 17.03) 
5.20 (-8.71 to 19.12) 
-1.81 (-14.46 to 10.84) 











Chronic back pain 





Total number of comorbidities  
 
-1.72 (-11.93 to 8.48) 
-12.67 (-22.52 to 2.81) 
3.43 (-6.40 to 12.26) 
-2.67 (-11.57 to 6.23) 
-10.64 (-29.90 to 8.61) 
-1.65 (-15.44 to 12.14) 
8.83 (-5.38 to 23.04) 
-8.46 (-17.87 to 0.94) 
0.01 (-0.05 to 0.07) 
-2.62 (-11.67 to 6.43) 
-2.47 (-11.36 to 6.42) 
-4.18 (-18.58 to 10.21) 
-3.33 (-13.99 to 7.32) 
















Total number of cardiorespiratory 
and metabolic comorbidities*  
-1.77 (-5.04 to 1.51) 0.29 
     Total number of physical and 
musculoskeletal comorbidities†  
-3.33 (-8.37 to 1.71) 0.19 
Medication 
Angiotensin II receptor antagonist 
ACE inhibitor 
 
-0.99 (-10.74 to 8.76) 
5.54 (-3.47 to 14.56) 















-8.31 (-17.13 to 0.51) 
-3.34 (-14.57 to 7.89) 
-2.71 (-14.63 to 9.21) 
12.82 (-5.30 to 30.94) 
1.37 (-8.41 to 11.15) 
-9.24 (-24.63 to 3.15) 








Type of HF (HFrEF vs HFpEF) -2.57 (-15.59 to 10.46) 0.70 
ISWT (peak distance) (N=188) 
baseline 
0.06 (0.02 to 0.09) 0.001 
Overall ENMO 1.12 (-0.23 to 2.47) 0.10 
  MLHFQ 
   Overall 
-0.12 (-0.32 to 0.07) 0.21 
   Physical -0.26 (-0.65 to 0.13) 0.20 
   Emotional -.025 (-0.86 to 0.36) 0.42 
HADS   
   Anxiety 0.30 (-0.71 to 1.32) 0.56 
   Depression -0.01 (-1.39 to 1.37) 0.99 
HeartQoL   
   Global 4.36 (-1.58 to 10.30) 0.15 
   Physical  4.52 (-0.97 to 10.00) 0.11 
   Emotional 1.56 (-3.62 to 6.75) 0.55 
EQ-5D-5L (N=196) 7.54 (-10.96 to 26.03) 0.42 
SCHFI   
   Maintenance -0.32 (-0.60 to -0.04) 0.03 
   Management (N=106) 
   Confidence 
0.06 (-0.22 to 0.34) 
-0.07 (-0.25 to 0.11) 
0.69 
0.43 
BMI: body mass index; NYHA: New York Heart Association; HF: heart failure; 
LVEF: left ventricular ejection fraction; NT-proBNP: N-terminal proB-type 
natriuretic peptide; MI: myocardial infection; COPD: chronic obstructive 
pulmonary disease; HFrEF: heart failure with reduced ejection fraction; HFpEF: 
heart failure with preserved ejection fraction; ISWT: incremental shuttle walk 
test; ENMO: Euclidean norm minus one; MLHFQ: Minnesota living with heart 
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failure questionnaire; HADS: hospital anxiety and depression scale; SCHFI: 




Appendix 5.7: Comparison of multivariable models to predict change in minutes/day MVPA at post-intervention follow-up. 
Multivariable model Variables included in 
model (p<0.05) 













Live with parent 
Diabetes 
constant 
0.48 (-6.24 to 7.22) 
-0.12 (-0.18 to -0.06) 
0.18 (-2.12 to 2.54) 
-3.93 (-12.96 to 5.11) 
34.98 (13.41 to 56.55) 
-12.17 (-20.08 to -4.27) 
















2. Exercise capacity 







0.18 (-6.0 to 6.34) 
-0.15 (-0.21 to -0.09) 
0.54 (-1.61 to 2.68) 
-2.03 (-10.29 to 6.23) 
0.04 (0.02 to 0.07) 






















2.02 (-4.8 to 8.83) 
-0.16 (-0.23 to -0.09) 
0.80 (-1.59 to 3.20) 
















37.47 (13.69 to 61.24) 
-11.99 (-19.98 to -4.01) 
0.04 (0.01 to 0.06) 









MVPA: moderate-to-vigorous physical activity; BNP 2000: NT-proBNP above or below 2000 pg/ml; ISWT: incremental shuttle walk 
test; HADS: hospital anxiety and depression score 
* all variables p<0.05 from multivariate models 1 and 2 
 
